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INTRODUCTION  
Type 2 diabetes (T2D) is a common metabolic disease characterized by hyperglycemia. At present, 
more than 380 million people live with T2D.1 T2D has been estimated as the sixth leading cause of 
death, largely attributable to high blood glucose and increased risks of cardiovascular diseases and 
other complications, which put a huge burden on health-care systems.2 The epidemiology of T2D is 
influenced by multiple risk factors including multiple genetic, environmental, and behavioral factors 
(Table 1).3 These multiple risk factors together fuel the development of T2D by possibly inducing 
pathophysiological defects in target organs or organ systems, such as insulin resistance in muscle and 
adipose tissue (Table 2).1 In the process of development of T2D, there is a precursor condition 
referred to as prediabetes that is defined by blood glucose levels higher than normal, but not high 
enough yet to T2D thresholds.4 Around 5–10% of people with prediabetes become diabetic every 
year, although the conversion rate varies with population characteristics and prediabetes definitions.4  
Table 1. Examples of known risk factors for type 2 diabetes 
Modifiable risk factors Non-modifiable risk factors 
Nutrition Age 
Physical inactivity Sex 
Sedentary behavior Ethnicity 
Overweight or obesity History of gestational diabetes 
Socioeconomics Polycystic ovary syndrome 
Components of the metabolic syndrome Family history of diabetes 
Cigarette smoking Genetic predisposition, such as TCF7L2 gene 
Inflammation  
Gut microbiome  
Some medications, such as beta-blockers, 
thiazides, and statins 
 
 
Table 2. Pathophysiological defects of type 2 diabetes 
Organs/ organ systems Pathophysiological defect 
Pancreatic α and β cells Loss of cell mass and function, impaired insulin secretion, 
dysregulated glucagon secretion, and increased glucagon 
concentration 
Muscle and adipose tissue Reduced peripheral glucose uptake, insulin resistance 
Inflammation Immune dysregulation 
Liver Increased hepatic glucose output 
Kidney Increased glucose reabsorption caused by of SGLT-2 receptors 
Brain Increased appetite, lack of satiety 
Stomach or intestine Increased rate of glucose absorption 
Colon  Unbalanced gut microbiome 
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Despite increasing knowledge regarding risk factors for T2D, the incidence and prevalence of T2D 
continues to rise globally.2 This calls for more effort to further address impact of risk factors on T2D. 
Nutrition, as a relatively easy modifiable risk factor, has attracted much attention, but much remains 
unclear.5 Gut microbiome, a novel risk factor, has been suggested to play an important 
pathophysiological role in the development of T2D.6, 7 As gut microbiome composition can be largely 
influenced by nutrition, and gut microbiome has been linked to T2D, gut microbiome has been 
proposed as a potential pathway through which nutrition may influence the development of T2D.8 
Therefore, further research on potential role of nutrition and gut microbiome in T2D risk can help 
provide new insight into etiology, mechanisms and thereby into the prevention, and therapy of T2D.  
Nutrition and type 2 diabetes  
To date, a large body of human studies has indicated the importance of nutrition in the prevention 
and management of T2D.3, 5 Many studies have indicated that dietary macronutrients, such as 
carbohydrate, protein, and fat may affect T2D risk, which could differ by their specific subtypes.5 
Literature has also indicated that higher intake of certain foods, such as fruits, vegetables, and legumes, 
and lower intake of for example red and processed meat, are associated with lower T2D risk.5 
Although research on individual nutrients and food items is valuable, people generally do not consume 
isolated micronutrients or foods. Therefore, in addition to research on nutrients and foods, many 
researchers have paid much attention to dietary patterns. Evidence has indicated that adherence to 
some dietary patterns, such as a Mediterranean diet, the Dietary Approach to Stop Hypertension 
(DASH) diet, and plant-based diets, are associated with lower T2D risk.9, 10 Overall, much effort and 
progress have been made in the nutrition research field for prevention of T2D. However, there are 
still a lot of inconsistencies in previous findings or limited data for certain topics. For example, 
although high long-term habitual animal protein intake has been consistently linked to higher T2D 
risk, the results for plant protein and T2D risk are mixed.11 Furthermore, although associations for 
the Mediterranean diet and the DASH diet and T2D have been widely and consistently reported, data 
on plant-based diets are more limited.12-14 Moreover, these topics have only been studied in certain 
specific populations, and diet habits are likely to vary according to sex, socioeconomic status, 
geographical location, ethnic group and culture, and vary over time, which calls for more nutrition 
research among diverse populations over time to further elucidate associations of nutrition with 
T2D.15 Additionally, to better understand the role of nutrition in T2D risk and to identify targets for 
early prevention, it is reasonable to further explore associations of nutritional factors with risk factors 
and earlier stages of T2D, such as obesity, insulin resistance, and prediabetes, for which, to date less 
studies have been performed.  
  
 
 
 
Gut microbiome and type 2 diabetes  
The human gut microbiome is composed of bacteria, archaea, viruses and eukaryotic microbes that 
reside in and on our gut. These trillions of gut microorganisms reside in a complex ecosystem which 
operates as a “hidden organ” to influence our health and diseases.16 New technologies, such as rapid 
nucleic acid sequencing, and advanced statistical technologies, have provided powerful tools to help 
our understanding of the gut microbiome. Recently, some studies have indicated that gut microbiome 
may play an important role in T2D.6, 7, 17-19 For example, compared to non-diabetic participants, T2D 
patients have less alpha diversity in their gut microbiome composition.20 Lean male donor fecal 
microbiota transplantation in males with metabolic syndrome resulted in a significant improvement in 
insulin sensitivity, along with an increased gut microbial diversity, including a distinct increase in 
butyrate-producing bacterial strains.21 However, these previous studies had some limitations. They 
were limited by small sample size, by unclear inclusion and exclusion criteria of participants, and by 
their lack of control for important confounders, such as physical activity or social economic status.6, 
17-19 Furthermore, given most of these studies were conducted under trial conditions with a small 
number of specific participants, it is unclear whether these findings are applicable to real-world settings. 
Therefore, large population-based studies examining associations between gut microbiome 
composition and T2D risk with comprehensive adjustment for confounders are needed to further 
elucidate the role of gut microbiome in T2D risk in real-life settings.17  
Nutrition and gut microbiome  
Ongoing efforts have suggested that gut microbiome composition is modifiable and that it can be 
largely influenced by nutrition.22, 23 However, these efforts have been mainly concentrated in 
researching the role of certain individual nutrients, such as fiber intake.24 To date, few studies have 
examined the role of habitual overall diet in the gut microbiome composition in population-based 
settings.25 To extend and update evidence on the role of diet in gut microbiome composition, well-
conducted, large population-based studies considering key confounders, such as socioeconomic status, 
smoking and other lifestyle factors, are needed. Combined with ongoing research on gut microbiome 
and T2D risk, research on how nutrition affects gut microbiome could better help in developing 
strategies for prevention and treatment of T2D.  
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THIS THESIS  
Objectives  
The aim of this thesis was to study the role of nutrition and gut microbiome in T2D risk. To better 
unravel the role of nutrition and gut microbiome in T2D risk, I also included major risk factor and 
earlier stages of T2D, including adiposity, insulin resistance, and prediabetes (Figure 1). Therefore, the 
objectives were:  
1. To examine associations of nutritional factors with adiposity, insulin resistance, prediabetes, T2D, 
and mortality. 
2. To investigate associations between gut microbiome composition with insulin resistance and T2D.  
3. To examine associations between nutritional factors and gut microbiome composition. 
 
 
Figure 1. Overview of objectives of this thesis  
 
Study design  
Studies presented in this thesis were mainly carried out in the Rotterdam Study. These analyses were 
extended with analyses in the Lifelines-Deep Study and with a systematic review of existing literature.  
The Rotterdam Study  
The Rotterdam Study is a large ongoing population-based prospective cohort study among individuals 
aged ≥ 45 years in Ommoord district of Rotterdam, the Netherlands. The rationale and design of the 
Rotterdam Study are described in detail elsewhere.26 Briefly, so far, a total of 14926 individuals of 
Ommoord district have been included in the three sub-cohorts of the study. The first sub-cohort, 
 
 
 
Rotterdam Study-I (RS-I), was launched in 1990 and recruited 7983 inhabitants of the Ommoord 
district aged 55 years or older; the second sub-cohort, Rotterdam Study-II (RS-II), started in 2000 and 
included 3011 inhabitants of the Ommoord district aged 55 years or above; the third sub-cohort, 
Rotterdam Study-III (RS-III) started in 2006 by recruiting 3932 inhabitants in the study district with 
age 45 years or above. Upon entering the study, the participants underwent home-structured 
interviews and a series of examinations in our research center every 3-5 year. The Rotterdam Study 
has been approved by the Medical Ethics Committee according to the Wet Bevolkingsonderzoek: 
ERGO (Population Study Act: Rotterdam Study), executed by the Ministry of Health, Welfare and 
Sports of The Netherlands. All participants gave informed consent.  
The Lifelines-Deep Study  
The Lifelines-Deep Study is a sub-cohort of the Lifelines Cohort Study, a population-based cohort 
including all age groups living in the three provinces in the northern region of the Netherlands: 
Groningen, Friesland and Drenthe.27 From 2006 through 2013, over 167000 individuals registered in 
the Lifelines Cohort Study. These participants received follow-up examinations every 5 years. From 
April to August 2013, 1539 Lifelines participants aged ≥ 18 years were invited to participate in the 
Lifelines-Deep Study. In the Lifelines-Deep Study, additional examinations were performed, including 
collection of fecal samples for gut microbiome composition. The Lifelines-Deep Study was approved 
by the ethics committee of the University Medical Centre Groningen. All participants signed an 
informed consent prior to enrolment.28 
Systematic review and Meta-analysis  
For Chapter 2.2, I conducted a systematic review and meta-analysis to include and pool results from 
several prospective cohorts. For the systematic review and meta-analysis, we performed extensive 
literature searches in several databases, including Medline via Ovid, EMBASE, Web of Science Core 
Collection, Cochrane CENTRAL via Wiley, PubMed and Google Scholar. No limits were set on 
language or year of publication. In order to identify additional relevant articles, the reference lists of 
the included studies and reviews were screened as well. We screened eligible articles and extracted data 
from individual studies by two independent reviewers. Finally, we pooled data from individual studies 
including the Rotterdam Study using a random-effects meta-analysis model.29  
 
THESIS OUTLINE  
Subsequent to this general introduction (Chapter 1), Chapter 2 of this thesis mainly focuses on the 
role of nutrition in T2D. Chapter 2.1 describes dietary protein intake in relation to insulin resistance, 
and risk of prediabetes and T2D in the Rotterdam Study. Chapter 2.2 demonstrates dietary protein 
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by the ethics committee of the University Medical Centre Groningen. All participants signed an 
informed consent prior to enrolment.28 
Systematic review and Meta-analysis  
For Chapter 2.2, I conducted a systematic review and meta-analysis to include and pool results from 
several prospective cohorts. For the systematic review and meta-analysis, we performed extensive 
literature searches in several databases, including Medline via Ovid, EMBASE, Web of Science Core 
Collection, Cochrane CENTRAL via Wiley, PubMed and Google Scholar. No limits were set on 
language or year of publication. In order to identify additional relevant articles, the reference lists of 
the included studies and reviews were screened as well. We screened eligible articles and extracted data 
from individual studies by two independent reviewers. Finally, we pooled data from individual studies 
including the Rotterdam Study using a random-effects meta-analysis model.29  
 
THESIS OUTLINE  
Subsequent to this general introduction (Chapter 1), Chapter 2 of this thesis mainly focuses on the 
role of nutrition in T2D. Chapter 2.1 describes dietary protein intake in relation to insulin resistance, 
and risk of prediabetes and T2D in the Rotterdam Study. Chapter 2.2 demonstrates dietary protein 
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intake linked to risk of all-cause mortality and cause-specific mortality in the Rotterdam Study and a 
meta-analysis of prospective cohort studies. Chapter 2.3 and 2.4 focus on the associations between a 
plant-based diet with insulin resistance, risk of prediabetes and T2D (Chapter 2.3), and adiposity over 
time (Chapter 2.4) in the Rotterdam Study. Chapter 3 investigates the associations between gut 
microbiome composition and insulin resistance and risk of T2D in the Rotterdam Study and the 
Lifelines-Deep Study. Chapter 4 describes the association between diet quality and components of 
diet quality with gut microbiome composition in the Rotterdam Study. Chapter 5 provides an overview 
of the main findings from all studies in this thesis. Furthermore, in this chapter, I discuss the 
implications of our findings, methodological considerations of the studies and directions of future 
research.  
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ABSTRACT  
Background: High protein intake has been linked to increased type 2 diabetes (T2D) risk. However, 
if this association differs by protein from specific food sources, and if a habitual high protein intake 
affects insulin resistance and prediabetes risk are largely unknown.  
Objectives: We aimed to investigate associations between protein intake from different food sources 
with longitudinal insulin resistance, and risk of prediabetes and T2D.  
Methods: Our analyses included 6822 participants aged ≥45 years without diabetes at baseline in 
three sub-cohorts of the prospective population-based Rotterdam Study. We measured protein intake 
at baseline using food-frequency questionnaires. Data on longitudinal homeostatic model assessment 
of insulin resistance (HOMA-IR), and incidence of prediabetes and T2D were available from 1993-
2014.  
Results: During follow-up, we documented 931 prediabetes cases and 643 T2D cases. After adjusting 
for sociodemographic, lifestyle, and dietary factors, higher total protein intake was associated with 
higher longitudinal HOMA-IR and with higher risk of prediabetes and T2D (per 5% increment in 
energy from protein at the expense of carbohydrate, for HOMA-IR: β=0.10, (95%CI 0.07, 0.12); for 
prediabetes: HR=1.34 (1.24 1.44); for T2D: HR=1.37 (1.26, 1.49)). These associations were mainly 
driven by total animal protein (for HOMA-IR: 0.10 (0.07, 0.12); for prediabetes: 1.35 (1.24, 1.45); for 
T2D: 1.37 (1.26, 1.49)). The harmful associations of total animal protein were contributed to by 
protein from meat, fish, and dairy (e.g. for HOMA-IR: protein from meat, 0.13 (0.10, 0.17); from fish, 
0.08 (0.03, 0.13); from dairy, 0.04 (0.0003, 0.08)). After additional adjustment for longitudinal waist 
circumference, associations of total protein and total animal protein with longitudinal HOMA-IR and 
prediabetes risk were attenuated but remained statistically significant. Total plant protein, as well as 
protein from legumes and nuts, from grains, from potatoes, or from fruits and vegetables, was not 
associated with any of the outcomes.  
Conclusions: Higher intake of animal protein, from meat, dairy and fish food sources, is associated 
with higher longitudinal insulin resistance and risk of prediabetes and T2D, which may be partly 
mediated by obesity over time. Furthermore, plant protein from different sources is not related to 
insulin resistance, and risk of prediabetes and T2D. Our findings highlight the importance of specific 
protein food sources and that habitual high animal protein intake may already in early stages be 
harmful in the development of T2D. 
 
 
 
 
 
INTRODUCTION  
Diet is considered an important component of a healthy lifestyle in the prevention of type 2 diabetes 
(T2D).1 One of the dietary factors of interest is protein. Short-term trials have reported beneficial 
effects of energy-restricted high-protein diet on obesity,2 an important diabetes risk factor, due to 
increased satiety and energy expenditure.3 However, several mechanistic and epidemiological studies 
have indicated that high levels of certain amino acids metabolized from dietary protein intake, such as 
branched-chain and aromatic amino acids, adversely affect glucose metabolism and insulin resistance.4-
6 Also, a recent review of eleven prospective cohort studies, reported that overall, higher habitual total 
protein intake is associated with higher T2D risk.7 Most studies in the review observed that this 
positive association was mainly driven by total animal protein,7 whereas evidence for plant protein is 
mixed.7-9  
However, the effect of habitual protein intake on insulin resistance and prediabetes is unknown. T2D 
has a long asymptomatic continuous physiological process, preceded by insulin resistance, a core 
defect of the pathogenesis of T2D,10 and by prediabetes, an early risk stage of T2D.11 Although 
previous studies reported associations of protein intake with ultimate T2D risk, pathophysiological 
mechanisms behind these different earlier risk stages are not completely consistent;12 thus effects of 
protein intake on insulin resistance and prediabetes risk might not be the same as for effects on T2D 
risk. To infer causal relations, longitudinal studies that seek to identify associations of protein intake 
with insulin resistance and prediabetes are warranted. However, to our knowledge, no studies have 
directly examined the associations between protein intake with longitudinal insulin resistance and 
prediabetes risk. Furthermore, almost all previous studies have investigated associations for intake of 
total protein, total animal protein and total plant protein, but not of protein from more specific food 
sources, especially for plant protein sources, for which evidence is very inconsistent.7, 13  
Therefore, we aimed to investigate the associations between protein intake from different food 
sources in an iso-energetic diet, with longitudinal insulin resistance and risk of prediabetes and T2D 
in a large Dutch population-based study.  
 
METHODS  
Study population  
The current study was embedded within the Rotterdam Study (RS), a population-based cohort study 
including people aged ≥ 45 years living in the Ommoord District of Rotterdam, the Netherlands. 
Details on the design of the Rotterdam Study are described elsewhere.14 The cohort consisted of three 
sub-cohorts. The baseline examination of the first sub-cohort (RS-I) was done in 1989-93 among 
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participants aged 55 years and over (n= 7983). In 2000-01, the study was extended with a second sub-
cohort (RS-II) of new individuals who had aged to 55 years or moved into the study area after 1990 
(n=3011). In 2006, a third sub-cohort (RS-III) with new individuals was recruited and included 
inhabitants aged 45 years and older (n=3932). Follow-up examinations were performed every 3-5 years 
in each sub-cohort. The study has been approved by the Medical Ethics Committee of Erasmus 
University Medical Center and all participants gave informed consent.  
Population for current analyses  
We used data from all three sub-cohorts (Supplemental Figure 1). For 6822 participants who were 
free of diabetes at baseline (RS-I-1: n=2976, RS-II-1: n=1418, and RS-III-1: n=2428), we had dietary 
data available at baseline. For the analyses of insulin resistance, from this group (n=6822) we excluded 
participants without data on homeostatic model assessment of insulin resistance (HOMA-IR) at 
baseline and follow-up, resulting in 6657 participants (RS-I: n=2899, RS-II: n=1396, RS-III: n=2362). 
For the analyses of prediabetes risk, from the group (n=6822) we excluded participants with 
prediabetes at baseline or without follow-up data of prediabetes, resulting in 5795 participants (RS-I: 
n=2492, RS-II: n=1152, RS-III: n=2151). Finally, for the analyses of T2D, we excluded participants 
without follow-up data of T2D still from the 6822 participants, resulting in 6813 participants (RS-I: 
n=2976, RS-II: n=1414, RS-III: n=2423). Data on the outcomes were available from 1993 to 2014.  
Assessment of protein intake  
At the baseline visits of RS-I and RS-II, food intake data were obtained using a semi-quantitative 170-
item food-frequency questionnaire (FFQ). For dietary assessment at baseline in RS-III (2006-08) and 
for the follow-up measurements in RS-I (RS-I-5, 2009-11) and RS-II (RS-II-3, 2011-12), a semi-
quantitative 389-item FFQ was used. Both FFQs were previously validated for nutrient intakes against 
other dietary assessment methods, for which results have been described elsewhere.15-17 Food intake 
data were converted to energy and nutrient intake using the Dutch Food Composition tables 1993, 
2001, 2006, and 2011 (NEVO). Intakes of protein and other macronutrients were expressed as 
percentage of total energy. Data on protein intake at baseline were analyzed in main analyses, and data 
on protein intake at follow-up in RS-I and RS-II were analyzed in sensitivity analyses.  
Assessment of insulin resistance  
Fasting blood was drawn at the research center at two time points in each sub-cohort (at RS-I-3 (1997-
99) and I-5 (2009-11), at RS-II-1 (2000-01) and II-3 (2011-12), and at RS-III-1 (2006-08) and III-2 
(2012-14)). Glucose levels were measured using the glucose hexokinase method. Serum insulin levels 
were measured on a Roche Modular Analytics E170 analyzer. The HOMA-IR was calculated using 
the formula: fasting insulin (mU/L) × fasting glucose (mmol/L)/22.5.  
 
 
 
Prevalence and incidence of type 2 diabetes and prediabetes  
At baseline and during follow-up, information from general practitioners, structured home interviews, 
pharmacy dispensing records, and follow-up examinations in our research center, was used to identify 
incident T2D and prediabetes cases. We defined T2D and prediabetes according to WHO guidelines.18 
Participants who fulfilled at least one of the following criteria were diagnosed as incident T2D: 1. 
Fasting blood glucose concentration of 7.0 mmol/L or higher; 2. Non-fasting blood glucose 
concentration of 11.1 mmol/L or higher; 3. The use of blood glucose-lowering medications. 
Prediabetes was defined as having fasting blood glucose between 6.0 and 7.0 mmol/L or non-fasting 
blood glucose between 7.7 and 11.1 mmol/L. All potential incident T2D and prediabetes were 
independently identified by two study physicians. In case of disagreement, consensus was sought by 
consulting endocrinologists. These cases were monitored until 2012.  
Assessment of covariates  
Information on smoking, medication use, and education levels, was obtained during home interviews 
at baseline. Waist circumference (WC) was measured at the research center at baseline (RS-I-1 (1989-
93), RS-II-1 (2000-01), RS-III-1 (2006-08)) and follow-up period (RS-I-3 (1997-99) and RS-I-5 (2009-
11); RS-II-2 (2004-05) and RS-II-3 (2011-12); RS-III-2 (2012-14)). WC was measured at the level 
midway between the lower rib margin and the iliac crest with the participant in a standing position. 
Physical activity was assessed with an adapted version of the Zutphen Physical Activity Questionnaire 
at RS-I-3 and RS-II-1, and with the LASA Physical Activity Questionnaire at RS-III-1. Physical 
activities were further weighted by their intensity with Metabolic Equivalent of Task (MET), obtained 
from the 2011 version of the Compendium of Physical Activities. Overall dietary quality was taken 
into account according to the Dutch Guidelines for a Healthy Diet, for which a sum score for 
adherence to these dietary guidelines (0-14) was calculated from the FFQ data.17  
Hypertension at baseline was defined using the following criteria: systolic blood pressure ≥ 140 mmHg; 
or/and diastolic blood pressure ≥ 90 mmHg; or use of blood pressure-lowering medication. 
Cardiovascular disease (CVD) at baseline and during follow-up was defined as having a medical record 
of myocardial infarction, coronary artery bypass surgery, or percutaneous transluminal coronary 
angioplasty.19 Serum cholesterol and triacylglycerol were measured at baseline with an automated 
enzymatic procedure. Information on family history of diabetes was available at RS-I-1 and RS-II-1 
and was defined as having at least one parent or sibling with T2D.  
Data analysis  
Descriptive data were expressed as mean (SD), median (25th percentile–75th percentile), or in 
percentages. To better approximate normal data distributions, we used natural log-transformed values 
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participants aged 55 years and over (n= 7983). In 2000-01, the study was extended with a second sub-
cohort (RS-II) of new individuals who had aged to 55 years or moved into the study area after 1990 
(n=3011). In 2006, a third sub-cohort (RS-III) with new individuals was recruited and included 
inhabitants aged 45 years and older (n=3932). Follow-up examinations were performed every 3-5 years 
in each sub-cohort. The study has been approved by the Medical Ethics Committee of Erasmus 
University Medical Center and all participants gave informed consent.  
Population for current analyses  
We used data from all three sub-cohorts (Supplemental Figure 1). For 6822 participants who were 
free of diabetes at baseline (RS-I-1: n=2976, RS-II-1: n=1418, and RS-III-1: n=2428), we had dietary 
data available at baseline. For the analyses of insulin resistance, from this group (n=6822) we excluded 
participants without data on homeostatic model assessment of insulin resistance (HOMA-IR) at 
baseline and follow-up, resulting in 6657 participants (RS-I: n=2899, RS-II: n=1396, RS-III: n=2362). 
For the analyses of prediabetes risk, from the group (n=6822) we excluded participants with 
prediabetes at baseline or without follow-up data of prediabetes, resulting in 5795 participants (RS-I: 
n=2492, RS-II: n=1152, RS-III: n=2151). Finally, for the analyses of T2D, we excluded participants 
without follow-up data of T2D still from the 6822 participants, resulting in 6813 participants (RS-I: 
n=2976, RS-II: n=1414, RS-III: n=2423). Data on the outcomes were available from 1993 to 2014.  
Assessment of protein intake  
At the baseline visits of RS-I and RS-II, food intake data were obtained using a semi-quantitative 170-
item food-frequency questionnaire (FFQ). For dietary assessment at baseline in RS-III (2006-08) and 
for the follow-up measurements in RS-I (RS-I-5, 2009-11) and RS-II (RS-II-3, 2011-12), a semi-
quantitative 389-item FFQ was used. Both FFQs were previously validated for nutrient intakes against 
other dietary assessment methods, for which results have been described elsewhere.15-17 Food intake 
data were converted to energy and nutrient intake using the Dutch Food Composition tables 1993, 
2001, 2006, and 2011 (NEVO). Intakes of protein and other macronutrients were expressed as 
percentage of total energy. Data on protein intake at baseline were analyzed in main analyses, and data 
on protein intake at follow-up in RS-I and RS-II were analyzed in sensitivity analyses.  
Assessment of insulin resistance  
Fasting blood was drawn at the research center at two time points in each sub-cohort (at RS-I-3 (1997-
99) and I-5 (2009-11), at RS-II-1 (2000-01) and II-3 (2011-12), and at RS-III-1 (2006-08) and III-2 
(2012-14)). Glucose levels were measured using the glucose hexokinase method. Serum insulin levels 
were measured on a Roche Modular Analytics E170 analyzer. The HOMA-IR was calculated using 
the formula: fasting insulin (mU/L) × fasting glucose (mmol/L)/22.5.  
 
 
 
Prevalence and incidence of type 2 diabetes and prediabetes  
At baseline and during follow-up, information from general practitioners, structured home interviews, 
pharmacy dispensing records, and follow-up examinations in our research center, was used to identify 
incident T2D and prediabetes cases. We defined T2D and prediabetes according to WHO guidelines.18 
Participants who fulfilled at least one of the following criteria were diagnosed as incident T2D: 1. 
Fasting blood glucose concentration of 7.0 mmol/L or higher; 2. Non-fasting blood glucose 
concentration of 11.1 mmol/L or higher; 3. The use of blood glucose-lowering medications. 
Prediabetes was defined as having fasting blood glucose between 6.0 and 7.0 mmol/L or non-fasting 
blood glucose between 7.7 and 11.1 mmol/L. All potential incident T2D and prediabetes were 
independently identified by two study physicians. In case of disagreement, consensus was sought by 
consulting endocrinologists. These cases were monitored until 2012.  
Assessment of covariates  
Information on smoking, medication use, and education levels, was obtained during home interviews 
at baseline. Waist circumference (WC) was measured at the research center at baseline (RS-I-1 (1989-
93), RS-II-1 (2000-01), RS-III-1 (2006-08)) and follow-up period (RS-I-3 (1997-99) and RS-I-5 (2009-
11); RS-II-2 (2004-05) and RS-II-3 (2011-12); RS-III-2 (2012-14)). WC was measured at the level 
midway between the lower rib margin and the iliac crest with the participant in a standing position. 
Physical activity was assessed with an adapted version of the Zutphen Physical Activity Questionnaire 
at RS-I-3 and RS-II-1, and with the LASA Physical Activity Questionnaire at RS-III-1. Physical 
activities were further weighted by their intensity with Metabolic Equivalent of Task (MET), obtained 
from the 2011 version of the Compendium of Physical Activities. Overall dietary quality was taken 
into account according to the Dutch Guidelines for a Healthy Diet, for which a sum score for 
adherence to these dietary guidelines (0-14) was calculated from the FFQ data.17  
Hypertension at baseline was defined using the following criteria: systolic blood pressure ≥ 140 mmHg; 
or/and diastolic blood pressure ≥ 90 mmHg; or use of blood pressure-lowering medication. 
Cardiovascular disease (CVD) at baseline and during follow-up was defined as having a medical record 
of myocardial infarction, coronary artery bypass surgery, or percutaneous transluminal coronary 
angioplasty.19 Serum cholesterol and triacylglycerol were measured at baseline with an automated 
enzymatic procedure. Information on family history of diabetes was available at RS-I-1 and RS-II-1 
and was defined as having at least one parent or sibling with T2D.  
Data analysis  
Descriptive data were expressed as mean (SD), median (25th percentile–75th percentile), or in 
percentages. To better approximate normal data distributions, we used natural log-transformed values 
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for HOMA-IR. We used linear mixed models with a random-effects structure including a random 
intercept and slope (for time of repeated measurements of HOMA-IR) to analyze the associations 
between protein intake and longitudinal HOMA-IR. We used Cox proportional hazard models to 
analyze the associations between protein intake and risk of prediabetes and T2D. Because effects of 
macronutrient intake cannot be separated from the effects of overall energy intake or intake of other 
macronutrients, we modelled macronutrient substitution effects.  
For all models we used multivariable nutrient density substitution models for protein intake at the 
expense of carbohydrate.20 As no indications for non-linear associations for the main models were 
found, all primary analyses were performed using models assuming linearity. All macronutrients were 
entered in the models per 5 energy percent (E%).20, 21 We first examined the associations for total 
protein intake at the expense of carbohydrate by including total protein intake, total energy, total fat 
intake, and alcohol, in the model (i.e. all macronutrients except for carbohydrate). Subsequently we 
examined the associations for total animal and total plant protein intake at the expense of carbohydrate 
in similar models, for which we mutually adjusted for total animal and total plant protein. The 
coefficients in these models indicated change in outcomes (e.g. average change in longitudinal 
HOMA-IR over time) by replacement of carbohydrate by other nutrients. The effect estimate for 
protein in this model could therefore be interpreted as a 5 E% higher protein intake at the expense of 
an isocaloric amount of carbohydrates. For all main analyses, model 1 included intake of protein, total 
fat, total energy, alcohol, baseline age, and sex, and for the analyses of longitudinal HOMA-IR we 
additionally adjusted for the time of repeated measurements of HOMA-IR; model 2 was additionally 
adjusted for smoking status, educational levels, diet quality score, physical activity, and family history 
of diabetes. In model 3, we additionally adjusted for longitudinal WC to account for the potential 
effect of obesity over time in the potential associations between protein intake with longitudinal insulin 
resistance, and risk of prediabetes and T2D. Especially in model 3, to account for the potential effect 
of obesity over time in the associations with risk of prediabetes and T2D, we used novel joint models 
combing linear mixed model with a random-effects structure including a random intercept and slope 
(for time of repeated measurements of WC) and cox proportional hazard model. The cox model part 
of the joint model was the same as model 2 and the linear mixed model part of joint model, in which 
the outcomes were the repeated measurements of WC before the onset of prediabetes or T2D, was 
additionally adjusted for the time of longitudinal WC measurements, and the interactions between 
protein and the time of these repeated measurements.22  
Effect modification was examined by including interactions of intake of total protein, total animal 
protein, and total plant protein with age, sex in model 2, and longitudinal WC (continuous data) in 
model 3. In case of significant interactions (p<0.05), the analyses would be stratified. We performed 
several sensitivity analyses based on model 2 to test whether the associations of total protein, total 
animal protein, and total plant protein with outcomes were robust. First, we replaced total fat by 
 
 
 
carbohydrate, to examine whether it made a difference if protein was consumed at the expense of fat; 
and we split total fat in subgroups of fatty acids (saturated fatty acids (SFA), monounsaturated fatty 
acids (MUFA), polyunsaturated fatty acids (PUFA), trans-unsaturated fatty acids (Trans-fat) at the 
expense of carbohydrate to control the effect of subgroups of fatty acids. Second, we additionally 
added cholesterol, hypertension, triglycerides, and CVD history, since these factors could mediate 
associations. Third, we excluded participants who developed CVD during follow-up to exclude the 
possibility of significant change of diet and lifestyle. Fourth, we examined the associations of total 
protein, total animal protein, and total plant protein with longitudinal HOMA-IR using data of 
HOMA-IR that was measured before onset of T2D at follow-up. Last, we further adjusted for protein 
intake 20 years after baseline in RS-I and 10 years after baseline in RS-II to examine whether our main 
results were robust after incorporating potential effect of dietary intake at follow-up among the 
participants with these data available in RS-I and RS-II.  
To further explore whether the associations of animal protein and plant protein differ by more specific 
food sources, we further examined the associations of isocaloric replacement of carbohydrate with 
protein from meat, protein from dairy, protein from fish, protein from legumes and nuts, protein from 
potato, protein from grains, and protein from fruits and vegetables with longitudinal insulin resistance, 
and risk of prediabetes and T2D. In this modelling approach, the percentage of energy intake from 
protein from meat, dairy, fish, legumes and nuts, potatoes, grains, and fruits and vegetables were 
simultaneously included in one model, with adjustment for total energy, alcohol, SFA, MUFA, PUFA, 
Trans-fat, fiber, age, sex, smoking status, educational levels, diet quality score, physical activity, and 
family history of diabetes for analyses of risk of prediabetes and T2D. The time of longitudinal 
HOMA-IR measurements was additionally included in the multivariate model for analysis of 
longitudinal insulin resistance.  
All analyses were performed separately for RS-I, RS-II, and RS-III, and the results were pooled using 
fixed-effects meta-analysis. To adjust for potential bias associated with missing data (Supplemental 
Table 1), a multiple imputation procedure (n=10) was used for missing data of covariates. Statistical 
procedures were performed with the use of SPSS statistical software, version 21.0 (IBM Corp, Armonk, 
NY) and R version 3.3.1 (The R Foundation for Statistical Computing, Vienna, Austria).  
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for HOMA-IR. We used linear mixed models with a random-effects structure including a random 
intercept and slope (for time of repeated measurements of HOMA-IR) to analyze the associations 
between protein intake and longitudinal HOMA-IR. We used Cox proportional hazard models to 
analyze the associations between protein intake and risk of prediabetes and T2D. Because effects of 
macronutrient intake cannot be separated from the effects of overall energy intake or intake of other 
macronutrients, we modelled macronutrient substitution effects.  
For all models we used multivariable nutrient density substitution models for protein intake at the 
expense of carbohydrate.20 As no indications for non-linear associations for the main models were 
found, all primary analyses were performed using models assuming linearity. All macronutrients were 
entered in the models per 5 energy percent (E%).20, 21 We first examined the associations for total 
protein intake at the expense of carbohydrate by including total protein intake, total energy, total fat 
intake, and alcohol, in the model (i.e. all macronutrients except for carbohydrate). Subsequently we 
examined the associations for total animal and total plant protein intake at the expense of carbohydrate 
in similar models, for which we mutually adjusted for total animal and total plant protein. The 
coefficients in these models indicated change in outcomes (e.g. average change in longitudinal 
HOMA-IR over time) by replacement of carbohydrate by other nutrients. The effect estimate for 
protein in this model could therefore be interpreted as a 5 E% higher protein intake at the expense of 
an isocaloric amount of carbohydrates. For all main analyses, model 1 included intake of protein, total 
fat, total energy, alcohol, baseline age, and sex, and for the analyses of longitudinal HOMA-IR we 
additionally adjusted for the time of repeated measurements of HOMA-IR; model 2 was additionally 
adjusted for smoking status, educational levels, diet quality score, physical activity, and family history 
of diabetes. In model 3, we additionally adjusted for longitudinal WC to account for the potential 
effect of obesity over time in the potential associations between protein intake with longitudinal insulin 
resistance, and risk of prediabetes and T2D. Especially in model 3, to account for the potential effect 
of obesity over time in the associations with risk of prediabetes and T2D, we used novel joint models 
combing linear mixed model with a random-effects structure including a random intercept and slope 
(for time of repeated measurements of WC) and cox proportional hazard model. The cox model part 
of the joint model was the same as model 2 and the linear mixed model part of joint model, in which 
the outcomes were the repeated measurements of WC before the onset of prediabetes or T2D, was 
additionally adjusted for the time of longitudinal WC measurements, and the interactions between 
protein and the time of these repeated measurements.22  
Effect modification was examined by including interactions of intake of total protein, total animal 
protein, and total plant protein with age, sex in model 2, and longitudinal WC (continuous data) in 
model 3. In case of significant interactions (p<0.05), the analyses would be stratified. We performed 
several sensitivity analyses based on model 2 to test whether the associations of total protein, total 
animal protein, and total plant protein with outcomes were robust. First, we replaced total fat by 
 
 
 
carbohydrate, to examine whether it made a difference if protein was consumed at the expense of fat; 
and we split total fat in subgroups of fatty acids (saturated fatty acids (SFA), monounsaturated fatty 
acids (MUFA), polyunsaturated fatty acids (PUFA), trans-unsaturated fatty acids (Trans-fat) at the 
expense of carbohydrate to control the effect of subgroups of fatty acids. Second, we additionally 
added cholesterol, hypertension, triglycerides, and CVD history, since these factors could mediate 
associations. Third, we excluded participants who developed CVD during follow-up to exclude the 
possibility of significant change of diet and lifestyle. Fourth, we examined the associations of total 
protein, total animal protein, and total plant protein with longitudinal HOMA-IR using data of 
HOMA-IR that was measured before onset of T2D at follow-up. Last, we further adjusted for protein 
intake 20 years after baseline in RS-I and 10 years after baseline in RS-II to examine whether our main 
results were robust after incorporating potential effect of dietary intake at follow-up among the 
participants with these data available in RS-I and RS-II.  
To further explore whether the associations of animal protein and plant protein differ by more specific 
food sources, we further examined the associations of isocaloric replacement of carbohydrate with 
protein from meat, protein from dairy, protein from fish, protein from legumes and nuts, protein from 
potato, protein from grains, and protein from fruits and vegetables with longitudinal insulin resistance, 
and risk of prediabetes and T2D. In this modelling approach, the percentage of energy intake from 
protein from meat, dairy, fish, legumes and nuts, potatoes, grains, and fruits and vegetables were 
simultaneously included in one model, with adjustment for total energy, alcohol, SFA, MUFA, PUFA, 
Trans-fat, fiber, age, sex, smoking status, educational levels, diet quality score, physical activity, and 
family history of diabetes for analyses of risk of prediabetes and T2D. The time of longitudinal 
HOMA-IR measurements was additionally included in the multivariate model for analysis of 
longitudinal insulin resistance.  
All analyses were performed separately for RS-I, RS-II, and RS-III, and the results were pooled using 
fixed-effects meta-analysis. To adjust for potential bias associated with missing data (Supplemental 
Table 1), a multiple imputation procedure (n=10) was used for missing data of covariates. Statistical 
procedures were performed with the use of SPSS statistical software, version 21.0 (IBM Corp, Armonk, 
NY) and R version 3.3.1 (The R Foundation for Statistical Computing, Vienna, Austria).  
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RESULTS  
Baseline characteristics  
Characteristics and dietary intakes of the study population are presented in Table 1. Average total 
protein intake in our population was 85.8 ± 25.1 g/day, this corresponded to 1.20 ± 0.3 g/kg BW/day, 
which is higher than the recommended intake of 0.8 g/kg BW/day.23 In our study population, most 
protein came from animal sources (total animal protein: 53.6 ± 19.0 g/day). Mean percentage of 
energy intake from total protein was 16.3%, from total animal protein was 10.3%, and from total plant 
sources was 6.0%. Main animal protein sources were meat and dairy; the main plant protein source 
was grains. During a median 5.7 years of follow-up, we documented 931 prediabetes cases among 
5795 participants. During a median 7.2 years of follow-up, we documented 643 T2D cases among 
6813 participants.  
Intake of total protein, total animal protein, and total plant protein with insulin resistance, 
risk of prediabetes and T2D  
After multivariable adjustment (Model 2), higher intake of total protein and of total animal protein 
was associated with higher longitudinal insulin resistance (for per 5 E% higher total protein at the 
expense of carbohydrate, β=0.10 (95%CI 0.07, 0.12)); for total animal protein at the expense of 
carbohydrate, β=0.10 (95%CI 0.07, 0.12)) (Table 2). After additional adjustment for longitudinal WC 
(Model 3), the estimates were attenuated but still statistically significant.  
In line with this, higher total protein intake was associated with higher prediabetes risk (hazard ratio 
(HR) 1.34 (95%CI 1.24, 1.44)), also mainly driven by total animal protein (1.35 (95%CI 1.24, 1.45)) 
not by total plant protein (Table 3). After additional adjustment for longitudinal WC (model 3), these 
estimates were slightly attenuated but still statistically significant.  
Similarly, higher intake of total protein and total animal, but not total plant protein, was associated 
with higher T2D risk (HR for total protein 1.37 (95%CI 1.26, 1.49)) (Table 4). After additional 
adjustment for longitudinal WC, the associations attenuated and no longer statistically significant (e.g. 
for total protein intake: 1.12 (95%CI 0.96, 1.30)).  
 
  T
ab
le
 1.
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s o
f s
tu
dy
 p
ar
tic
ip
an
ts
  
 
R
S-
I 
R
S-
II
 
R
S-
II
I 
Po
ol
ed
 
 
(n
=2
97
6)
 
(n
=1
41
8)
 
(n
=2
42
8)
 
(n
=6
82
2)
 
A
ge
 a
t d
iet
ar
y 
as
se
ss
m
en
t (
ye
ar
s)
 
79
.1
±
4.
6 
72
.1
±
4.
9 
56
.8
±
6.
4 
65
.4
±
11
.3
 
Se
x,
 m
ale
 (%
) 
40
.4
 
45
.0
 
40
.5
 
41
.4
 
W
ais
t c
irc
um
fe
re
nc
e 
(c
m
) 
88
.8
±
10
.8
 
93
.7
±
26
.8
 
92
.5
±
22
.6
 
91
.2
±
19
.7
 
Ph
ys
ic
al 
ac
tiv
ity
 (M
E
T-
ho
ur
s/
w
ee
k)
 
 
 
 
 
- Z
ut
ph
en
 P
hy
sic
al 
A
ct
iv
ity
 
Q
ue
st
io
nn
air
e 
80
.7
 (5
5.
4-
11
6.
3)
 
77
.3
 (5
2.
9-
10
5.
0)
 
N
A
 
\ 
- L
A
SA
 P
hy
sic
al 
A
ct
iv
ity
 Q
ue
st
io
nn
air
e 
N
A
 
N
A
 
42
·9
 (1
7·
7-
82
·8
) 
\ 
E
du
ca
tio
n 
lev
el
 (%
) 
 
 
 
 
- P
rim
ar
y 
 
15
.7
 
7.
1 
9.
5 
11
.7
 
- L
ow
er
  
43
.7
 
45
.2
 
34
.4
 
40
.6
 
- I
nt
er
m
ed
iat
e 
 
30
.2
 
28
.4
 
27
.4
 
28
.8
 
- H
ig
he
r  
10
.0
 
17
.9
 
28
.4
 
18
.2
 
Sm
ok
in
g 
(%
) 
 
 
 
 
- N
ev
er
 
28
.9
 
28
.9
 
31
.9
 
32
.0
 
- E
ve
r 
47
.6
 
47
.6
 
43
.5
 
44
.7
 
- C
ur
re
nt
 
23
.0
 
23
.0
 
24
.4
 
22
.8
 
D
iet
ar
y 
in
ta
ke
 
 
 
 
 
E
ne
rg
y 
in
ta
ke
 (k
ca
l/
da
y)
 
19
85
±
50
5 
21
55
±
56
9 
23
37
±
86
5 
21
46
±
68
5 
Ca
rb
oh
yd
ra
te
 in
ta
ke
 (g
/d
ay
) 
20
7.
1 
(1
72
.7
-2
49
.3
) 
21
3.
7(
17
0.
7-
26
3.
0)
 
24
9.
1 
(1
98
.7
-3
09
.6
) 
21
6.
1 
(1
23
.5
-3
22
.9
) 
Ca
rb
oh
yd
ra
te
 in
ta
ke
 (E
%
) 
43
.5
 (3
9.
1-
47
.8
) 
41
.7
 (3
6.
7-
46
.1
) 
45
.0
 (4
0.
9-
49
.5
) 
43
.7
 (3
9.
1-
85
.8
) 
To
ta
l f
at
 in
ta
ke
 (g
/d
ay
) 
80
.2
±
27
.6
 
88
.4
±
25
.9
 
85
.8
±
49
.1
 
83
.9
±
36
.6
 
To
ta
l f
at
 in
ta
ke
 (E
%
) 
34
.2
±
6.
3 
34
.6
±
5.
7 
29
.9
±
6.
6 
32
.8
±
6.
6 
A
lc
oh
ol
 in
ta
ke
 (g
/d
ay
) 
4.
5 
(0
.3
5-
15
.3
) 
8.
7(
0.
7-
22
.6
) 
8.
1 
(1
.4
-1
9.
7)
 
6.
5 
(0
-4
4.
1)
 
A
lc
oh
ol
 in
ta
ke
 (E
%
) 
1.
6 
(0
.1
4,
 5
.5
) 
2.
8 
(0
.2
7-
7.
1)
 
2.
6 
(0
.4
3,
 6
.1
) 
2.
0 
(0
.1
8,
 6
.2
) 
To
ta
l p
ro
te
in
 in
ta
ke
 (g
/d
ay
) 
81
.8
±
19
.4
 
88
.8
±
25
.7
 
89
.0
±
29
.8
4 
85
.8
±
25
.1
3 
To
ta
l p
ro
te
in
 in
ta
ke
 (E
%
) 
16
.8
±
3.
0 
16
.6
±
2.
9 
15
.6
±
2.
6 
16
.3
±
2.
9 
 
Dietary protein and type 2 diabetes
31
2.1
 
 
 
RESULTS  
Baseline characteristics  
Characteristics and dietary intakes of the study population are presented in Table 1. Average total 
protein intake in our population was 85.8 ± 25.1 g/day, this corresponded to 1.20 ± 0.3 g/kg BW/day, 
which is higher than the recommended intake of 0.8 g/kg BW/day.23 In our study population, most 
protein came from animal sources (total animal protein: 53.6 ± 19.0 g/day). Mean percentage of 
energy intake from total protein was 16.3%, from total animal protein was 10.3%, and from total plant 
sources was 6.0%. Main animal protein sources were meat and dairy; the main plant protein source 
was grains. During a median 5.7 years of follow-up, we documented 931 prediabetes cases among 
5795 participants. During a median 7.2 years of follow-up, we documented 643 T2D cases among 
6813 participants.  
Intake of total protein, total animal protein, and total plant protein with insulin resistance, 
risk of prediabetes and T2D  
After multivariable adjustment (Model 2), higher intake of total protein and of total animal protein 
was associated with higher longitudinal insulin resistance (for per 5 E% higher total protein at the 
expense of carbohydrate, β=0.10 (95%CI 0.07, 0.12)); for total animal protein at the expense of 
carbohydrate, β=0.10 (95%CI 0.07, 0.12)) (Table 2). After additional adjustment for longitudinal WC 
(Model 3), the estimates were attenuated but still statistically significant.  
In line with this, higher total protein intake was associated with higher prediabetes risk (hazard ratio 
(HR) 1.34 (95%CI 1.24, 1.44)), also mainly driven by total animal protein (1.35 (95%CI 1.24, 1.45)) 
not by total plant protein (Table 3). After additional adjustment for longitudinal WC (model 3), these 
estimates were slightly attenuated but still statistically significant.  
Similarly, higher intake of total protein and total animal, but not total plant protein, was associated 
with higher T2D risk (HR for total protein 1.37 (95%CI 1.26, 1.49)) (Table 4). After additional 
adjustment for longitudinal WC, the associations attenuated and no longer statistically significant (e.g. 
for total protein intake: 1.12 (95%CI 0.96, 1.30)).  
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Intake of protein from various food sources with insulin resistance, risk of prediabetes and 
T2D  
We further examined the associations of protein from more specific animal and plant food sources 
with longitudinal insulin resistance, and risk of prediabetes and T2D. In multivariable models, higher 
intakes of protein from meat, from fish, and from dairy were all associated with higher longitudinal 
insulin resistance, and risk of prediabetes and T2D (e.g. for HOMA-IR: protein from meat, 0.13 
(95%CI 0.10, 0.17), from fish, 0.08 (95%CI 0.03, 0.l3), and from dairy, 0.04 (95%CI 0.0003, 0.08); and 
for prediabetes risk: protein from meat, 1.54 (95%CI 1.31, 1.80), from fish, 1.31 (95%CI 1.03, 1.65), 
from dairy, 1.26 (95%CI 1.06, 1.49)). Protein from legumes and nuts, protein from grains, protein 
from potato, and protein from fruits and vegetables, were not associated with longitudinal insulin 
resistance, and risk of prediabetes and T2D (Table 5).  
Sensitivity analyses  
The associations between total protein, total animal protein, and total plant protein with longitudinal 
insulin resistance and risk of prediabetes and T2D did not differ by age, sex, or longitudinal WC (all 
interactions p>0.05). In all sensitivity analyses, including for example the additional adjustments for 
cholesterol, hypertension, triglycerides and CVD history; and modelling replacement of protein at the 
expense of fat instead of carbohydrate, the estimates were similar and remained statistically significant 
(Supplemental Tables 2-17).  
 
DISCUSSION  
In this large population-based prospective cohort, higher habitual protein intake, mainly from animal 
food sources, was associated with a persistently higher insulin resistance over time and a higher risk 
of prediabetes and T2D. Obesity over time appeared to be a mediator in these associations. We 
observed that protein from meat, from fish, and from dairy all contributed to these associations. Intake 
of total plant protein and protein from legumes and nuts, protein from potatoes, protein from grains 
or protein from fruits and vegetables were not associated with longitudinal insulin resistance, risk of 
prediabetes or T2D.  
Our results for T2D risk support those of previous observational studies that found positive 
associations between total protein and total animal protein and T2D risk.7 Furthermore, we extended 
this evidence by also reporting associations of higher total protein and total animal protein with higher 
longitudinal insulin resistance and risk of prediabetes. Some small previous human studies also 
indicated harmful effects of high protein diets on insulin resistance when the intake was prolonged.24 
More importantly, our study further extended the evidence in this field by examining the associations 
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Intake of protein from various food sources with insulin resistance, risk of prediabetes and 
T2D  
We further examined the associations of protein from more specific animal and plant food sources 
with longitudinal insulin resistance, and risk of prediabetes and T2D. In multivariable models, higher 
intakes of protein from meat, from fish, and from dairy were all associated with higher longitudinal 
insulin resistance, and risk of prediabetes and T2D (e.g. for HOMA-IR: protein from meat, 0.13 
(95%CI 0.10, 0.17), from fish, 0.08 (95%CI 0.03, 0.l3), and from dairy, 0.04 (95%CI 0.0003, 0.08); and 
for prediabetes risk: protein from meat, 1.54 (95%CI 1.31, 1.80), from fish, 1.31 (95%CI 1.03, 1.65), 
from dairy, 1.26 (95%CI 1.06, 1.49)). Protein from legumes and nuts, protein from grains, protein 
from potato, and protein from fruits and vegetables, were not associated with longitudinal insulin 
resistance, and risk of prediabetes and T2D (Table 5).  
Sensitivity analyses  
The associations between total protein, total animal protein, and total plant protein with longitudinal 
insulin resistance and risk of prediabetes and T2D did not differ by age, sex, or longitudinal WC (all 
interactions p>0.05). In all sensitivity analyses, including for example the additional adjustments for 
cholesterol, hypertension, triglycerides and CVD history; and modelling replacement of protein at the 
expense of fat instead of carbohydrate, the estimates were similar and remained statistically significant 
(Supplemental Tables 2-17).  
 
DISCUSSION  
In this large population-based prospective cohort, higher habitual protein intake, mainly from animal 
food sources, was associated with a persistently higher insulin resistance over time and a higher risk 
of prediabetes and T2D. Obesity over time appeared to be a mediator in these associations. We 
observed that protein from meat, from fish, and from dairy all contributed to these associations. Intake 
of total plant protein and protein from legumes and nuts, protein from potatoes, protein from grains 
or protein from fruits and vegetables were not associated with longitudinal insulin resistance, risk of 
prediabetes or T2D.  
Our results for T2D risk support those of previous observational studies that found positive 
associations between total protein and total animal protein and T2D risk.7 Furthermore, we extended 
this evidence by also reporting associations of higher total protein and total animal protein with higher 
longitudinal insulin resistance and risk of prediabetes. Some small previous human studies also 
indicated harmful effects of high protein diets on insulin resistance when the intake was prolonged.24 
More importantly, our study further extended the evidence in this field by examining the associations 
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of protein from more detailed animal food sources with longitudinal insulin resistance, and risk of 
prediabetes and T2D in long-term follow-up. We observed independent associations of higher intake 
of protein from meat, from fish, and from dairy with higher insulin resistance, and risk of prediabetes 
and T2D, indicating that the observed associations were not mainly driven by protein from a particular 
animal food source. Few previous studies have observed associations between animal protein from 
more specific animal food sources with insulin resistance, and risk of prediabetes and T2D.8, 13 Similar 
to our findings, van Nielen et al. observed that the association of animal protein with T2D risk was 
not explained by protein from a particular animal food source by examining whether the association 
of animal protein substantially changed when excluding protein from meat, fish, or dairy from total 
animal protein.8 In contrast, a recent study by Heli et al. reported null associations of protein from 
meat, fish or dairy with T2D risk.13 The discrepancy could be explained by the lower animal protein 
intakes in the study of Heli et al13 as compared to animal protein intakes in van Nielen et al.’s and our 
studies.  
The potential mechanisms behind the associations of habitual high long-term animal protein with the 
development of T2D, are largely unknown. One mechanism could involve effects of specific amino 
acids metabolized mainly from animal protein. Dietary branched-chain and aromatic amino acids are 
mainly derived from animal-sourced protein, and they can lead to phosphorylation of the insulin 
receptor by activating mammalian target of rapamycin (mTOR), thereby undermining the normal 
regulation of glucose and insulin levels.4, 24, 25 Previous studies also proposed other possible 
mechanisms. For example, co-occurrence of nutrients in animal protein-rich foods, such as heme iron, 
saturated fat, nitrites, and advanced glycation end products might attribute to the positive 
associations.9, 26 However, we observed that the associations of animal protein intake were independent 
of other macronutrients and overall diet quality, in which red and processed meat, rich in heme iron, 
saturated fat, nitrites, and advanced glycation end products, is an important component, suggesting 
specific effect of animal protein. In contrast, some short-term randomized trials reported beneficial 
effects of high protein diets (mean protein contents were 1.25 ± 0.17 g/kg BW/day in these 
randomized control trials) on obesity, a main risk factor of T2D, which may be explained by induced 
satiety and energy expenditure due to short-term high protein intake.3 On short-term, high protein 
intake may increase gluconeogenesis and cause a high ketogenic state, which contribute to increased 
satiety and energy expenditure.3, 27, 28 This increased satiety and energy expenditure can result in a lower 
energy intake and a negative energy balance, and thereby promote weight loss and weight 
maintenance.29  
Our results were also in line with most of previous studies reporting null associations of total plant 
protein.7 In contrast, the studies in American populations reported a modest inverse association with 
T2D risk.9 Moreover, we extended this evidence by further exploring the associations of plant protein 
from more specific food sources, including protein from legumes and nuts, grains, potatoes, fruits and 
 
 
 
vegetables, for which we observed null associations. Little previous evidence for protein from more 
specific plant food sources and T2D risk was available and was mainly limited to classification of total 
plant protein as protein from grains and non-grains only.13 For example, Virtanen et al. reported null 
associations between protein from grains or from non-grains with T2D risk, but did not examine the 
associations for protein from more specific plant food sources.13  
Finally, we also observed that after additional adjustment for longitudinal WC, the associations of total 
and animal protein intake with insulin resistance, and risk of prediabetes and T2D were attenuated, 
although still statistically significant for insulin resistance, and risk of prediabetes. This suggests that 
obesity seems to be a mediator in the associations. Previous studies7-9 reported that obesity could be a 
mediator but were limited by adjusting for only baseline obesity. Because obesity is a factor of an 
overall unhealthy lifestyle, obesity could be both intermediate and confounder in the associations. 
However, in our analyses we adjusted for main indicators of lifestyle, such as physical activity and 
overall diet quality, before correcting for longitudinal measures of obesity, therefore, the attenuation 
of the associations by additional adjustment for obesity is more likely to be explained by the mediation 
role of obesity.  
Strengths and limitations  
Our study has several strengths. First, our study is the first study that directly examined associations 
of protein intake with longitudinal insulin resistance and prediabetes risk in large population. Studying 
these early risk stages help minimize reverse causation and understand how protein intake influence 
the development of T2D. We found that the associations of protein intake with longitudinal insulin 
resistance and risk of prediabetes and T2D were consistent, which indicates that it could be beneficial 
to limit habitual high animal protein intake already for early stages in the development of T2D. Second, 
to our knowledge, this is also the first prospective study to use longitudinal obesity as a time-varying 
covariate in linear mixed model and Joint model to examine the role of obesity in the development of 
T2D, namely, we have accounted for the effect of longitudinal obesity in the associations between 
protein intake and the development of T2D. Third, our study comprehensively examined these 
associations for protein from more specific food sources instead of protein from total animal protein 
and plant protein, which adds literature into this field and may facilitate public health 
recommendations. Fourth, we adjusted for a wide range of potential confounders, including many 
lifestyle and dietary variables, which is important, especially when studying a single nutrient. Last, our 
results were robust to various sensitivity analyses, including additional adjustment for a broad range 
of other cardiovascular risk factors, and different macronutrient substitution effects.  
There are several limitations we should consider. First, we only used data on protein intake at baseline 
in main analyses, which may not represent long-time protein intake. Therefore, analysis of data on 
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of protein from more detailed animal food sources with longitudinal insulin resistance, and risk of 
prediabetes and T2D in long-term follow-up. We observed independent associations of higher intake 
of protein from meat, from fish, and from dairy with higher insulin resistance, and risk of prediabetes 
and T2D, indicating that the observed associations were not mainly driven by protein from a particular 
animal food source. Few previous studies have observed associations between animal protein from 
more specific animal food sources with insulin resistance, and risk of prediabetes and T2D.8, 13 Similar 
to our findings, van Nielen et al. observed that the association of animal protein with T2D risk was 
not explained by protein from a particular animal food source by examining whether the association 
of animal protein substantially changed when excluding protein from meat, fish, or dairy from total 
animal protein.8 In contrast, a recent study by Heli et al. reported null associations of protein from 
meat, fish or dairy with T2D risk.13 The discrepancy could be explained by the lower animal protein 
intakes in the study of Heli et al13 as compared to animal protein intakes in van Nielen et al.’s and our 
studies.  
The potential mechanisms behind the associations of habitual high long-term animal protein with the 
development of T2D, are largely unknown. One mechanism could involve effects of specific amino 
acids metabolized mainly from animal protein. Dietary branched-chain and aromatic amino acids are 
mainly derived from animal-sourced protein, and they can lead to phosphorylation of the insulin 
receptor by activating mammalian target of rapamycin (mTOR), thereby undermining the normal 
regulation of glucose and insulin levels.4, 24, 25 Previous studies also proposed other possible 
mechanisms. For example, co-occurrence of nutrients in animal protein-rich foods, such as heme iron, 
saturated fat, nitrites, and advanced glycation end products might attribute to the positive 
associations.9, 26 However, we observed that the associations of animal protein intake were independent 
of other macronutrients and overall diet quality, in which red and processed meat, rich in heme iron, 
saturated fat, nitrites, and advanced glycation end products, is an important component, suggesting 
specific effect of animal protein. In contrast, some short-term randomized trials reported beneficial 
effects of high protein diets (mean protein contents were 1.25 ± 0.17 g/kg BW/day in these 
randomized control trials) on obesity, a main risk factor of T2D, which may be explained by induced 
satiety and energy expenditure due to short-term high protein intake.3 On short-term, high protein 
intake may increase gluconeogenesis and cause a high ketogenic state, which contribute to increased 
satiety and energy expenditure.3, 27, 28 This increased satiety and energy expenditure can result in a lower 
energy intake and a negative energy balance, and thereby promote weight loss and weight 
maintenance.29  
Our results were also in line with most of previous studies reporting null associations of total plant 
protein.7 In contrast, the studies in American populations reported a modest inverse association with 
T2D risk.9 Moreover, we extended this evidence by further exploring the associations of plant protein 
from more specific food sources, including protein from legumes and nuts, grains, potatoes, fruits and 
 
 
 
vegetables, for which we observed null associations. Little previous evidence for protein from more 
specific plant food sources and T2D risk was available and was mainly limited to classification of total 
plant protein as protein from grains and non-grains only.13 For example, Virtanen et al. reported null 
associations between protein from grains or from non-grains with T2D risk, but did not examine the 
associations for protein from more specific plant food sources.13  
Finally, we also observed that after additional adjustment for longitudinal WC, the associations of total 
and animal protein intake with insulin resistance, and risk of prediabetes and T2D were attenuated, 
although still statistically significant for insulin resistance, and risk of prediabetes. This suggests that 
obesity seems to be a mediator in the associations. Previous studies7-9 reported that obesity could be a 
mediator but were limited by adjusting for only baseline obesity. Because obesity is a factor of an 
overall unhealthy lifestyle, obesity could be both intermediate and confounder in the associations. 
However, in our analyses we adjusted for main indicators of lifestyle, such as physical activity and 
overall diet quality, before correcting for longitudinal measures of obesity, therefore, the attenuation 
of the associations by additional adjustment for obesity is more likely to be explained by the mediation 
role of obesity.  
Strengths and limitations  
Our study has several strengths. First, our study is the first study that directly examined associations 
of protein intake with longitudinal insulin resistance and prediabetes risk in large population. Studying 
these early risk stages help minimize reverse causation and understand how protein intake influence 
the development of T2D. We found that the associations of protein intake with longitudinal insulin 
resistance and risk of prediabetes and T2D were consistent, which indicates that it could be beneficial 
to limit habitual high animal protein intake already for early stages in the development of T2D. Second, 
to our knowledge, this is also the first prospective study to use longitudinal obesity as a time-varying 
covariate in linear mixed model and Joint model to examine the role of obesity in the development of 
T2D, namely, we have accounted for the effect of longitudinal obesity in the associations between 
protein intake and the development of T2D. Third, our study comprehensively examined these 
associations for protein from more specific food sources instead of protein from total animal protein 
and plant protein, which adds literature into this field and may facilitate public health 
recommendations. Fourth, we adjusted for a wide range of potential confounders, including many 
lifestyle and dietary variables, which is important, especially when studying a single nutrient. Last, our 
results were robust to various sensitivity analyses, including additional adjustment for a broad range 
of other cardiovascular risk factors, and different macronutrient substitution effects.  
There are several limitations we should consider. First, we only used data on protein intake at baseline 
in main analyses, which may not represent long-time protein intake. Therefore, analysis of data on 
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repeated measurements of dietary protein intake over time would be preferable. However, the 
exclusion of participants who were likely to change their diet during follow-up, such as participants 
with cardiovascular diseases at baseline or follow-up, and the additional adjustment for protein intake 
20 years after baseline in RS-I and 10 years after baseline in RS-II, did not change the results; 
furthermore, estimates were similar in three sub-cohorts with different follow-up. Combined, the 
results from these sensitivity analyses indicated that our conclusions were robust. Second, as our 
current study was conducted within an observational population-based cohort study among general 
population, the variation in protein intake was not that large. A larger variation would be preferable 
to explore the role of plant protein intake in the development of T2D risk. However, several previous 
cohort studies reported similar amount of variation of plant protein intake, and also observed 
associations between plant protein intake and T2D risk. This indicates that the amount of variation of 
plant protein among our participants would have been sufficient to pick up associations with these 
outcomes. Third, misclassification of protein intake could have occurred. However, given the 
prospective study design, this measurement error was likely to be non-differential, which would have 
attenuated observed associations. Fourth, although we adjusted for many potential confounders, the 
possibility of residual confounding cannot be dismissed, for example, through the meal distribution 
of protein and energy. Finally, our results may not be generalizable to people of other age or race and 
need further replication.  
Conclusions  
In this large prospective cohort study, higher intake of total protein and total animal protein was 
associated with higher longitudinal insulin resistance and risk of prediabetes and T2D. Obesity over 
time appeared to partly mediate these associations. Protein from meat, fish and dairy all contributed 
to these associations. Intake of protein from legumes and nuts, grains, potatoes, or vegetables and 
fruits was not associated with insulin resistance, risk of prediabetes or T2D. Our findings indicate the 
importance of protein sources and that limiting high intake of protein from animal food sources may 
be beneficial in preventing development of T2D. 
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repeated measurements of dietary protein intake over time would be preferable. However, the 
exclusion of participants who were likely to change their diet during follow-up, such as participants 
with cardiovascular diseases at baseline or follow-up, and the additional adjustment for protein intake 
20 years after baseline in RS-I and 10 years after baseline in RS-II, did not change the results; 
furthermore, estimates were similar in three sub-cohorts with different follow-up. Combined, the 
results from these sensitivity analyses indicated that our conclusions were robust. Second, as our 
current study was conducted within an observational population-based cohort study among general 
population, the variation in protein intake was not that large. A larger variation would be preferable 
to explore the role of plant protein intake in the development of T2D risk. However, several previous 
cohort studies reported similar amount of variation of plant protein intake, and also observed 
associations between plant protein intake and T2D risk. This indicates that the amount of variation of 
plant protein among our participants would have been sufficient to pick up associations with these 
outcomes. Third, misclassification of protein intake could have occurred. However, given the 
prospective study design, this measurement error was likely to be non-differential, which would have 
attenuated observed associations. Fourth, although we adjusted for many potential confounders, the 
possibility of residual confounding cannot be dismissed, for example, through the meal distribution 
of protein and energy. Finally, our results may not be generalizable to people of other age or race and 
need further replication.  
Conclusions  
In this large prospective cohort study, higher intake of total protein and total animal protein was 
associated with higher longitudinal insulin resistance and risk of prediabetes and T2D. Obesity over 
time appeared to partly mediate these associations. Protein from meat, fish and dairy all contributed 
to these associations. Intake of protein from legumes and nuts, grains, potatoes, or vegetables and 
fruits was not associated with insulin resistance, risk of prediabetes or T2D. Our findings indicate the 
importance of protein sources and that limiting high intake of protein from animal food sources may 
be beneficial in preventing development of T2D. 
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ABSTRACT 
Background: Short-term high protein diets appear to improve cardiometabolic risk profile, but long-
term high protein intake has been associated with higher cardiometabolic diseases risk. Evidence for 
associations between protein intake with mortality is inconsistent.  
Objectives: We aimed to examine associations of dietary protein from different sources with all-cause 
and cause-specific mortality. 
Methods: We followed 7786 participants from three sub-cohorts of the Rotterdam Study, a 
population-based cohort in the Netherlands. Dietary data were collected using food-frequency 
questionnaires at baseline (1989-93, 2000-01, 2006-08). Deaths were followed until 2018. Associations 
were examined using Cox regression. Additionally, we performed a highest versus lowest meta-analysis 
and a dose-response meta-analysis to summarize results from the Rotterdam Study and previous 
prospective cohorts.   
Results: During a median follow-up of 13.0 years, 3589 deaths were documented in the Rotterdam 
Study. In this cohort, after multivariable adjustment, higher total protein intake was associated with 
higher all-cause mortality (e.g. highest versus lowest quartile of total protein intake as percentage of 
energy (Q4 versus Q1), HR=1.12 (1.01, 1.25)); mainly explained by higher animal protein and CVD 
mortality (Q4 versus Q1, CVD mortality: 1.28 (1.03, 1.60)). Plant protein intake was not associated 
with all-cause or cause-specific mortality. These findings for total and animal protein intake were 
corroborated in a meta-analysis of eleven prospective cohort studies including the Rotterdam Study 
(total 64306 deaths among 350452 participants): higher total protein intake was associated with higher 
all-cause mortality (pooled RR for highest versus lowest quantile 1.05 (1.01, 1.10)), and for dose-
response per 5 energy percent (E%) increment, 1.02 (1.004, 1.04)); again mainly driven by an 
association between animal protein and CVD mortality (highest versus lowest, 1.09 (1.01, 1.18), per 5 
E% increment, 1.05 (1.02, 1.09)). Furthermore, in the meta-analysis a higher plant protein intake was 
associated with lower all-cause and CVD mortality (e.g. for all-cause mortality, highest versus lowest, 
0.93 (0.87, 0.99), per 5 E% increment, 0.87 (0.78, 0.98); for CVD mortality, highest versus lowest 0.86 
(0.73, 1.00)).  
Conclusions: Evidence from prospective cohort studies to date suggests that total protein intake is 
positively associated with all-cause mortality, mainly driven by a harmful association of animal protein 
with CVD mortality. Plant protein intake is inversely associated with all-cause and CVD mortality. 
Our findings support current dietary recommendations to increase intake of plant protein in place of 
animal protein. 
 
 
 
 
INTRODUCTION  
Defining the role of dietary protein intake in health has been a long-standing research topic of interest 
and remains a high priority in nutrition research. Although protein delivers amino acids that are crucial 
for various body functions, protein intake in the general population tends to be much higher than 
required.1 Short-term randomized clinical trials have indicated that a higher protein intake replacing 
carbohydrate favors weight management and improves blood lipid and lipoprotein profiles and 
glycemic regulation.2-4 These beneficial effects on cardiometabolic risk profile have been shown to be 
partly dependent on weight loss and possibly owing to the enhanced postprandial satiety and energy 
expenditure when replacing carbohydrate with protein.5 However, several prospective observational 
studies have reported that long-term high intake of total and animal protein is associated with higher 
risk of type 2 diabetes6 and cardiovascular diseases (CVD).7   
Recently, to further explore the role of dietary protein intake in overall health, several previous studies 
have examined the associations between protein intake and all-cause and cause-specific mortality, but 
with apparently inconsistent results.8-16 For example, Song et al. reported that higher animal protein 
intake was associated with higher CVD mortality risk, while higher plant protein intake was associated 
with lower risk of all-cause and CVD mortality.12 In contrast, Kelemen et al. reported null associations 
of total and animal protein with risk of all-cause and CVD mortality, but beneficial association of plant 
protein with CVD mortality.9 Tharrey et al. observed that higher animal protein intake was associated 
with higher CVD mortality, while plant protein intake was not associated with CVD mortality.15  
Therefore, we aimed to investigate the associations of total, animal, and plant protein intake with all-
cause and cause-specific mortality in the Rotterdam Study. Furthermore, to clarify the currently mixed 
evidence from previous studies, we also systematically reviewed and meta-analyzed our findings with 
those from previous prospective studies to evaluate the association of dietary protein intake with 
mortality. 
 
METHODS 
The current study consisted of two stages. First, we analyzed the associations of protein intake with 
all-cause and cause-specific mortality in the Rotterdam study. Second, we conducted a systematic 
review and meta-analysis by combining the new results from the Rotterdam Study with results from 
previous prospective cohort studies.  
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ABSTRACT 
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Methods in the Rotterdam Study   
Study design and population in the Rotterdam Study  
The first stage of this study was conducted within three sub-cohorts of the Rotterdam study (RS), a 
large prospective cohort study of participants aged 45 years and above in Rotterdam, the 
Netherlands.17 Briefly, the first sub-cohort of the Rotterdam Study (RS-I) was initiated in the period 
of 1989-93 by recruiting participants aged ≥ 55 years from the district of Ommoord (n=7983). In 
2000-01, the study was extended with a second sub-cohort (RS-II) including new individuals who had 
become 55 years of age or moved into the study area (n=3011). In 2006-08, a third sub-cohort (RS-
III) was started of new individuals aged 45 years and older (n=3932). Until the end of 2008, 14926 
participants were contained in the three sub-cohorts at baseline. We collected information every 3-5 
years through interviews for which we visited the participants at their homes, through questionnaires 
which the participants returned, and through examinations in our dedicated research center which is 
in the Ommoord district. In the home interviews, we collected information such as education level, 
smoking status, medical history, and income. At the examination center, we mainly focused on 
examinations of imaging (of heart, blood vessels, eyes, skeleton, and later brain) and on collecting 
biospecimens that enabled further in-depth molecular and genetic analysis. The Rotterdam Study has 
been approved by the institutional review board (Medical Ethics Committee) of Erasmus Medical 
Center and by the review board of The Netherlands Ministry of Health, Welfare and Sports. The 
approval has been renewed every 5 years. All participants gave informed consent.17 
For the current analysis within the Rotterdam Study, of the 14926 participants who participated at 
baseline, we had reliable dietary data available for 9701. Reasons for absence of valid dietary data were: 
not having received dietary assessment because of logistic reasons; living in a resident home for elderly, 
or suspected dementia; not having completed the dietary assessment; or unreliable dietary intake 
according to a trained nutritionist or an estimated energy intake of <500 or >5000 kcal/day).18, 19 From 
these 9701 participants, we further excluded 1914 participants with CVD, diabetes, or cancer at 
baseline, and 1 participant without follow-up data on mortality, leaving 7786 participants for the main 
analyses (Supplemental Figure 1).  
Dietary assessment 
Dietary intake in the Rotterdam Study was assessed at baseline in all three sub-cohorts using a semi-
quantitative food questionnaire (FFQ) as described in more details elsewhere.19, 20 Briefly, we used an 
FFQ with 170 food items to assess dietary intake at baseline of RS-I (1989-93) and at baseline of RS-
II (2000-01). This 170-item FFQ was validated against fifteen 24-hour food records and four 24-hour 
urinary urea excretion samples which were collected on non-consecutive days over a period of a year 
in a subsample of the Rotterdam Study (n=80), as described in detail elsewhere21: Adjusted Pearson’s 
 
 
 
correlation intake against the food records were 0.66 for total protein intake and 0.59 for plant protein 
intake; and Spearman’s correlation for protein intake against urinary urea was 0.67. A 389-item FFQ 
was used to assess dietary intake at baseline of RS-III (2006-08). This 389-item FFQ was previously 
validated in two other Dutch populations using a 9-day dietary record22 and a 4-week dietary history23: 
Pearson’s correlations for intakes of different nutrients varied from 0.40 to 0.86. Food intake data 
were converted to energy and nutrient intake based on the Dutch Food Composition tables.  
Ascertainment of death 
Information on vital status of the participants was obtained from clinical follow-up data collection 
and from municipal records. General practitioners reported events of interest by means of a 
computerized system or notified new events annually. Trained research assistants subsequently 
collected information from medical records at the general practitioners’ offices, hospitals and nursing 
homes. Two research physicians independently identified the events according to the International 
Classification of Diseases, Tenth revision (ICD-10). Afterwards, a senior physician reviewed all coded 
events. Cause-specific mortality was recoded according to the ICD-10 codes (CVD cause: F01, I05-
99 (non-stroke CVD cause: I05-51, 70-99, stroke cause: F01, I60-69); cancer cause: C01-97). Coded 
information on all-cause mortality was available until May 2018 and coded information on cause-
specific mortality was available until January 2015. 
Covariates 
Information on age, sex, smoking status, and education level was obtained from questionnaires at 
baseline. Information on physical activity was obtained using the adapted version of the Zutphen 
Physical Activity Questionnaire at the third visit of RS-I (1997-99) and at baseline of RS-II, and the 
LASA Physical Activity Questionnaire at baseline of RS-III. Physical activities were weighted 
according to intensity with Metabolic Equivalent of Task (MET), from the Compendium of Physical 
Activities version 2011. To account for differences between the two questionnaires, questionnaire-
specific z-scores of MET-hours per week were calculated. We measured body weight and height at 
baseline in our research center and body mass index (BMI) was calculated. A previously defined diet 
quality score was calculated to reflect adherence to Dutch dietary guidelines as described in detail 
elsewhere.20 Briefly, this was a sum-score of the adherence to guidelines for 14 individual foods items, 
including: vegetables (≥200 g/day), fruit (≥200 g/day), whole-grains (≥90 g/day), legumes (≥135 
g/week), nuts (≥15 g/day), dairy (≥350 g/day), fish (≥100 g/week), tea (≥450 mL/day), ratio whole-
grains: total grains (≥50%), ratio unsaturated fats and oils: total fats (≥50%), red and processed meat 
(<300 g/week), sugar-containing beverages (≤150 mL/day), alcohol (≤10 g/day) and salt (≤6 g/day). 
We scored every participant as adhering to this item (‘yes’ scored as 1) or not adhering to the item 
(‘no’ scored as 0). The total diet quality score theoretically ranged from 0 (no adherence) through 14 
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(‘no’ scored as 0). The total diet quality score theoretically ranged from 0 (no adherence) through 14 
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(full adherence). We previously reported that a higher score was associated with a lower premature 
mortality risk and a lower risk of developing some of the chronic diseases on which the guidelines 
were based.20 Information on CVD, diabetes, and cancers was obtained from general practitioners, 
pharmacies’ datasets, Nationwide Medical Register, or follow-up examinations in our research center. 
Data analyses 
We expressed intake of dietary protein and other macronutrients as a percentage of total energy 
consumption. Baseline characteristics of the Rotterdam population are presented for the whole group 
and by quartiles of total, animal, or plant protein intake. Trends of these characteristics across quartiles 
of protein intake were examined by using means and linear regression for continuous variables, or chi-
square tests for categorical variables. After confirming that the assumption for proportional hazards 
was met on the basis of Schoenfeld residuals,24 we used Cox proportional hazard models to analyze 
associations of dietary protein intake with all-cause and cause-specific mortality. Because effects of 
macronutrient intake cannot be separated from the effects of overall energy intake or intake of other 
macronutrients, we modelled macronutrient substitution effects. For our main models, we used 
multivariable nutrient density substitution models for protein intake at the expense of carbohydrate. 
For this aim, models were used with adjustment for total energy intake and percentage of energy from 
subtypes of fats (saturated fat (SFA), monounsaturated fat (MUFA), polyunsaturated fat (PUFA), and 
trans-fat (TSF)), and from alcohol.25 Therefore, coefficients from these models were interpreted as the 
estimated effects of substituting a certain percentage of energy from protein intake for equivalent 
energy from carbohydrate intake. We estimated hazard ratios (HRs) and their 95% confidence 
intervals (CIs) of mortality by comparing participants in each quartile of protein intake as percentage 
of energy with those in the lowest quartile. To quantify a linear trend, we assigned the median within 
each quartile and modeled this variable continuously. Furthermore, we also modelled dietary protein 
intake as continuous variable and estimated HRs and 95%CIs per 5 energy percent (E%) increment 
from protein at the expense of carbohydrate.  
For all main analyses, we included intake of protein, SFA, MUFA, PUFA, TSF, total energy, alcohol, 
baseline age, sex, and RS-cohort in model 1; we additionally adjusted for smoking status, education 
level, overall diet quality score, fiber intake, physical activity, and BMI in model 2. For analysis of 
animal and plant protein intake, mutual adjustment for plant and animal protein was performed. 
Sensitivity analyses 
We conducted a series of sensitivity analyses to test robustness of our main results. First, we replaced 
fat intake by carbohydrate in the main models (model 2), to examine whether it made a difference if 
dietary protein was consumed at the expense of fat instead of carbohydrate. Second, we examined if 
the associations of animal protein intake with all-cause and cause-specific mortality differed by protein 
 
 
 
from specific animal food sources, such as meat, dairy, fish, and eggs at expense of carbohydrate. In 
this modelling approach, the percentages of energy intake from protein from meat, dairy, fish, and 
eggs were simultaneously included in one model, with adjustment for plant protein and all other 
covariates in model 2. Third, we examined the interaction effect of total, animal, or plant protein with 
age, sex, BMI, or physical activity by including their interaction terms in model 2, to explore whether 
the associations of protein intake and mortality differed by these factors. Last, to minimize reverse 
causality bias, we excluding the participants who died within the first 2 years of follow-up in the 
Rotterdam study. 
We performed all analyses based on combined data from RS-I, RS-II, and RS-III. All variables 
included in analyses were used to predict missingness patterns. Missing values on covariates were 
assumed to be missing at random and accounted for using multiple imputations (m=10 imputations).26 
Supplemental Table 1 shows the percentage of missing data for covariates in the Rotterdam Study. 
Statistical procedures were performed with the use of R version 3.3.1 (The R Foundation for Statistical 
Computing, Vienna, Austria). 
Methods for the systematic review and meta-analysis  
The systematic review was conducted using a predefined protocol and reported in accordance with 
the PRISMA and MOOSE guidelines.27, 28 Medline (Ovid), Embase.com, and the Cochrane Central 
Register of Controlled Trials were searched from inception until August 27, 2019 (date last searched), 
with assistance of an experienced biomedical information specialist. The detailed search strategy is 
shown in Supplemental Table 2. Two independent reviewers conducted an initial screening of all titles 
or abstracts and then evaluated all potentially relevant articles based on full text reviews. Eligible 
studies were included if they (i) were observational studies with a longitudinal design (i.e., prospective 
cohort); and (ii) had assessed the variance of estimates of the association between dietary protein 
intake (total, animal and/or plant protein) with all-cause mortality and/or cause-specific mortality in 
a general population (i.e., populations that were not selected based on pre-existing health conditions). 
We contacted the investigators for relevant data if their studies were potentially eligible for this study. 
We extracted the following characteristics from the included studies: first author, cohort name, 
country, publication year, age at entry, sex, sample size, duration of follow-up, assessment of dietary 
protein intake, ascertainment of outcomes, the most adjusted association estimates and corresponding 
measures of variation, and variables that were entered into the multivariable model as potential 
confounders. In case of multiple publications from the same study, we included the most up-to date 
or comprehensive information. We used the nine-star Newcastle–Ottawa Scale (NOS) to assess study 
quality on the basis of selection of three domains: selection of participants (population 
representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of 
interest. Nine points on the NOS reflects the highest study quality.29 
Dietary protein and mortality
61
2.2
 
 
 
(full adherence). We previously reported that a higher score was associated with a lower premature 
mortality risk and a lower risk of developing some of the chronic diseases on which the guidelines 
were based.20 Information on CVD, diabetes, and cancers was obtained from general practitioners, 
pharmacies’ datasets, Nationwide Medical Register, or follow-up examinations in our research center. 
Data analyses 
We expressed intake of dietary protein and other macronutrients as a percentage of total energy 
consumption. Baseline characteristics of the Rotterdam population are presented for the whole group 
and by quartiles of total, animal, or plant protein intake. Trends of these characteristics across quartiles 
of protein intake were examined by using means and linear regression for continuous variables, or chi-
square tests for categorical variables. After confirming that the assumption for proportional hazards 
was met on the basis of Schoenfeld residuals,24 we used Cox proportional hazard models to analyze 
associations of dietary protein intake with all-cause and cause-specific mortality. Because effects of 
macronutrient intake cannot be separated from the effects of overall energy intake or intake of other 
macronutrients, we modelled macronutrient substitution effects. For our main models, we used 
multivariable nutrient density substitution models for protein intake at the expense of carbohydrate. 
For this aim, models were used with adjustment for total energy intake and percentage of energy from 
subtypes of fats (saturated fat (SFA), monounsaturated fat (MUFA), polyunsaturated fat (PUFA), and 
trans-fat (TSF)), and from alcohol.25 Therefore, coefficients from these models were interpreted as the 
estimated effects of substituting a certain percentage of energy from protein intake for equivalent 
energy from carbohydrate intake. We estimated hazard ratios (HRs) and their 95% confidence 
intervals (CIs) of mortality by comparing participants in each quartile of protein intake as percentage 
of energy with those in the lowest quartile. To quantify a linear trend, we assigned the median within 
each quartile and modeled this variable continuously. Furthermore, we also modelled dietary protein 
intake as continuous variable and estimated HRs and 95%CIs per 5 energy percent (E%) increment 
from protein at the expense of carbohydrate.  
For all main analyses, we included intake of protein, SFA, MUFA, PUFA, TSF, total energy, alcohol, 
baseline age, sex, and RS-cohort in model 1; we additionally adjusted for smoking status, education 
level, overall diet quality score, fiber intake, physical activity, and BMI in model 2. For analysis of 
animal and plant protein intake, mutual adjustment for plant and animal protein was performed. 
Sensitivity analyses 
We conducted a series of sensitivity analyses to test robustness of our main results. First, we replaced 
fat intake by carbohydrate in the main models (model 2), to examine whether it made a difference if 
dietary protein was consumed at the expense of fat instead of carbohydrate. Second, we examined if 
the associations of animal protein intake with all-cause and cause-specific mortality differed by protein 
 
 
 
from specific animal food sources, such as meat, dairy, fish, and eggs at expense of carbohydrate. In 
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Chapter 2
62
 
 
 
Data synthesis and analysis 
We conducted highest versus lowest and dose-response meta-analyses, using the most adjusted 
association estimation from each original study. For the main meta-analysis, we estimated pooled RRs 
for highest versus lowest quantile of protein intake using random-effects models.30 Heterogeneity was 
determined using the Cochrane χ2 statistic and the I2 statistic.31 We additionally conducted dose-
response meta-analyses for all-cause, CVD, and cancer mortality, using a generalized least-squares 
regression approach.32 In estimating dose-response trends, several approximations across categories 
of dietary protein intake were applied: the midpoint or mean value of the amount of dietary protein 
intake, distributions of deaths and person years, HR and 95% CI. When sufficient data (n ≥ 5) studies33 
contributed to a dose-response meta-analysis, non-linearity was explored using restricted cubic splines 
with three knots (10%, 50%, and 90%).34 A Wald-type test was used to test statistical significance of 
non-linearity.34  
In the main meta-analyses comparing quantiles, we conducted subgroup analyses stratified by 
geographical study location. As sensitivity analysis, we examined the influence of individual studies on 
the overall risk estimates comparing quantiles by recalculating the pooled estimates after excluding 
one study at a time. As a second set of sensitivity analyses, we additionally incorporated studies 
reporting estimations not expressed in E% in the dose-response meta-analysis, for which we could 
only approximate protein intake in E%.15 Additionally, publication bias was evaluated through a funnel 
plot35 and Egger’s test.36, 37 We used STATA release 12 (Stata Corp, College Station, Texas) for all 
highest versus lowest meta-analyses. The dose-response meta-analysis was conducted with 
“dosresmeta” package34 in R version 3.3.1 (The R Foundation for Statistical Computing, Vienna, 
Austria).  
 
RESULTS 
Results in the Rotterdam Study 
Characteristics of population  
For the 7786 participants of the Rotterdam Study in our current analysis, mean age at baseline was 
63.7 ± 8.7 years, and 60.8% of all participants were female. Furthermore, average total protein intake 
was 85.8 ± 25.1 g/day (16.4% ± 2.3% of total energy), this corresponded to 1.20 ± 0.3 g/kg BW/day, 
which is higher than the recommended intake of 0.8 g/kg BW/day (34). Most protein came from 
animal sources (53.6 ± 19.0 g/day, and 10.3% ± 2.5% of total energy). Compared to participants in 
the lowest quartile of animal protein intake, those in the highest quartile of animal protein had a slightly 
higher BMI, were more often lower educated, and more likely to smoke. In contrast, compared to the 
 
 
 
participants in the lowest quartile of plant protein intake, those in the highest quartile of plant protein 
intake had higher overall diet quality, and were more often highly educated, and less likely to smoke 
(Table 1, Supplemental Table 3). 
Associations of protein intake with all-cause mortality and cause-specific mortality 
During a median follow-up of 13.0 years (25th-75th percentile, 8.3-19.1 years, data on all-cause 
mortality available until May 2018), we documented 3589 deaths. During a median follow-up of 12.8 
years (25th-75th percentile, 8.2-19.0 years, data on cause-specific mortality available until January 
2015), we documented 877 CVD deaths (of which, 594 non-stroke CVD deaths and 283 stroke deaths), 
896 cancer deaths, and 1289 deaths due to other causes (which consisted of various specific causes, 
all with relatively small numbers).  
As shown in Table 2, in multivariable models (Model 2), higher total protein intake was associated 
with higher risk of all-cause mortality, CVD mortality, and non-stroke CVD mortality (e.g. for all-
cause mortality, the highest quartile versus the lowest quartile of total protein intake as percentage of 
energy (Q4 versus Q1), HR: 1.12, 95%CI (1.01, 1.25); per 5 E% increment in total protein, HR: 1.09, 
95%CI (1.02, 1.17); and for CVD mortality, per 5 E% HR: 1.20, 95%CI (1.05, 1.37)). These 
associations were mainly explained by animal protein intake (Table 3) (e.g. Q4 versus Q1, for all-cause 
mortality, 1.18 (1.05, 1.31), for CVD mortality, 1.28 (1.03, 1.60); per 5 E% increment, for all-cause 
mortality, 1.20 (1.05, 1.37); for CVD mortality, 1.19 (1.04, 1.37). Total, or animal protein intake was 
not associated with stroke mortality, cancer mortality, and other mortality. Besides, plant protein 
intake was not associated with all-cause and cause-specific mortality (Tables 2-4).  
Sensitivity analyses  
In the Rotterdam Study, we observed similar results for protein intake and all-cause and cause-specific 
mortality when at the expense of fat instead of carbohydrate (Supplemental Table 4). We also observed 
that higher intake of protein from meat or from dairy was associated higher risk of all-cause mortality 
or CVD mortality (Supplemental Table 5). We observed no interaction effects of protein intake with 
age, BMI, or physical activity, but we did observe a significant interaction effect of animal protein 
intake with sex for all-cause mortality (p value for the interaction term = 0.02). Specifically, the 
association between animal protein intake and all-cause mortality was stronger in male participants 
(Q4 versus Q1: 1.42 (1.20, 1.68), per 5 E% increment: 1.42 (1.13, 1.77)); while the association was null 
in female participants (Q4 versus Q1: 1.01 (0.87, 1.17), per 5 E% increment: 1.04 (0.90, 1.21)). Last, 
the results were similar after excluding deaths cases within the first two years of follow-up 
(Supplemental Table 6). 
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highest versus lowest meta-analyses. The dose-response meta-analysis was conducted with 
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As shown in Table 2, in multivariable models (Model 2), higher total protein intake was associated 
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intake was not associated with all-cause and cause-specific mortality (Tables 2-4).  
Sensitivity analyses  
In the Rotterdam Study, we observed similar results for protein intake and all-cause and cause-specific 
mortality when at the expense of fat instead of carbohydrate (Supplemental Table 4). We also observed 
that higher intake of protein from meat or from dairy was associated higher risk of all-cause mortality 
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age, BMI, or physical activity, but we did observe a significant interaction effect of animal protein 
intake with sex for all-cause mortality (p value for the interaction term = 0.02). Specifically, the 
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Meta-analysis results of the Rotterdam Study and previous prospective cohort studies 
Literature search and characteristics of studies  
In the initial search, we identified 12152 potentially relevant unique citations. After screening and 
detailed full-text assessment, ten previously published articles were eligible for the systematic review.8-
15, 39, 40 Finally, ten previous studies were eligible for the meta-analysis,8-15, 39, 40 resulting in a total of 
eleven prospective studies including the Rotterdam study, with a total number of 350452 participants 
and 64306 deaths (Supplemental Figure 2). The number of participants (from 1100 to 131342) and 
deaths (from 60 to 36115) varied widely across these eleven studies. Median duration of follow-up 
ranged from 12.0 to 28.0 years. Of the eleven studies, eight9-12, 14, 15, 39 were conducted among North 
American and European populations (87% of total participants of this meta-analysis), in which the 
mean or median intake of total protein ranged from around 70 through 93 grams/day, mainly from 
animal protein intake with a mean or median ranging from around 54 through 65 grams/day. Three 
studies were conducted within Japanese populations, with a total of 82171participants.8, 13, 40 Detailed 
characteristics and quality assessment of these studies have been summarized in Table 5 and 
Supplemental Table 7. Overall, all the eleven studies were medium to high quality.  
Meta-analyzed associations for protein intake and all-cause and cause-specific mortality  
Highest versus lowest meta-analysis  
Nine studies8-14, 40 including the Rotterdam Study presented associations of comparing the highest with 
the lowest categories of protein intake with mortality, and thus were summarized into the highest 
versus lowest meta-analysis. Figure 1 shows the results of the highest versus lowest meta-analysis. Of 
the nine studies, six examined associations9, 11, 12, 14, 40 for total protein intake with all-cause mortality 
(59841 all-cause deaths among 247863 participants). Comparing the highest quantile of total protein 
intake with the lowest quantile, the pooled RR was 1.05, 95%CI (1.01, 1.10), I2 = 9.8%, Pheterogeneity = 
0.35 for all-cause mortality. Five studies9, 11, 12, 40 examined associations for total protein and CVD 
mortality (14704 CVD deaths among 245222 participants), with a pooled estimate of 1.08, 95%CI 
(0.98, 1.20), I2 = 20.4%, Pheterogeneity = 0.29. Six studies9-12, 40 examined associations for total protein and 
cancer mortality; and two studies12 on other mortality. For both these outcomes, pooled RRs were 
null (Figure 1A). For animal protein intake, five studies reported associations with all-cause mortality,9, 
12, 14, 40 CVD mortality,8, 9, 12, 40 or cancer mortality,9, 10, 12, 40 and two studies12 with other mortality (Figure 
1B). While null pooled associations were observed for all-cause, cancer, and other mortality, a 
significant pooled RR was observed for CVD mortality: 1.09, 95%CI (1.01, 1.18), I2 = 0.0%, Pheterogeneity 
= 0.43. For plant protein intake, similar studies were included with a pooled RR of 0.93, 95%CI (0.87, 
0.99), I2 = 38.7%, Pheterogeneity = 0.16 for all-cause mortality, and 0.86 (0.73, 1.00), I2= 48.2%, Pheterogeneity 
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Meta-analysis results of the Rotterdam Study and previous prospective cohort studies 
Literature search and characteristics of studies  
In the initial search, we identified 12152 potentially relevant unique citations. After screening and 
detailed full-text assessment, ten previously published articles were eligible for the systematic review.8-
15, 39, 40 Finally, ten previous studies were eligible for the meta-analysis,8-15, 39, 40 resulting in a total of 
eleven prospective studies including the Rotterdam study, with a total number of 350452 participants 
and 64306 deaths (Supplemental Figure 2). The number of participants (from 1100 to 131342) and 
deaths (from 60 to 36115) varied widely across these eleven studies. Median duration of follow-up 
ranged from 12.0 to 28.0 years. Of the eleven studies, eight9-12, 14, 15, 39 were conducted among North 
American and European populations (87% of total participants of this meta-analysis), in which the 
mean or median intake of total protein ranged from around 70 through 93 grams/day, mainly from 
animal protein intake with a mean or median ranging from around 54 through 65 grams/day. Three 
studies were conducted within Japanese populations, with a total of 82171participants.8, 13, 40 Detailed 
characteristics and quality assessment of these studies have been summarized in Table 5 and 
Supplemental Table 7. Overall, all the eleven studies were medium to high quality.  
Meta-analyzed associations for protein intake and all-cause and cause-specific mortality  
Highest versus lowest meta-analysis  
Nine studies8-14, 40 including the Rotterdam Study presented associations of comparing the highest with 
the lowest categories of protein intake with mortality, and thus were summarized into the highest 
versus lowest meta-analysis. Figure 1 shows the results of the highest versus lowest meta-analysis. Of 
the nine studies, six examined associations9, 11, 12, 14, 40 for total protein intake with all-cause mortality 
(59841 all-cause deaths among 247863 participants). Comparing the highest quantile of total protein 
intake with the lowest quantile, the pooled RR was 1.05, 95%CI (1.01, 1.10), I2 = 9.8%, Pheterogeneity = 
0.35 for all-cause mortality. Five studies9, 11, 12, 40 examined associations for total protein and CVD 
mortality (14704 CVD deaths among 245222 participants), with a pooled estimate of 1.08, 95%CI 
(0.98, 1.20), I2 = 20.4%, Pheterogeneity = 0.29. Six studies9-12, 40 examined associations for total protein and 
cancer mortality; and two studies12 on other mortality. For both these outcomes, pooled RRs were 
null (Figure 1A). For animal protein intake, five studies reported associations with all-cause mortality,9, 
12, 14, 40 CVD mortality,8, 9, 12, 40 or cancer mortality,9, 10, 12, 40 and two studies12 with other mortality (Figure 
1B). While null pooled associations were observed for all-cause, cancer, and other mortality, a 
significant pooled RR was observed for CVD mortality: 1.09, 95%CI (1.01, 1.18), I2 = 0.0%, Pheterogeneity 
= 0.43. For plant protein intake, similar studies were included with a pooled RR of 0.93, 95%CI (0.87, 
0.99), I2 = 38.7%, Pheterogeneity = 0.16 for all-cause mortality, and 0.86 (0.73, 1.00), I2= 48.2%, Pheterogeneity 
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= 0.09 for CVD mortality. We observed null associations for plant protein and cancer mortality and 
other mortality (Figure 1C). 
Dose-response meta-analysis 
We performed dose-response meta-analyses based on six studies11-14, 40 (Supplemental Table 8), from 
which sufficient data could be extracted to estimate dose-response estimates. In these studies, the 
median animal protein intake ranged from 4.3 E% through 20.0 E%, and plant protein from 2.6 E% 
through 8.4 E%. We found no evidence for non-linear associations (Wald test: p>0.05). In line with 
the highest versus lowest meta-analysis, we observed a positive linear association between total protein 
intake and all-cause mortality (per 5 E% increment, 1.02 (1.004, 1.04), I2= 37.9%, Pheterogeneity = 0.17), 
mainly driven by animal protein intake and CVD mortality (Per 5 E% increment, 1.05 (1.02, 1.09), I2= 
31.2%, Pheterogeneity = 0.23)) (Supplemental Table 8, and Figure 2A-B). Furthermore, we observed an 
inverse linear association between plant protein intake with all-cause mortality (per 5 E% increment, 
0.87 (0.78, 0.98), I2= 40.0%, Pheterogeneity = 0.17) (Supplemental Table 8, Figure 2C). We observed no 
dose-response associations for the other examined associations (Supplemental Table 8).  
Subgroup and sensitivity meta-analysis 
We observed that several meta-analysis results were modified by geographical study location 
(Supplemental Table 9). For total protein and all-cause mortality and for animal protein and CVD 
mortality, positive associations were observed in North American and European populations, whereas 
null associations were observed in Japanese populations. For plant protein, inverse associations with 
all-cause and CVD mortality were only observed in North American and Japanese populations, but 
not in European populations (Supplemental Table 9). For the sensitivity analyses, as shown in 
Supplemental Table 10, most of the pooled associations were similar after excluding one study at each 
turn; and thus, were not driven by one individual study. For plant protein and CVD mortality, 
excluding the Rotterdam Study substantially reduced the heterogeneity. Supplemental Table 11 shows 
the results of the second set of sensitivity analysis in which we included two additional studies in the 
dose-response meta-analysis that did not report associations for protein in E% but rather in g/day15 
or in SD.39 After incorporating results from the study by Bates et al.39 for total protein intake with all-
cause mortality and CVD mortality, the pooled dose-response association between total protein intake 
and all-cause mortality was null, but with high heterogeneity (I2= 87.8%, Pheterogeneity=0.004) 
(Supplemental Table 11). Estimates for animal and plant protein were not available in this study. After 
incorporating results from the study by Tharrey et al.15 for animal and plant protein and CVD mortality, 
the results remained similar (e.g. for animal protein and CVD mortality: per 5 E% increment, 1.08 
(1.01, 1.16)) (Supplemental Table 11). The appearance of funnel plots was symmetrical for all analyses, 
and Egger’s test results were not significant (Supplemental Figure 3), suggesting no publication bias. 
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= 0.09 for CVD mortality. We observed null associations for plant protein and cancer mortality and 
other mortality (Figure 1C). 
Dose-response meta-analysis 
We performed dose-response meta-analyses based on six studies11-14, 40 (Supplemental Table 8), from 
which sufficient data could be extracted to estimate dose-response estimates. In these studies, the 
median animal protein intake ranged from 4.3 E% through 20.0 E%, and plant protein from 2.6 E% 
through 8.4 E%. We found no evidence for non-linear associations (Wald test: p>0.05). In line with 
the highest versus lowest meta-analysis, we observed a positive linear association between total protein 
intake and all-cause mortality (per 5 E% increment, 1.02 (1.004, 1.04), I2= 37.9%, Pheterogeneity = 0.17), 
mainly driven by animal protein intake and CVD mortality (Per 5 E% increment, 1.05 (1.02, 1.09), I2= 
31.2%, Pheterogeneity = 0.23)) (Supplemental Table 8, and Figure 2A-B). Furthermore, we observed an 
inverse linear association between plant protein intake with all-cause mortality (per 5 E% increment, 
0.87 (0.78, 0.98), I2= 40.0%, Pheterogeneity = 0.17) (Supplemental Table 8, Figure 2C). We observed no 
dose-response associations for the other examined associations (Supplemental Table 8).  
Subgroup and sensitivity meta-analysis 
We observed that several meta-analysis results were modified by geographical study location 
(Supplemental Table 9). For total protein and all-cause mortality and for animal protein and CVD 
mortality, positive associations were observed in North American and European populations, whereas 
null associations were observed in Japanese populations. For plant protein, inverse associations with 
all-cause and CVD mortality were only observed in North American and Japanese populations, but 
not in European populations (Supplemental Table 9). For the sensitivity analyses, as shown in 
Supplemental Table 10, most of the pooled associations were similar after excluding one study at each 
turn; and thus, were not driven by one individual study. For plant protein and CVD mortality, 
excluding the Rotterdam Study substantially reduced the heterogeneity. Supplemental Table 11 shows 
the results of the second set of sensitivity analysis in which we included two additional studies in the 
dose-response meta-analysis that did not report associations for protein in E% but rather in g/day15 
or in SD.39 After incorporating results from the study by Bates et al.39 for total protein intake with all-
cause mortality and CVD mortality, the pooled dose-response association between total protein intake 
and all-cause mortality was null, but with high heterogeneity (I2= 87.8%, Pheterogeneity=0.004) 
(Supplemental Table 11). Estimates for animal and plant protein were not available in this study. After 
incorporating results from the study by Tharrey et al.15 for animal and plant protein and CVD mortality, 
the results remained similar (e.g. for animal protein and CVD mortality: per 5 E% increment, 1.08 
(1.01, 1.16)) (Supplemental Table 11). The appearance of funnel plots was symmetrical for all analyses, 
and Egger’s test results were not significant (Supplemental Figure 3), suggesting no publication bias. 
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Figure 1 A. Total protein and mortality 
Solid dots denote individual HRs, horizontal lines demote individual 95% CIs, open diamonds 
correspond to the pooled RRs including the 95% CIs, p values denote Pheterogeneity values, I-V Subtotal 
denotes fixed-effects analysis, and D+L Subtotal denotes random-effects analysis. Abbreviations: 
CVD mortality, cardiovascular mortality, RR, relative risk; CI, confidential interval 
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Figure 1 A. Total protein and mortality 
Solid dots denote individual HRs, horizontal lines demote individual 95% CIs, open diamonds 
correspond to the pooled RRs including the 95% CIs, p values denote Pheterogeneity values, I-V Subtotal 
denotes fixed-effects analysis, and D+L Subtotal denotes random-effects analysis. Abbreviations: 
CVD mortality, cardiovascular mortality, RR, relative risk; CI, confidential interval 
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Figure 1 B. Animal protein and mortality 
Solid dots denote individual HRs, horizontal lines demote individual 95% CIs, open diamonds 
correspond to the pooled RRs including the 95% CIs, p values denote Pheterogeneity values, I-V Subtotal 
denotes fixed-effects analysis, and D+L Subtotal denotes random-effects analysis. Abbreviations: 
CVD mortality, cardiovascular mortality, RR, relative risk; CI, confidential interval 
  
 
 
 
 
Figure 1 C. Plant protein and mortality 
Solid dots denote individual HRs, horizontal lines demote individual 95% CIs, open diamonds 
correspond to the pooled RRs including the 95% CIs, p values denote Pheterogeneity values, I-V Subtotal 
denotes fixed-effects analysis, and D+L Subtotal denotes random-effects analysis. Abbreviations: 
CVD mortality, cardiovascular mortality, RR, relative risk; CI, confidential interval 
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Figure 1 B. Animal protein and mortality 
Solid dots denote individual HRs, horizontal lines demote individual 95% CIs, open diamonds 
correspond to the pooled RRs including the 95% CIs, p values denote Pheterogeneity values, I-V Subtotal 
denotes fixed-effects analysis, and D+L Subtotal denotes random-effects analysis. Abbreviations: 
CVD mortality, cardiovascular mortality, RR, relative risk; CI, confidential interval 
  
 
 
 
 
Figure 1 C. Plant protein and mortality 
Solid dots denote individual HRs, horizontal lines demote individual 95% CIs, open diamonds 
correspond to the pooled RRs including the 95% CIs, p values denote Pheterogeneity values, I-V Subtotal 
denotes fixed-effects analysis, and D+L Subtotal denotes random-effects analysis. Abbreviations: 
CVD mortality, cardiovascular mortality, RR, relative risk; CI, confidential interval 
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Figure 2. Combined dose–response associations between dietary protein intake with mortality 
(solid line) with 95% conﬁdence intervals (shaded area).  
The median total protein intake ranged from 11.3 through 25.0 E%; the median animal protein intake 
ranged from 4.3 through 20.0 E%, the median plant protein intake ranged from 2.6 through 8.4 E%. 
 
DISCUSSION 
Main findings 
In the Rotterdam Study, we observed that higher total protein intake was associated with higher all-
cause mortality, which was mainly driven by higher animal protein intake and CVD mortality. Plant 
protein intake was not associated with all-cause or cause-specific mortality. A meta-analysis of elven 
prospective cohort studies including the Rotterdam Study corroborated that higher total protein intake 
may increase risk of all-cause mortality, driven by a harmful association between animal protein and 
CVD mortality. Furthermore, our overall meta-analysis also indicated that higher plant protein may 
decrease all-cause mortality and CVD mortality. These overall meta-analysis results were modified by 
geographical study location. As we further observed that the harmful associations of total and animal 
protein were mainly among the North American and European populations, and the inverse 
associations of plant protein were mainly among the North American and Japanese populations.  
Interpretations of our findings 
In contrast to reported beneficial short-term effects of dietary protein intake on weight management, 
and cardiovascular risk factors,2-5 we observed that a higher total protein intake was associated with 
higher all-cause mortality, which was mainly driven by a positive association between animal protein 
intake and CVD mortality.  
A B C 
 
 
 
The findings for higher animal protein intake and higher CVD mortality are supported by several 
biological mechanisms and pathways. First, animal protein is relatively high in dietary branched-chain 
and aromatic amino acids, which may result in insulin resistance41, 42 and overweight,42, 43 via mammalian 
target of rapamycin pathway.44 These are strong risk factors for various cardiometabolic diseases, in 
turn increasing CVD mortality risk.41 Second, higher protein intake, particularly from animal sources, 
may be harmful for kidney function, especially among individuals with impaired kidney function,45 
which presents another risk factor for CVD incidence and mortality.46 Last, the association could be 
fueled or amplified by other components in animal-based foods, such as SFA and sodium from red 
and processed meat, which have both been linked to higher CVD risk.12, 47 To investigate if the 
association of animal protein intake and CVD mortality would differ by more specific CVD causes, 
we further examined non-stroke CVD mortality and stroke mortality in the Rotterdam Study. We 
observed that the association of animal protein and CVD mortality was mainly driven by non-stroke 
CVD mortality, which is in line with previous studies which indicated a lack of association between 
animal protein intake with stroke.40, 48 Moreover, we observed in subgroup analyses that these harmful 
associations were mainly observed in North American and European populations, not in Japanese 
populations. That could be partly explained by different levels and food sources of animal protein 
intake. In the North American12 and European study populations,14 the major animal protein sources 
were red and processed meat, whereas in the Japanese study populations, population levels of animal 
protein intake were lower, and the main animal protein source was fish.40 
For plant protein, we observed inverse associations between plant protein intake and all-cause and 
CVD mortality in the overall meta-analysis. The difference of associations for animal protein and plant 
protein might be explained by their different amino acid composition. Unlike animal protein, plant 
protein is generally low in branched-chain acids and aromatic amino acids,6, 49 thereby, resulting in 
decreased risks of CVD.42 Furthermore, in subgroup analyses, we observed the inverse associations 
existed in North American and Japanese populations, but not in European populations. This may also 
be explained by different dietary plant protein sources among different populations. In the European 
populations, the main source was grains.41 Among the North American populations in the study by 
Song et al, the main plant protein sources were legumes, whole grains and nuts,12 and in the Japanese 
populations in the study by Budhathoki et al,40 the main source was legumes.  
Overall, the evidences provided herein indicates the importance of specific protein sources for overall 
health, especially CVD health, and support a replacement of animal protein intake with plant protein 
intake. For example, in our meta-analysis, we observed that those in the highest quantile of animal 
protein intake, may have an averagely 9% higher CVD mortality risk than those in the lowest quantile. 
Based on reports of the individual studies, we estimated that those in the highest quantile had a median 
animal protein intake of approximately 75 grams/day, and those in the lowest quantile around 38 
grams/day. This suggests that a decrease in animal protein intake from 75 grams/day (e.g. 
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protein might be explained by their different amino acid composition. Unlike animal protein, plant 
protein is generally low in branched-chain acids and aromatic amino acids,6, 49 thereby, resulting in 
decreased risks of CVD.42 Furthermore, in subgroup analyses, we observed the inverse associations 
existed in North American and Japanese populations, but not in European populations. This may also 
be explained by different dietary plant protein sources among different populations. In the European 
populations, the main source was grains.41 Among the North American populations in the study by 
Song et al, the main plant protein sources were legumes, whole grains and nuts,12 and in the Japanese 
populations in the study by Budhathoki et al,40 the main source was legumes.  
Overall, the evidences provided herein indicates the importance of specific protein sources for overall 
health, especially CVD health, and support a replacement of animal protein intake with plant protein 
intake. For example, in our meta-analysis, we observed that those in the highest quantile of animal 
protein intake, may have an averagely 9% higher CVD mortality risk than those in the lowest quantile. 
Based on reports of the individual studies, we estimated that those in the highest quantile had a median 
animal protein intake of approximately 75 grams/day, and those in the lowest quantile around 38 
grams/day. This suggests that a decrease in animal protein intake from 75 grams/day (e.g. 
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corresponding to around 220 grams red meat/day) to 42 grams/day (e.g., around 100 grams red 
meat/day), may attenuate risk of CVD mortality by around 9%, assuming other covariates remain 
stable. However, given that the populations in our meta-analysis were mainly general populations, and 
therefore, our results and public health implications cannot be generalized to patient groups who may 
have other protein requirements. For example, for severely ill patients or elderly, high dietary protein 
intake may be beneficial in recovery or to prevent sarcopenia. 
Strengths and limitations 
Our study has several strengths. First, the Rotterdam Study analysis was based on a prospective design 
and included comprehensive assessments of cause-specific deaths. Second, our meta-analysis is, to our 
knowledge, the first to summarize the associations of specific dietary protein intake with all-cause and 
cause-specific mortality, for which, we not only conducted highest versus lowest meta-analyses, but 
also dose-response meta-analyses. This can help to quantify the associations and test the shape of 
these possible associations. Third, the meta-analysis was based on several prospective cohort studies 
across various populations from different geographical locations. Moreover, the combined sample size 
was large, and the follow-up period was long, resulting in a substantial number of cases. Additionally, 
the cohort studies cohort studies in the meta-analysis were of medium to high quality, and their 
analyses included macronutrient substitution models as well as adjustments for other important 
confounding factors, such as total energy, physical activity, and BMI.  
We also need to acknowledge several limitations. First, the Rotterdam Study and most studies in the 
meta-analysis measured dietary intake data based on self-reported FFQs, 24-hour dietary recalls, or 
food records, for which measurements errors are unavoidable. However, as these methods were 
expected to adequately rank subjects according to food and nutrient intake, we do not expect these 
measurement-errors to have largely affected associations. Second, in all studies except one, dietary 
intake data were measured only once at baseline, and changes in diet over time may affect associations. 
However, our results were generally consistent with results from the only study with repeated dietary 
measurements.12 Third, in the Rotterdam Study analysis, a weak trend of an association between animal 
protein intake and other mortality might exist, but we could not further explore this due to limited 
numbers of cases for death from specific other causes. Fourth, we observed that the geographic study 
location modified the meta-analysis results. However, we could not further conduct subgroup analyses 
or meta-regression to explore other potential sources of the heterogeneity (e.g., age and sex). For 
example, we could not explore possible sex difference. Only two studies including the Rotterdam 
Study reported sex-stratified associations. The Rotterdam Study analysis observed that the association 
between animal protein intake and all-cause mortality, but not CVD mortality, differed by sex in the 
Rotterdam Study, with positive associations only in men. Only one other study examined sex 
differences for this association and observed null associations in both genders. Fifth, since all the 
 
 
 
studies included in the meta-analysis were conducted in general populations, our results may not be 
generalizable to populations with other protein requirements. Last, as a meta-analysis of observational 
studies, the results could be subject to residual or unmeasured confounding. Thus, the associations we 
report should be interpreted with caution. 
In conclusion, our study provides evidence that higher total protein intake is associated with higher 
all-cause mortality, primarily driven by a positive association between animal protein intake and CVD 
mortality. In contrast, higher plant protein intake is associated with lower all-cause and CVD mortality. 
Food source and level of protein intake may play a substantial role as we observed harmful associations 
of total and animal protein mainly in North American and European populations and beneficial 
associations of plant protein mainly in North American and Japanese populations. Further studies in 
other populations with different amounts and food sources of protein intakes or with different protein 
requirements are needed to improve global dietary recommendations and to define optimal ranges 
and sources of protein intake for different populations. 
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numbers of cases for death from specific other causes. Fourth, we observed that the geographic study 
location modified the meta-analysis results. However, we could not further conduct subgroup analyses 
or meta-regression to explore other potential sources of the heterogeneity (e.g., age and sex). For 
example, we could not explore possible sex difference. Only two studies including the Rotterdam 
Study reported sex-stratified associations. The Rotterdam Study analysis observed that the association 
between animal protein intake and all-cause mortality, but not CVD mortality, differed by sex in the 
Rotterdam Study, with positive associations only in men. Only one other study examined sex 
differences for this association and observed null associations in both genders. Fifth, since all the 
 
 
 
studies included in the meta-analysis were conducted in general populations, our results may not be 
generalizable to populations with other protein requirements. Last, as a meta-analysis of observational 
studies, the results could be subject to residual or unmeasured confounding. Thus, the associations we 
report should be interpreted with caution. 
In conclusion, our study provides evidence that higher total protein intake is associated with higher 
all-cause mortality, primarily driven by a positive association between animal protein intake and CVD 
mortality. In contrast, higher plant protein intake is associated with lower all-cause and CVD mortality. 
Food source and level of protein intake may play a substantial role as we observed harmful associations 
of total and animal protein mainly in North American and European populations and beneficial 
associations of plant protein mainly in North American and Japanese populations. Further studies in 
other populations with different amounts and food sources of protein intakes or with different protein 
requirements are needed to improve global dietary recommendations and to define optimal ranges 
and sources of protein intake for different populations. 
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Supplemental Figure 2. Selection of studies for meta-analysis   
Unique references identified through 
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Previous studies included for systematic 
review and meta-analysis (n=10) 
Therefore, a total of 11 studies including 
the Rotterdam Study for meta-analysis 
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Supplemental Figure 3. Funnel plots and Egger’s test results 
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Supplemental Table 1. Missing values in the Rotterdam study (n=7786) 
 Physical activity BMI Education level Smoking status 
RS-I     n=4309 NA=1515 (35.1%) NA=29 (0.67%) NA=23 (0.53%) NA=28 (0.64%) 
RS-II    n=1249 NA=6 (0.48%) NA=4 (0.32%) NA=14 (1.1%) NA=5 (0.40%) 
RS-III  n=2228 NA=195 (8.8%) NA=62 (2.8%) NA=7 (0.31%) NA=6 (0.27%) 
Total    n=7786 NA=1716 (22.0%) NA=95 (1.2%) NA=44 (0.56%) NA=39 (0.50%) 
In our main analyses, only four variables: physical activity, BMI, education level, and smoking status 
were with missing values. Abbreviations: NA, not available, (numbers of participants with missing 
values); BMI, body mass index, RS, Rotterdam Study. 
 
Supplemental Table 2. Detailed search terms and strategies 
Database Search term 
Embase.com ('protein diet'/exp OR 'protein intake'/de OR 'plant protein'/de OR 'red 
meat'/exp OR 'dairy product'/exp OR 'nut'/exp OR 'soybean protein'/exp OR 
'soybean milk'/exp  OR 'protein restriction'/exp OR meat/exp OR (protein/de 
AND 'diet supplementation'/de) OR (((protein*  OR nut OR nuts OR meat) 
NEAR/3 (intake OR diet* OR consum* OR nutrion OR food OR eating OR 
restrict* OR suppl* OR added OR rich OR enrich* OR meal*))  OR red-meat OR 
(milk NOT (breast-milk OR human-milk)) OR dairy OR cheese OR ((plant* OR 
animal OR soy) NEXT/1 protein*) OR yogurt  OR yoghurt ):ab,ti) AND 
('cardiovascular disease'/de OR 'heart failure'/de OR 'congestive heart failure'/de 
OR 'heart disease'/de OR 'coronary artery disease'/de OR 'ischemic heart 
disease'/exp OR 'cerebrovascular accident'/de OR 'atherosclerotic cardiovascular 
disease'/de OR 'brain ischemia'/exp OR 'mortality'/exp OR 'diabetes mellitus'/de 
OR 'non insulin dependent diabetes mellitus'/de  OR 'cardiovascular risk'/de OR 
(((cardiovascular OR coronar*) NEAR/3 (disease* OR event*))  OR cvd OR cvds 
OR ((ischemi* OR ischaemi* OR fail* OR insufficien*) NEAR/3 (heart OR 
cardia*)) OR (cerebrovascular* NEAR/3  accident*) OR cva OR stroke* OR 
((brain OR cerebral) NEAR/3 (ischemi* OR ischaemi*)) OR mortalit* OR 
(diabet* NOT ((type-1 OR type-I OR DM-1 OR DM-I OR t1d OR gestation* OR 
iddm) NOT (type-2 OR type-ii  OR type-2a OR type-iia  OR type-2b OR type-iib  
OR DM-2 OR DM-ii  OR t2d ))) OR niddm OR t2d OR t2dm OR ((chd OR cvd 
OR cardiovascul*) NEAR/3 risk*)):ab,ti) NOT ([animals]/lim NOT 
[humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim 
OR [Editorial]/lim) AND ('cohort analysis'/exp OR 'prospective study'/exp OR 
'longitudinal study'/exp  OR 'retrospective study'/exp OR 'follow up'/de OR 'case 
control study'/exp OR 'cross-sectional study'/exp OR 'clinical study'/exp OR 
'meta analysis'/de OR 'clinical trial'/exp OR 'major clinical study'/de OR ((cross 
NEXT/1 section*) OR (case NEXT/1 control*) OR cohort* OR trial* OR 
((clinical OR prospectiv* OR population* OR observation* OR 
retrospecti*):ab,ti) 
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Supplemental Figure 3. Funnel plots and Egger’s test results 
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Supplemental Table 1. Missing values in the Rotterdam study (n=7786) 
 Physical activity BMI Education level Smoking status 
RS-I     n=4309 NA=1515 (35.1%) NA=29 (0.67%) NA=23 (0.53%) NA=28 (0.64%) 
RS-II    n=1249 NA=6 (0.48%) NA=4 (0.32%) NA=14 (1.1%) NA=5 (0.40%) 
RS-III  n=2228 NA=195 (8.8%) NA=62 (2.8%) NA=7 (0.31%) NA=6 (0.27%) 
Total    n=7786 NA=1716 (22.0%) NA=95 (1.2%) NA=44 (0.56%) NA=39 (0.50%) 
In our main analyses, only four variables: physical activity, BMI, education level, and smoking status 
were with missing values. Abbreviations: NA, not available, (numbers of participants with missing 
values); BMI, body mass index, RS, Rotterdam Study. 
 
Supplemental Table 2. Detailed search terms and strategies 
Database Search term 
Embase.com ('protein diet'/exp OR 'protein intake'/de OR 'plant protein'/de OR 'red 
meat'/exp OR 'dairy product'/exp OR 'nut'/exp OR 'soybean protein'/exp OR 
'soybean milk'/exp  OR 'protein restriction'/exp OR meat/exp OR (protein/de 
AND 'diet supplementation'/de) OR (((protein*  OR nut OR nuts OR meat) 
NEAR/3 (intake OR diet* OR consum* OR nutrion OR food OR eating OR 
restrict* OR suppl* OR added OR rich OR enrich* OR meal*))  OR red-meat OR 
(milk NOT (breast-milk OR human-milk)) OR dairy OR cheese OR ((plant* OR 
animal OR soy) NEXT/1 protein*) OR yogurt  OR yoghurt ):ab,ti) AND 
('cardiovascular disease'/de OR 'heart failure'/de OR 'congestive heart failure'/de 
OR 'heart disease'/de OR 'coronary artery disease'/de OR 'ischemic heart 
disease'/exp OR 'cerebrovascular accident'/de OR 'atherosclerotic cardiovascular 
disease'/de OR 'brain ischemia'/exp OR 'mortality'/exp OR 'diabetes mellitus'/de 
OR 'non insulin dependent diabetes mellitus'/de  OR 'cardiovascular risk'/de OR 
(((cardiovascular OR coronar*) NEAR/3 (disease* OR event*))  OR cvd OR cvds 
OR ((ischemi* OR ischaemi* OR fail* OR insufficien*) NEAR/3 (heart OR 
cardia*)) OR (cerebrovascular* NEAR/3  accident*) OR cva OR stroke* OR 
((brain OR cerebral) NEAR/3 (ischemi* OR ischaemi*)) OR mortalit* OR 
(diabet* NOT ((type-1 OR type-I OR DM-1 OR DM-I OR t1d OR gestation* OR 
iddm) NOT (type-2 OR type-ii  OR type-2a OR type-iia  OR type-2b OR type-iib  
OR DM-2 OR DM-ii  OR t2d ))) OR niddm OR t2d OR t2dm OR ((chd OR cvd 
OR cardiovascul*) NEAR/3 risk*)):ab,ti) NOT ([animals]/lim NOT 
[humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim 
OR [Editorial]/lim) AND ('cohort analysis'/exp OR 'prospective study'/exp OR 
'longitudinal study'/exp  OR 'retrospective study'/exp OR 'follow up'/de OR 'case 
control study'/exp OR 'cross-sectional study'/exp OR 'clinical study'/exp OR 
'meta analysis'/de OR 'clinical trial'/exp OR 'major clinical study'/de OR ((cross 
NEXT/1 section*) OR (case NEXT/1 control*) OR cohort* OR trial* OR 
((clinical OR prospectiv* OR population* OR observation* OR 
retrospecti*):ab,ti) 
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Supplemental Table 2. Detailed search terms and strategies (Continued) 
Database Search term 
Medline ovid
  
 
(Diet, Protein-Restricted/ OR exp Diet, High-Protein/ OR exp Dietary Proteins/ 
OR exp Protein Deficiency/ OR exp Plant Proteins/ OR exp Dairy Products/ OR 
exp nuts/ OR exp Soy Foods/ OR exp meat/ OR (proteins/ AND Dietary 
Supplements/) OR (((protein*  OR nut OR nuts OR meat) ADJ3 (intake OR diet* 
OR consum* OR nutrion OR food OR eating OR restrict* OR suppl* OR added 
OR rich OR enrich* OR meal*))  OR red-meat OR (milk NOT (breast-milk OR 
human-milk)) OR dairy OR cheese OR ((plant* OR animal OR soy) ADJ protein*) 
OR yogurt  OR yoghurt ).ab,ti.) AND (Cardiovascular Diseases/ OR heart failure/ 
OR Heart Diseases/ OR Coronary Artery Disease/ OR exp Myocardial Ischemia/ 
OR stroke/ OR exp brain ischemia/ OR exp mortality/ OR exp Survival/ OR 
diabetes mellitus/ OR Diabetes Mellitus, Type 2/  OR (((cardiovascular OR 
coronar*) ADJ3 (disease* OR event*))  OR cvd OR cvds OR ((ischemi* OR 
ischaemi* OR fail* OR insufficien*) ADJ3 (heart OR cardia*)) OR 
(cerebrovascular* ADJ3  accident*) OR cva OR stroke* OR ((brain OR cerebral) 
ADJ3 (ischemi* OR ischaemi*)) OR mortalit* OR (diabet* NOT ((type-1 OR type-
I OR DM-1 OR DM-I OR t1d OR gestation* OR iddm) NOT (type-2 OR type-ii  
OR type-2a OR type-iia  OR type-2b OR type-iib  OR DM-2 OR DM-ii  OR t2d ))) 
OR niddm OR t2d OR t2dm OR ((chd OR cvd OR cardiovascul*) ADJ3 
risk*)).ab,ti.) NOT (exp animals/ NOT humans/) NOT (letter OR news OR 
comment OR editorial OR congresses OR abstracts).pt. AND (exp Cohort Studies/ 
OR Case-Control Studies/ OR cross-sectional study/ OR Meta-Analysis / OR exp 
clinical trial/ OR ((cross ADJ section*) OR (case ADJ control*) OR cohort* OR 
trial* OR ((clinical OR prospectiv* OR population* OR observation* OR 
retrospecti* OR intervention* ) ADJ3 stud*) OR follow up OR (meta ADJ analy*) 
OR metaanaly* OR trial OR random*).ab,ti.)  
 
Cochrane 
CENTRAL 
((((protein*  OR nut OR nuts OR meat) NEAR/3 (intake OR diet* OR consum* 
OR nutrion OR food OR eating OR restrict* OR suppl* OR added OR rich OR 
enrich* OR meal*))  OR red-meat OR (milk NOT (breast-milk OR human-milk)) 
OR dairy OR cheese OR ((plant* OR animal OR soy) NEXT/1 protein*) OR 
yogurt  OR yoghurt ):ab,ti) AND ((((cardiovascular OR coronar*) NEAR/3 
(disease* OR event*))  OR cvd OR cvds OR ((ischemi* OR ischaemi* OR fail* OR 
insufficien*) NEAR/3 (heart OR cardia*)) OR (cerebrovascular* NEAR/3  
accident*) OR cva OR stroke* OR ((brain OR cerebral) NEAR/3 (ischemi* OR 
ischaemi*)) OR mortalit* OR (diabet* NOT ((type-1 OR type-I OR DM-1 OR 
DM-I OR t1d OR gestation* OR iddm) NOT (type-2 OR type-ii  OR type-2a OR 
type-iia  OR type-2b OR type-iib  OR DM-2 OR DM-ii  OR t2d ))) OR niddm OR 
t2d OR t2dm OR ((chd OR cvd OR cardiovascul*) NEAR/3 risk*)):ab,ti)  
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Supplemental Table 2. Detailed search terms and strategies (Continued) 
Database Search term 
Medline ovid
  
 
(Diet, Protein-Restricted/ OR exp Diet, High-Protein/ OR exp Dietary Proteins/ 
OR exp Protein Deficiency/ OR exp Plant Proteins/ OR exp Dairy Products/ OR 
exp nuts/ OR exp Soy Foods/ OR exp meat/ OR (proteins/ AND Dietary 
Supplements/) OR (((protein*  OR nut OR nuts OR meat) ADJ3 (intake OR diet* 
OR consum* OR nutrion OR food OR eating OR restrict* OR suppl* OR added 
OR rich OR enrich* OR meal*))  OR red-meat OR (milk NOT (breast-milk OR 
human-milk)) OR dairy OR cheese OR ((plant* OR animal OR soy) ADJ protein*) 
OR yogurt  OR yoghurt ).ab,ti.) AND (Cardiovascular Diseases/ OR heart failure/ 
OR Heart Diseases/ OR Coronary Artery Disease/ OR exp Myocardial Ischemia/ 
OR stroke/ OR exp brain ischemia/ OR exp mortality/ OR exp Survival/ OR 
diabetes mellitus/ OR Diabetes Mellitus, Type 2/  OR (((cardiovascular OR 
coronar*) ADJ3 (disease* OR event*))  OR cvd OR cvds OR ((ischemi* OR 
ischaemi* OR fail* OR insufficien*) ADJ3 (heart OR cardia*)) OR 
(cerebrovascular* ADJ3  accident*) OR cva OR stroke* OR ((brain OR cerebral) 
ADJ3 (ischemi* OR ischaemi*)) OR mortalit* OR (diabet* NOT ((type-1 OR type-
I OR DM-1 OR DM-I OR t1d OR gestation* OR iddm) NOT (type-2 OR type-ii  
OR type-2a OR type-iia  OR type-2b OR type-iib  OR DM-2 OR DM-ii  OR t2d ))) 
OR niddm OR t2d OR t2dm OR ((chd OR cvd OR cardiovascul*) ADJ3 
risk*)).ab,ti.) NOT (exp animals/ NOT humans/) NOT (letter OR news OR 
comment OR editorial OR congresses OR abstracts).pt. AND (exp Cohort Studies/ 
OR Case-Control Studies/ OR cross-sectional study/ OR Meta-Analysis / OR exp 
clinical trial/ OR ((cross ADJ section*) OR (case ADJ control*) OR cohort* OR 
trial* OR ((clinical OR prospectiv* OR population* OR observation* OR 
retrospecti* OR intervention* ) ADJ3 stud*) OR follow up OR (meta ADJ analy*) 
OR metaanaly* OR trial OR random*).ab,ti.)  
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((((protein*  OR nut OR nuts OR meat) NEAR/3 (intake OR diet* OR consum* 
OR nutrion OR food OR eating OR restrict* OR suppl* OR added OR rich OR 
enrich* OR meal*))  OR red-meat OR (milk NOT (breast-milk OR human-milk)) 
OR dairy OR cheese OR ((plant* OR animal OR soy) NEXT/1 protein*) OR 
yogurt  OR yoghurt ):ab,ti) AND ((((cardiovascular OR coronar*) NEAR/3 
(disease* OR event*))  OR cvd OR cvds OR ((ischemi* OR ischaemi* OR fail* OR 
insufficien*) NEAR/3 (heart OR cardia*)) OR (cerebrovascular* NEAR/3  
accident*) OR cva OR stroke* OR ((brain OR cerebral) NEAR/3 (ischemi* OR 
ischaemi*)) OR mortalit* OR (diabet* NOT ((type-1 OR type-I OR DM-1 OR 
DM-I OR t1d OR gestation* OR iddm) NOT (type-2 OR type-ii  OR type-2a OR 
type-iia  OR type-2b OR type-iib  OR DM-2 OR DM-ii  OR t2d ))) OR niddm OR 
t2d OR t2dm OR ((chd OR cvd OR cardiovascul*) NEAR/3 risk*)):ab,ti)  
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Supplemental Table 10. Sensitivity analysis for meta-analysis by excluding each one study one 
at a time1 
 RR (95% CI) I2 Pheterogeneity 
Pooled association of total protein and all-cause 
mortality, after excluding 
   
- Kelemen et al, 2005 1.05 (1.00, 1.11) 26.2% 0.73 
- Levine et al, 2014  1.06 (1.01, 1.10) 11.3% 0.31 
- Song et al, 2016  1.05 (0.97, 1.14) 27.8% 0.97 
- Virtanen et al, 2019  1.05 (1.01,1.08) 0% 0.20 
- Budhathoki et al, 2019  1.06 (1.02, 1.10) 0% 0.19 
- Chen et al, 2019 1.04 (1.00, 1.08) 0% 0.21 
Pooled association of total protein and CVD 
mortality, after excluding 
   
- Kelemen et al, 2005  1.08 (0.96, 1.21) 34.1% 0.49 
- Levine et al, 2014  1.11 (1.01, 1.21) 7.4% 0.18 
- Song et al, 2016  1.03 (0.88, 1.21) 23.1% 0.29 
- Budhathoki et al, 2019  1.12 (1.01,1.23) 7.3% 0.18 
- Chen et al, 2019  1.05 (0.93, 1.18) 23.2% 0.29 
Pooled association of total protein and cancer 
mortality, after excluding 
   
- Kelemen et al, 2005  1.01 (0.95, 1.08) 0% 0.19 
- Smit et al, 2007  1.01 (0.95, 1.09) 3.5% 0.30 
- Levine et al, 2014  1.02 (0.94, 1.11) 18.2% 0.57 
- Song et al, 2016  1.01 (0.88, 1.15) 20.6% 0.67 
- Budhathoki et al, 2019  1.02 (0.91,1.14) 22.1% 0.78 
- Chen et al, 2019 1.04 (0.97, 1.11) 0% 0.13 
Pooled associations of animal protein and all-
cause mortality, after excluding 
   
- Kelemen et al, 2005  1.06 (0.98, 1.15) 58.6% 0.06 
- Song et al, 2016  1.05 (0.93, 1.20) 65.8% 0.03 
- Virtanen et al, 2019  1.04 (0.95,1.14) 64.7% 0.04 
- Budhathoki et al, 2019  1.07 (0.97, 1.19) 61.3% 0.05 
- Chen et al, 2019 1.02 (0.96, 1.08) 20.3% 0.28 
Pooled associations of animal protein and CVD 
mortality, after excluding 
   
- Sauvaget et al, 2004  1.09 (0.99, 1.21) 16.8% 0.66 
- Kelemen et al, 2005  1.09 (0.99, 1.21) 13.9% 0.57 
- Song et al, 2016  1.08 (0.90, 1.30) 21.1% 0.97 
- Budhathoki et al, 2019  1.11 (1.02, 1.21) 0% 0.23 
- Chen et al, 2019 1.06 (0.98, 1.16) 0% 0.12 
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Supplemental Table 10. Sensitivity analysis for meta-analysis by excluding each one study one 
at a time1 
 RR (95% CI) I2 Pheterogeneity 
Pooled association of total protein and all-cause 
mortality, after excluding 
   
- Kelemen et al, 2005 1.05 (1.00, 1.11) 26.2% 0.73 
- Levine et al, 2014  1.06 (1.01, 1.10) 11.3% 0.31 
- Song et al, 2016  1.05 (0.97, 1.14) 27.8% 0.97 
- Virtanen et al, 2019  1.05 (1.01,1.08) 0% 0.20 
- Budhathoki et al, 2019  1.06 (1.02, 1.10) 0% 0.19 
- Chen et al, 2019 1.04 (1.00, 1.08) 0% 0.21 
Pooled association of total protein and CVD 
mortality, after excluding 
   
- Kelemen et al, 2005  1.08 (0.96, 1.21) 34.1% 0.49 
- Levine et al, 2014  1.11 (1.01, 1.21) 7.4% 0.18 
- Song et al, 2016  1.03 (0.88, 1.21) 23.1% 0.29 
- Budhathoki et al, 2019  1.12 (1.01,1.23) 7.3% 0.18 
- Chen et al, 2019  1.05 (0.93, 1.18) 23.2% 0.29 
Pooled association of total protein and cancer 
mortality, after excluding 
   
- Kelemen et al, 2005  1.01 (0.95, 1.08) 0% 0.19 
- Smit et al, 2007  1.01 (0.95, 1.09) 3.5% 0.30 
- Levine et al, 2014  1.02 (0.94, 1.11) 18.2% 0.57 
- Song et al, 2016  1.01 (0.88, 1.15) 20.6% 0.67 
- Budhathoki et al, 2019  1.02 (0.91,1.14) 22.1% 0.78 
- Chen et al, 2019 1.04 (0.97, 1.11) 0% 0.13 
Pooled associations of animal protein and all-
cause mortality, after excluding 
   
- Kelemen et al, 2005  1.06 (0.98, 1.15) 58.6% 0.06 
- Song et al, 2016  1.05 (0.93, 1.20) 65.8% 0.03 
- Virtanen et al, 2019  1.04 (0.95,1.14) 64.7% 0.04 
- Budhathoki et al, 2019  1.07 (0.97, 1.19) 61.3% 0.05 
- Chen et al, 2019 1.02 (0.96, 1.08) 20.3% 0.28 
Pooled associations of animal protein and CVD 
mortality, after excluding 
   
- Sauvaget et al, 2004  1.09 (0.99, 1.21) 16.8% 0.66 
- Kelemen et al, 2005  1.09 (0.99, 1.21) 13.9% 0.57 
- Song et al, 2016  1.08 (0.90, 1.30) 21.1% 0.97 
- Budhathoki et al, 2019  1.11 (1.02, 1.21) 0% 0.23 
- Chen et al, 2019 1.06 (0.98, 1.16) 0% 0.12 
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Supplemental Table 10. Sensitivity analysis for meta-analysis by excluding each one study one 
at a time1 (Continued) 
 RR (95% CI) I2 Pheterogeneity 
Pooled associations of animal protein and cancer 
mortality, after excluding 
   
- Kelemen et al, 2005  1.01 (0.94, 1.08) 0% 0.93 
- Smit et al, 2007  1.01 (0.94, 1.08) 0% 0.99 
- Song et al, 2016  0.98 (0.87, 1.10) 0% 0.60 
- Budhathoki et al, 2019  1.02 (0.94, 1.09) 0% 0.61 
- Chen et al, 2019 1.01 (0.94, 1.08) 0% 0.80 
Pooled associations of plant protein and all-
cause mortality, after excluding 
   
- Kelemen et al. 2005  0.93 (0.85, 1.01) 51.9% 0.10 
- Song et al, 2016  0.95 (0.86, 1.05) 42.4% 0.16 
- Virtanen et al, 2019  0.93 (0.86,1.00) 51.9% 0.10 
- Budhathoki et al, 2019  0.95 (0.87, 1.04) 44.5% 0.14 
- Chen et al, 2019 0.90 (0.85, 0.94) 0% 0.69 
Pooled associations of plant protein and CVD 
mortality, after excluding 
   
- Sauvaget et al, 2004  0.84 (0.71, 1.00) 55.5% 0.06 
- Kelemen et al, 2005  0.88 (0.74, 1.05) 52.4% 0.08 
- Song et al, 2016  0.86 (0.68, 1.09) 58.6% 0.05 
- Kurihara et al, 2019  0.87 (0.72, 1.04) 58.1% 0.05 
- Budhathoki et al, 2019  0.90 (0.75, 1.07) 45.4% 0.12 
- Chen et al, 2019 0.81 (0.73, 0.90) 0% 0.57 
Pooled associations of plant protein and cancer 
mortality, after excluding 
   
- Kelemen et al, 2005  0.95 (0.87, 1.04) 0% 0.66 
- Smit et al, 2007  0.96 (0.89, 1.04) 0% 0.48 
- Song et al, 2016  1.00 (0.91, 1.10) 0% 0.28 
- Budhathoki et al, 2019  0.95 (0.87, 1.03) 0% 0.33 
- Chen et al, 2019 0.97 (0.90, 1.05) 0% 0.59 
Effect estimates are Risk ratios (RRs) and 95% confidence intervals (95%CIs) derived from random-
effect highest versus lowest meta-analysis. 1This sensitivity analysis was not conducted for other 
mortality, because there were only two studies this outcome. 
  
 
 
 
Supplemental Table 11. Sensitivity analysis of dose-response meta-analysis 
 RR (95% CI) I2 Pheterogeneity 
Total protein and all-cause mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
1.02 (1.004, 1.04) 37.9% 0.17 
The result from the study by Bates et al (Per 5 
E%) 
0.86 (0.77, 0.97) - - 
Pooled results (Per 5 E%) 0.94 (0.80, 1.12) 87.8% 0.004 
Total protein and CVD mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
1.04 (0.997, 1.09) 37.4% 0.19 
The result from the study by Bates et al (Per 5 
E%) 
0.79 (0.67, 0.94) - - 
Pooled results (Per 5 E%) 0.91 (0.70, 1.20) 89.4% 0.002 
Animal protein and CVD mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
1.05 (1.02, 1.09) 31.2% 0.23 
The result from the study by Tharrey et al (Per 5 
E%) 
1.12 (1.05, 1.19) - - 
Pooled results (Per 5 E%) 1.08 (1.01, 1.16) 68.6% 0.07 
Plant protein and CVD mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
0.77 (0.52, 1.16) 73.2% 0.01 
The result from the study by Tharrey (Per 5 E%) 0.95 (0.89, 1.05) - - 
Pooled results (Per 5 E%) 0.94 (0.87, 1.01) 2.3% 0.31 
Effect estimates are Risk ratios (RRs) and 95%-confidence intervals (95%CIs) derived from random-
effects meta-analysis. 
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Supplemental Table 10. Sensitivity analysis for meta-analysis by excluding each one study one 
at a time1 (Continued) 
 RR (95% CI) I2 Pheterogeneity 
Pooled associations of animal protein and cancer 
mortality, after excluding 
   
- Kelemen et al, 2005  1.01 (0.94, 1.08) 0% 0.93 
- Smit et al, 2007  1.01 (0.94, 1.08) 0% 0.99 
- Song et al, 2016  0.98 (0.87, 1.10) 0% 0.60 
- Budhathoki et al, 2019  1.02 (0.94, 1.09) 0% 0.61 
- Chen et al, 2019 1.01 (0.94, 1.08) 0% 0.80 
Pooled associations of plant protein and all-
cause mortality, after excluding 
   
- Kelemen et al. 2005  0.93 (0.85, 1.01) 51.9% 0.10 
- Song et al, 2016  0.95 (0.86, 1.05) 42.4% 0.16 
- Virtanen et al, 2019  0.93 (0.86,1.00) 51.9% 0.10 
- Budhathoki et al, 2019  0.95 (0.87, 1.04) 44.5% 0.14 
- Chen et al, 2019 0.90 (0.85, 0.94) 0% 0.69 
Pooled associations of plant protein and CVD 
mortality, after excluding 
   
- Sauvaget et al, 2004  0.84 (0.71, 1.00) 55.5% 0.06 
- Kelemen et al, 2005  0.88 (0.74, 1.05) 52.4% 0.08 
- Song et al, 2016  0.86 (0.68, 1.09) 58.6% 0.05 
- Kurihara et al, 2019  0.87 (0.72, 1.04) 58.1% 0.05 
- Budhathoki et al, 2019  0.90 (0.75, 1.07) 45.4% 0.12 
- Chen et al, 2019 0.81 (0.73, 0.90) 0% 0.57 
Pooled associations of plant protein and cancer 
mortality, after excluding 
   
- Kelemen et al, 2005  0.95 (0.87, 1.04) 0% 0.66 
- Smit et al, 2007  0.96 (0.89, 1.04) 0% 0.48 
- Song et al, 2016  1.00 (0.91, 1.10) 0% 0.28 
- Budhathoki et al, 2019  0.95 (0.87, 1.03) 0% 0.33 
- Chen et al, 2019 0.97 (0.90, 1.05) 0% 0.59 
Effect estimates are Risk ratios (RRs) and 95% confidence intervals (95%CIs) derived from random-
effect highest versus lowest meta-analysis. 1This sensitivity analysis was not conducted for other 
mortality, because there were only two studies this outcome. 
  
 
 
 
Supplemental Table 11. Sensitivity analysis of dose-response meta-analysis 
 RR (95% CI) I2 Pheterogeneity 
Total protein and all-cause mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
1.02 (1.004, 1.04) 37.9% 0.17 
The result from the study by Bates et al (Per 5 
E%) 
0.86 (0.77, 0.97) - - 
Pooled results (Per 5 E%) 0.94 (0.80, 1.12) 87.8% 0.004 
Total protein and CVD mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
1.04 (0.997, 1.09) 37.4% 0.19 
The result from the study by Bates et al (Per 5 
E%) 
0.79 (0.67, 0.94) - - 
Pooled results (Per 5 E%) 0.91 (0.70, 1.20) 89.4% 0.002 
Animal protein and CVD mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
1.05 (1.02, 1.09) 31.2% 0.23 
The result from the study by Tharrey et al (Per 5 
E%) 
1.12 (1.05, 1.19) - - 
Pooled results (Per 5 E%) 1.08 (1.01, 1.16) 68.6% 0.07 
Plant protein and CVD mortality    
The main dose-response meta-analysis results (Per 
5 E%) 
0.77 (0.52, 1.16) 73.2% 0.01 
The result from the study by Tharrey (Per 5 E%) 0.95 (0.89, 1.05) - - 
Pooled results (Per 5 E%) 0.94 (0.87, 1.01) 2.3% 0.31 
Effect estimates are Risk ratios (RRs) and 95%-confidence intervals (95%CIs) derived from random-
effects meta-analysis. 
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ABSTRACT  
Background: Vegan or vegetarian diets have been suggested to reduce type 2 diabetes (T2D) risk. 
However, not much is known on whether variation in the degree of having a plant-based versus 
animal-based diet may be beneficial for prevention of T2D.  
Objectives: We aimed to investigate whether level of adherence to a diet high in plant-based foods 
and low in animal-based foods is associated with insulin resistance, prediabetes, and T2D. 
Methods: Our analysis included 6798 participants (62.7 ± 7.8 years) from the Rotterdam Study (RS), 
a prospective population-based cohort in the Netherlands. Dietary intake data were collected with 
food-frequency questionnaires at baseline of three sub-cohorts of RS (RS-I-1: 1989-93, RS-II-1: 2000-
01, RS-III-1: 2006-08). We constructed a continuous plant-based dietary index (range 0-92) assessing 
adherence to a plant-based versus animal-based diet. Insulin resistance at baseline and follow-up was 
assessed using homeostasis model assessment of insulin resistance (HOMA-IR). Prediabetes and T2D 
were collected from general practitioners’ records, pharmacies’ databases, and follow-up examinations 
in our research center until 2012. We used multivariable linear mixed models to examine association 
of the index with longitudinal HOMA-IR, and multivariable Cox proportional-hazards regression 
models to examine associations of the index with risk of prediabetes and T2D. 
Results: During median 5.7 years, and 7.3 years of follow-up, we documented 928 prediabetes cases 
and 642 T2D cases. After adjusting for sociodemographic and lifestyle factors, a higher score on the 
plant-based dietary index was associated with lower insulin resistance (per 10 units higher score: β= -
0.09, 95% CI: -0.10, -0.08), lower prediabetes risk (HR=0.89, 95% CI: 0.81, 0.98), and lower T2D risk 
(HR=0.82 (0.73, 0.92)). After additional adjustment for BMI, associations attenuated and remained 
statistically significant for longitudinal insulin resistance (β= -0.05 (-0.06, -0.04)) and T2D risk 
(HR=0.87 (0.79, 0.99)), but no longer for prediabetes risk (HR=0.93 (0.85, 1.03)).  
Conclusions: A more plant-based and less animal-based diet may lower risk of insulin resistance, 
prediabetes and T2D. These findings strengthen recent dietary recommendations to adopt a more 
plant-based diet. 
 
 
 
 
 
 
 
 
INTRODUCTION  
Diet is an important modifiable lifestyle determinant in the development of type 2 diabetes (T2D).1 
Among these dietary determinants, several plant-based foods such as root vegetables, green leafy 
vegetables, whole grains, nuts and peanut butter, have been associated with a lower risk of T2D.2-5 By 
contrast, several animal-based foods, including red meat, processed meat, and daily consumption of 
eggs have been associated with an increased risk of T2D.4, 6, 7 
Although multiple food groups seem to influence the risk of T2D, humans generally do not consume 
single food items or food groups, and the role of diet in health may be better described by overall 
dietary patterns.8 Previous studies have observed that vegan or vegetarian diets are associated with 
improved glycemic control9 and lower T2D risk.10 However, these previous studies dichotomously 
classified participants, and only defined diets as vegetarian or vegan versus non-vegetarian diets. A 
dichotomous classification of vegans or vegetarians versus their non-vegetarian counterparts might 
not be an optimal approach in understanding the effect of a plant-based diet in Western countries, 
because it does not reflect dietary patterns of a large proportion of the population. For public health 
advice, it is interesting to know if a more plant-based and less animal-based diet may also influence 
insulin resistance and risk of prediabetes and T2D beyond strict adherence to a vegetarian or vegan 
diet. To our knowledge, only one previous study, a large prospective cohort study in the US, examined 
associations between variations in the degree of adherence to plant-based versus animal-based diets 
with T2D risk and observed that a more plant-based diet was associated with a lower T2D risk.11 
Studies on the associations of such plant-based dietary patterns with T2D risk in other populations 
are needed. In addition, the association of such plant-based dietary patterns with intermediate risk 
factors for T2D, such as insulin resistance and prediabetes remain unknown.  
Therefore, we aimed to investigate whether adherence to a more plant-based, and less animal-based 
diet is associated with insulin resistance, and risk of prediabetes and T2D in a Dutch middle-aged and 
older general population. 
 
METHODS  
Study population  
This study was carried out within three sub-cohorts of the Rotterdam Study (RS), a prospective cohort 
study of adult aged 45 years and older living in the well-defined district of Ommoord in Rotterdam, 
the Netherlands. A detailed description of the Rotterdam Study methodology is described elsewhere.12 
Briefly, recruitment of participants for the first sub-cohort (RS-I) started in the period of 1989-93 
among inhabitants aged ≥ 55 years (n=7983). In 2000-01, the study was extended with a second sub-
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ABSTRACT  
Background: Vegan or vegetarian diets have been suggested to reduce type 2 diabetes (T2D) risk. 
However, not much is known on whether variation in the degree of having a plant-based versus 
animal-based diet may be beneficial for prevention of T2D.  
Objectives: We aimed to investigate whether level of adherence to a diet high in plant-based foods 
and low in animal-based foods is associated with insulin resistance, prediabetes, and T2D. 
Methods: Our analysis included 6798 participants (62.7 ± 7.8 years) from the Rotterdam Study (RS), 
a prospective population-based cohort in the Netherlands. Dietary intake data were collected with 
food-frequency questionnaires at baseline of three sub-cohorts of RS (RS-I-1: 1989-93, RS-II-1: 2000-
01, RS-III-1: 2006-08). We constructed a continuous plant-based dietary index (range 0-92) assessing 
adherence to a plant-based versus animal-based diet. Insulin resistance at baseline and follow-up was 
assessed using homeostasis model assessment of insulin resistance (HOMA-IR). Prediabetes and T2D 
were collected from general practitioners’ records, pharmacies’ databases, and follow-up examinations 
in our research center until 2012. We used multivariable linear mixed models to examine association 
of the index with longitudinal HOMA-IR, and multivariable Cox proportional-hazards regression 
models to examine associations of the index with risk of prediabetes and T2D. 
Results: During median 5.7 years, and 7.3 years of follow-up, we documented 928 prediabetes cases 
and 642 T2D cases. After adjusting for sociodemographic and lifestyle factors, a higher score on the 
plant-based dietary index was associated with lower insulin resistance (per 10 units higher score: β= -
0.09, 95% CI: -0.10, -0.08), lower prediabetes risk (HR=0.89, 95% CI: 0.81, 0.98), and lower T2D risk 
(HR=0.82 (0.73, 0.92)). After additional adjustment for BMI, associations attenuated and remained 
statistically significant for longitudinal insulin resistance (β= -0.05 (-0.06, -0.04)) and T2D risk 
(HR=0.87 (0.79, 0.99)), but no longer for prediabetes risk (HR=0.93 (0.85, 1.03)).  
Conclusions: A more plant-based and less animal-based diet may lower risk of insulin resistance, 
prediabetes and T2D. These findings strengthen recent dietary recommendations to adopt a more 
plant-based diet. 
 
 
 
 
 
 
 
 
INTRODUCTION  
Diet is an important modifiable lifestyle determinant in the development of type 2 diabetes (T2D).1 
Among these dietary determinants, several plant-based foods such as root vegetables, green leafy 
vegetables, whole grains, nuts and peanut butter, have been associated with a lower risk of T2D.2-5 By 
contrast, several animal-based foods, including red meat, processed meat, and daily consumption of 
eggs have been associated with an increased risk of T2D.4, 6, 7 
Although multiple food groups seem to influence the risk of T2D, humans generally do not consume 
single food items or food groups, and the role of diet in health may be better described by overall 
dietary patterns.8 Previous studies have observed that vegan or vegetarian diets are associated with 
improved glycemic control9 and lower T2D risk.10 However, these previous studies dichotomously 
classified participants, and only defined diets as vegetarian or vegan versus non-vegetarian diets. A 
dichotomous classification of vegans or vegetarians versus their non-vegetarian counterparts might 
not be an optimal approach in understanding the effect of a plant-based diet in Western countries, 
because it does not reflect dietary patterns of a large proportion of the population. For public health 
advice, it is interesting to know if a more plant-based and less animal-based diet may also influence 
insulin resistance and risk of prediabetes and T2D beyond strict adherence to a vegetarian or vegan 
diet. To our knowledge, only one previous study, a large prospective cohort study in the US, examined 
associations between variations in the degree of adherence to plant-based versus animal-based diets 
with T2D risk and observed that a more plant-based diet was associated with a lower T2D risk.11 
Studies on the associations of such plant-based dietary patterns with T2D risk in other populations 
are needed. In addition, the association of such plant-based dietary patterns with intermediate risk 
factors for T2D, such as insulin resistance and prediabetes remain unknown.  
Therefore, we aimed to investigate whether adherence to a more plant-based, and less animal-based 
diet is associated with insulin resistance, and risk of prediabetes and T2D in a Dutch middle-aged and 
older general population. 
 
METHODS  
Study population  
This study was carried out within three sub-cohorts of the Rotterdam Study (RS), a prospective cohort 
study of adult aged 45 years and older living in the well-defined district of Ommoord in Rotterdam, 
the Netherlands. A detailed description of the Rotterdam Study methodology is described elsewhere.12 
Briefly, recruitment of participants for the first sub-cohort (RS-I) started in the period of 1989-93 
among inhabitants aged ≥ 55 years (n=7983). In 2000-01, the study was extended with a second sub-
Chapter 2
112
 
 
 
cohort (RS-II) of new individuals (n=3011) who had become 55 years of age or moved into the study 
area after 1990. In 2006-08, a third sub-cohort (RS-III) was recruited with new individuals aged 45 
years and older (n=3932). By the end of 2008, the overall study population contained 14926 
participants. Upon entering the study, participants underwent home interviews and a series of 
examinations in our research center every 3-5 year.  
The Rotterdam Study has been approved by the institutional review board (Medical Ethics Committee) 
of Erasmus Medical Center and by the review board of The Netherlands Ministry of Health, Welfare 
and Sports. The approval has been renewed every 5 years. All participants gave informed consent. 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Participants selection 
 
Population for current analyses  
For the current study, we used data from all three sub-cohorts (Figure 1). Of the 14926 participants, 
we excluded those without valid dietary data (no dietary data (n=5141) or unreliable dietary intake 
according to a trained nutritionist or an estimated energy intake of <500 or >5000 kcal/day (n=84)13) 
at baseline (RS-I-1: 1989-93, RS-II-1: 2000-01, RS-III-1: 2006-08), and those without diabetes 
information or with prevalent T2D at baseline (n=2903), leaving 6798 participants included as main 
population for analysis.  
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From this group of 6798 participants, 6514 participants had data on HOMA-IR before onset of T2D 
and were included in the longitudinal HOMA-IR analyses. For the analyses on prediabetes risk, we 
excluded those with prevalent prediabetes at baseline (n=1005) or without follow-up of prediabetes 
(n=25), leaving 5768 participants. In the analyses assessing risk of T2D, we excluded participants 
without follow-up of T2D (n=28), leaving 6770 participants. The flow-diagram of the included 
participants is presented in Figure 1. 
Dietary assessment 
Dietary intake was assessed at baseline in all three sub-cohorts using semi-quantitative food-frequency 
questionnaires (FFQ) as described in more detail elsewhere.13 We used an FFQ with 170 food items 
to assess dietary intake at baseline of RS-I (1989-93) and RS-II (2000-01);14 and at baseline of RS-III 
(2006-08) we used an FFQ with 389 food items.15 The 170-item FFQ was validated in a subsample of 
the Rotterdam Study (n=80) against fifteen 24-h food records and four 24h urinary urea excretion 
samples;14 and the 389-item FFQ was previously validated in other Dutch population against 
measurement of biomarkers, against a 9-day dietary record, and against a 4 week dietary history.16 In 
general, the validation studies demonstrated that the FFQs were able to adequately rank participants 
according to their intake.13 Food intake data were converted to energy and nutrient intake based on 
Dutch Food Composition tables (NEVO).  
Plant-based dietary index 
We constructed an overall plant-based dietary index, which was a modified version of two previously 
created indices.11, 17 More specifically, our index is similar to the “provegetarian food pattern” of 
Martínez-Gonzáles et al.17 and to the “overall plant-based diet index” of Satija et al.,11 but was adapted 
to include slightly different types and numbers of food categories.  
First, the food items as measured by the FFQs were divided into 23 food categories (Supplemental 
Table 1), on the basis of the main food groups in the Dutch diet and the Dutch food-based dietary 
guidelines.18, 19 Twelve of the categories were plant-based and eleven were animal-based. Food items 
that were not clearly animal-based or plant-based, such as pizza, as well dietary supplements, were not 
included in the food categories for the index. 
Dietary intake for each of the 23 food categories (g/d) was calculated for each participant. 
Subsequently, for each category, the intake was divided into cohort-specific quintiles. Each quintile 
was assigned a value between 0 and 4. For the twelve plant-based food categories, consumption within 
the highest quintile was scored a 4, consumption within the second highest quintile was scored a 3, 
and so on, ending with consumption within the lowest quintile receiving a score of 0. The eleven 
animal-based food categories were scored reversely: consumption within the highest quintile was 
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scored a 0 consumption within the second highest quintile was scored a 1, ending with consumption 
within the lowest quintile receiving a score of 4. Furthermore, we ensured that all participants with 
null consumption were given the score belonging to the lowest quintile by re-scoring when necessary.  
Finally, these category quintile-scores were added up for per participant to create their overall score 
on the plant-based dietary index. The resulting index yielded a score for each participant that measured 
adherence to a plant-based versus animal-based diet on a continuous scale, with a lowest possible 
score of 0 (low adherence to a plant-based diet) and a highest possible score of 92 (high adherence: 
high plant-based and low animal-based). Information on intake of each food category across quintiles 
of scores on the plant-based dietary index is shown in Supplemental Table 2. 
Assessment of insulin resistance 
Fasting blood samples were collected at RS-I (RS-I-3: 1997-99, RS-I-5: 2009-10), RS-II (RS-II-1: 2000-
01, RS-II-3: 2010-11), and RS-III (RS-III-1: 2006-08, RS-III-2: 2011-12). Glucose levels were 
examined with the glucose hexokinase method. Serum insulin was measured by electro 
chemiluminescence immunoassay technology. Insulin resistance was calculated using the homeostasis 
model assessment of insulin resistance (HOMA-IR). The following formula was used: fasting insulin 
(mU/L) × fasting glucose (mmol/L) / 22.5. 
Assessment of prediabetes and type 2 diabetes 
Information on prediabetes and T2D was collected from general practitioners’ records, pharmacies’ 
databases, and follow-up examinations in our research center. Data of prediabetes and T2D in our 
analyses were collected until January 1, 2012. Prediabetes and T2D were identified according to WHO 
criteria: prediabetes was defined as a fasting blood glucose concentration of > 6.0 and < 7.0 mmol/L, 
or a non-fasting blood glucose concentration of > 7.7 mmol/L and < 11.1 mmol/L; T2D was defined 
as a fasting blood glucose concentration of ≥ 7.0 mmol/L, a non-fasting blood glucose concentration 
of ≥ 11.1 mmol/L (when fasting samples were unavailable), or the use of blood glucose-lowering 
drugs or dietary treatment and registration of the diagnosis diabetes. All possible cases of prediabetes 
and T2D were formally judged by two independently working study physicians or, in case of 
disagreement, by an endocrinologist.20  
Assessment of covariates  
Information on age, sex, smoking status, educational level, medication use, food supplement use, and 
family history of diabetes, was obtained from questionnaires at baseline. Information on physical 
activity was obtained using the adapted version of the Zutphen Physical Activity Questionnaire at RS-
I-3 and RS-II-1 and using the LASA Physical Activity Questionnaire at RS-III-1. Physical activities 
were weighted according to intensity with Metabolic Equivalent of Task (MET), from the 
 
 
 
Compendium of Physical Activities version 2011. To account for differences between the two 
questionnaires, questionnaire-specific z-scores of MET-hours per week were calculated. At our 
research center at baseline, body weight was measured using a digital scale and body height was 
measured using a stadiometer, while participants wore light clothing and no shoes, and BMI was 
calculated (kg/m2). Information on hypertension, hypercholesterolemia, coronary heart disease 
(CHD), cancers, and stroke was obtained from general practitioners, pharmacies’ databases, 
Nationwide Medical Register, or follow-up examinations in our research center.  
Data analysis  
To obtain a normal distribution for HOMA-IR, we applied a natural-log transformation. Non-linearity 
of associations of score on the plant-based dietary index with all outcomes were explored using natural 
cubic splines (degrees of freedom = 3). As no indications for non-linear associations for the main 
models were found, all primary analyses were performed using models assuming linearity. We 
examined the association between score on the plant-based dietary index with longitudinal HOMA-
IR using linear mixed models, with a random-effects structure including a random intercept and slope 
(for time of repeated measurements of HOMA-IR). We examined the association between score on 
the plant-based dietary index and risk of prediabetes and risk of T2D using Cox proportional-hazards 
regressions. Hazard ratios (HRs) and regression coefficients (βs) were presented per 10 units higher 
score on the plant-based dietary index, along with the corresponding 95% confidence intervals (CIs). 
All analyses were performed in participants of the three sub-cohorts combined and in the three sub-
cohorts separately.  
All analyses were adjusted for energy intake, age, sex and RS sub-cohort in model 1, and for the 
analyses of longitudinal HOMA-IR we additionally adjusted for the time of repeated measurements 
of HOMA-IR. In model 2, we additionally adjusted for smoking status, educational level, physical 
activity, food supplement use, and family history of diabetes. Baseline BMI was added to model 3 to 
examine its potential mediating effect. 
We examined effect modification by including interactions of the plant-based index with age, sex, or 
BMI for all outcomes in model 2. 
Several sensitivity analyses were performed based on model 2. First, to check if the associations were 
driven by any specific components of the plant-based dietary index, we repeated our main analyses by 
excluding each one of the 23 components from the plant-based dietary index one by one at a time, 
and additionally adjusting for the excluded component. Second, to check if the associations were 
mainly driven by plant-based beverages combined, we examined the associations by excluding all 
plant-based beverages combined (category “coffee and tea”, category “alcoholic beverages”, and 
category “sugary beverages”) from the plant-based dietary index at a time, and additionally adjusting 
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for them. Third, we examined the associations by excluding less healthy plant-based foods combined 
(category “sweets”, category “sugary beverages”, category “potatoes”, and category “refined grains”) 
from the plant-based dietary index at a time, and additionally adjusting for them. To further examine 
whether these less healthy plant foods contributed to the association of the plant-based dietary index; 
we created a less healthy plant foods score, for which, positive scores were given to these four types 
of less healthy plant-based food groups; and reverse scores were given to healthy plant food groups 
and animal food groups.21 Fourth, to examine if potential associations of the plant-based dietary score 
with outcomes were independent of overall quality of the diet based on adherence to dietary guidelines, 
we examined the correlation between the plant-based dietary score and the dietary guidelines score; 
and we repeated analyses with additional adjustment for dietary guidelines score. Fifth, we additionally 
adjusted for hypertension and hypercholesterolemia. Sixth, we excluded the participants with chronic 
diseases at baseline, such as participants with CHD, cancers, or stroke, to exclude the possibility of a 
significant change of diet and lifestyle at follow-up. Last, we excluded the participants who developed 
prediabetes and T2D in the first 2 years of follow-up in the analyses for risk of prediabetes and T2D, 
respectively.  
Missing values on covariates (ranging from 0.3% to 3.9%) were accounted for using multiple 
imputations (n=10 imputations). We used SPSS version 21 (IBM Corp., Armonk, NY, USA) and R 
version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) to perform these analyses.  
 
RESULTS  
Baseline characteristics  
Baseline characteristics of the study population are shown in Table 1. In our population of 6798 
participants, baseline scores on the plant-based dietary index (with a theoretical range from 0 to 92) 
ranged from 24 to 75, with a mean ± SD score of 49.3 ± 7.1. Mean age of the study population was 
62.0 ± 7.8 years and 41.3% of the participants were male. Mean BMI was 26.6 ± 3.9 kg/m2. 
Characteristics were similar before and after multiple imputation (Supplemental Table 3). 
Supplemental Table 4 shows baseline characteristics of the participants not included in our analyses.  
 
  
 
 
 
Table 1. Baseline characteristics of study participants (n=6798) 
Characteristics Mean (SD), median (IQR), or % 
Age (years) 62.0 (7.8) 
Sex (% male) 41.3 % 
BMI (kg/m2) 26.6 (3.9) 
Smoking (%) 
 
- Never 32.2 % 
- Ever 45.1 % 
- Current 22.7 % 
Physical activity1 (MET-hours/week) 
 
- RS-I and RS-II (Zutphen Questionnaire, n=4393) 86.7 (44.7) 
- RS-III (LASA Questionnaire, n=2194) 58.4 (55.8) 
Hypertension (%) 42.3 % 
Hypercholesterolemia (%) 45.4 % 
Family history of diabetes (%) 10.8 % 
Highest level of education (%)  
- Primary  11.8 % 
- Lower 40.9 % 
- Intermediate 29.0 % 
- Higher  18.3 % 
Current food supplement use (%) 16.5 % 
Total energy intake (kcal/day) 2134 (615) 
Plant-based food category intake (grams/day)  
- Fruit 212.2 (115.5, 332.3) 
- Vegetables 209.1 (147.9, 286.87) 
- Whole grains 105.7 (61.3, 152.5) 
- Nuts 3.9 (0.0, 12.0) 
- Legumes 4.1 (0.0, 19.4) 
- Potatoes 99.7 (61.4, 148.2) 
- Vegetable oils 19.7 (9.2, 30.0) 
- Tea and coffee 758.9 (580.4, 1000) 
- Sugary beverages 46.3 (0.0, 139.6) 
- Refined grains 50.7 (23.9, 102.1) 
- Sweets 63.8 (37.1, 97.4) 
- Alcoholic beverages 56.4 (4.9, 159.8) 
Animal-based food category intake (grams/day)  
- Low-fat milk 82.3 (0.0, 232.3) 
- Full-fat milk 0.0 (0.0, 0.0) 
- Low-fat yoghurt 56.1 (0.0, 164.6) 
- Full-fat yoghurt 0.0 (0.0, 4.9) 
- Cheese 30.8 (20, 47.1) 
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Table 1. Baseline characteristics of study participants (n=6798) (Continued) 
Characteristics Mean (SD), median (IQR), or % 
- Unprocessed lean meat 10.7 (4.3, 18.1) 
- Fish 15.9 (3.9, 30.7) 
- Eggs 14.3 (7.1, 19.6) 
- Animal fat 0.0 (0.0, 0.9) 
- Desserts/ dairy with sugars 14.1 (0.0, 54.6) 
- Processed meat/ red meat 86.8 (60.4, 118.9) 
Plant-based dietary index (score) 49.3 (7.1) 
Plant-based dietary index: a higher score indicates a higher adherence to a plant-based diet (theoretical 
range from 0 to 92). Values shown are based on pooled results of imputed data. 
1Values shown for MET-hours are un-imputed; imputation was performed on z-scores of   physical 
activity. 
Abbreviations: MET, metabolic equivalent of task; SD, standard deviation. 
 
Plant-based dietary index and insulin resistance 
After adjustment for confounders in model 2, a higher score on the plant-based dietary index was 
associated with lower longitudinal HOMA-IR (per 10 units higher score on the index: β= -0.09, (95% 
CI: -0.10, -0.08)) (Table 2). Adding BMI to the model (Model 3), attenuated the association, but it 
remained statistically significant (β= -0.05 (-0.06, -0.04)).  
Plant-based dietary index and incidence of prediabetes 
During 43773 person-years of follow-up amongst 5768 participants (median follow-up 5.7 years), 928 
participants developed prediabetes. After adjustment for confounders in model 2 (Table 2), a higher 
score on the plant-based dietary index was associated with a lower incidence of prediabetes (per 10 
units higher score on the index: HR=0.89, (95%CI 0.81, 0.98)). After additional adjustment for BMI 
(Model 3) the association was attenuated, and no longer statistically significant (HR=0.93 (0.85, 1.03)).  
Plant-based dietary index and incidence of type 2 diabetes 
During 54024 person-years of follow-up amongst 6770 participants (median follow-up 7.3 years), 642 
participants developed T2D. In model 2, a higher score on the plant-based dietary index was associated 
with a lower incidence of T2D (per 10 units higher score on the index: HR=0.82, (95%CI 0.73, 0.92)) 
(Table 2). Additional adjustment for BMI (Model 3) attenuated this association, but it was still 
statistically significant (HR=0.87 (0.79, 0.99)).  
 
 
 
 
Table 2. Associations of the plant-based dietary index with longitudinal insulin resistance 
(HOMA-IR), risk of prediabetes, and risk of type 2 diabetes 
 HOMA-IR Prediabetes Type 2 diabetes 
 n=6514 n=5768 n=6770 
 β (95% CI) HR (95% CI) HR (95% CI)  
Model 1 -0.09 (-0.10, -0.08)*** 0.88 (0.80, 0.97)** 0.82 (0.73, 0.92)*** 
Model 2 -0.09 (-0.10, -0.08)*** 0.89 (0.81, 0.98)* 0.82 (0.73, 0.92)** 
Model 3 -0.05 (-0.06, -0.04)*** 0.93(0.85, 1.03) 0.87 (0.79, 0.99)* 
Effect estimates are regression coefficients (β) for ln HOMA-IR or hazard ratios (HRs) for incidence 
of prediabetes or type 2 diabetes with their 95%-confidence intervals (95%CIs), per 10 units higher 
score on the plant-based dietary index. Estimates are based on pooled results of imputed data. 
Model 1 is adjusted for energy intake (kcal), sex (male or female), age (years) and RS sub-cohort (RS-
I, -II, or -III); and only for the HOMA analyses additionally for the time measurements of longitudinal 
HOMA. 
Model 2 is additionally adjusted for education (primary, lower, intermediate, or higher), smoking status 
(never, ever, current); family history of diabetes (yes, no, or unknown); physical activity (z-score of 
MET-hours/week); and food supplement use (yes or no). 
Model 3 is additionally adjusted for BMI 
*p<0.05; **p<0.01; ***p<0.001 
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; MET, metabolic 
equivalent of task; RS, Rotterdam-Study. 
 
The associations between the plant-based dietary index with longitudinal insulin resistance, and risk 
of prediabetes and T2D were similar in three sub-cohorts (Supplemental Tables 5-7). Associations did 
not differ by age, sex or baseline BMI (p-values for all interaction terms were >0.05). 
Sensitivity analyses 
The exclusion of each one of 23 foods from the index one by one at a time did not substantially 
change the estimates (Supplemental Table 8). Excluding all plant-based beverages combined at a time 
(coffee and tea, alcoholic beverages and sugary beverages) did not substantially change the estimates 
(per 10 units higher score on the index, insulin resistance: β= -0.06 (-0.10, -0.03), prediabetes risk: 
HR=0.93 (0.84, 1.02), and T2D risk: HR=0.85 (0.80, 0.96)). The estimates also remained similar after 
excluding these less healthy plant-based foods combined at a time (sweets, sugary beverages, potatoes, 
and refined grains) (per 10 units higher score on the index, insulin resistance: β= -0.09 (-0.10, -0.07), 
prediabetes risk: HR=0.90 (0.84, 0.98), and T2D risk: HR=0.83 (0.74, 0.94)), but the less healthy plant 
foods score was not associated with insulin resistance or with risk of prediabetes or type 2 diabetes 
(insulin resistance: β= -0.002 (-0.01, 0.006), risk of prediabetes: HR=1.00 (-0.99, 1.01), and risk of type 
2 diabetes: HR=0.99 (0.98, 1.00)). The Pearson’s correlation coefficient between the plant-based 
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range from 0 to 92). Values shown are based on pooled results of imputed data. 
1Values shown for MET-hours are un-imputed; imputation was performed on z-scores of   physical 
activity. 
Abbreviations: MET, metabolic equivalent of task; SD, standard deviation. 
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After adjustment for confounders in model 2, a higher score on the plant-based dietary index was 
associated with lower longitudinal HOMA-IR (per 10 units higher score on the index: β= -0.09, (95% 
CI: -0.10, -0.08)) (Table 2). Adding BMI to the model (Model 3), attenuated the association, but it 
remained statistically significant (β= -0.05 (-0.06, -0.04)).  
Plant-based dietary index and incidence of prediabetes 
During 43773 person-years of follow-up amongst 5768 participants (median follow-up 5.7 years), 928 
participants developed prediabetes. After adjustment for confounders in model 2 (Table 2), a higher 
score on the plant-based dietary index was associated with a lower incidence of prediabetes (per 10 
units higher score on the index: HR=0.89, (95%CI 0.81, 0.98)). After additional adjustment for BMI 
(Model 3) the association was attenuated, and no longer statistically significant (HR=0.93 (0.85, 1.03)).  
Plant-based dietary index and incidence of type 2 diabetes 
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participants developed T2D. In model 2, a higher score on the plant-based dietary index was associated 
with a lower incidence of T2D (per 10 units higher score on the index: HR=0.82, (95%CI 0.73, 0.92)) 
(Table 2). Additional adjustment for BMI (Model 3) attenuated this association, but it was still 
statistically significant (HR=0.87 (0.79, 0.99)).  
 
 
 
 
Table 2. Associations of the plant-based dietary index with longitudinal insulin resistance 
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Model 2 -0.09 (-0.10, -0.08)*** 0.89 (0.81, 0.98)* 0.82 (0.73, 0.92)** 
Model 3 -0.05 (-0.06, -0.04)*** 0.93(0.85, 1.03) 0.87 (0.79, 0.99)* 
Effect estimates are regression coefficients (β) for ln HOMA-IR or hazard ratios (HRs) for incidence 
of prediabetes or type 2 diabetes with their 95%-confidence intervals (95%CIs), per 10 units higher 
score on the plant-based dietary index. Estimates are based on pooled results of imputed data. 
Model 1 is adjusted for energy intake (kcal), sex (male or female), age (years) and RS sub-cohort (RS-
I, -II, or -III); and only for the HOMA analyses additionally for the time measurements of longitudinal 
HOMA. 
Model 2 is additionally adjusted for education (primary, lower, intermediate, or higher), smoking status 
(never, ever, current); family history of diabetes (yes, no, or unknown); physical activity (z-score of 
MET-hours/week); and food supplement use (yes or no). 
Model 3 is additionally adjusted for BMI 
*p<0.05; **p<0.01; ***p<0.001 
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; MET, metabolic 
equivalent of task; RS, Rotterdam-Study. 
 
The associations between the plant-based dietary index with longitudinal insulin resistance, and risk 
of prediabetes and T2D were similar in three sub-cohorts (Supplemental Tables 5-7). Associations did 
not differ by age, sex or baseline BMI (p-values for all interaction terms were >0.05). 
Sensitivity analyses 
The exclusion of each one of 23 foods from the index one by one at a time did not substantially 
change the estimates (Supplemental Table 8). Excluding all plant-based beverages combined at a time 
(coffee and tea, alcoholic beverages and sugary beverages) did not substantially change the estimates 
(per 10 units higher score on the index, insulin resistance: β= -0.06 (-0.10, -0.03), prediabetes risk: 
HR=0.93 (0.84, 1.02), and T2D risk: HR=0.85 (0.80, 0.96)). The estimates also remained similar after 
excluding these less healthy plant-based foods combined at a time (sweets, sugary beverages, potatoes, 
and refined grains) (per 10 units higher score on the index, insulin resistance: β= -0.09 (-0.10, -0.07), 
prediabetes risk: HR=0.90 (0.84, 0.98), and T2D risk: HR=0.83 (0.74, 0.94)), but the less healthy plant 
foods score was not associated with insulin resistance or with risk of prediabetes or type 2 diabetes 
(insulin resistance: β= -0.002 (-0.01, 0.006), risk of prediabetes: HR=1.00 (-0.99, 1.01), and risk of type 
2 diabetes: HR=0.99 (0.98, 1.00)). The Pearson’s correlation coefficient between the plant-based 
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dietary score with the dietary guidelines score was 0.16 (P<0.05); and controlling for the dietary 
guidelines score did not substantially affect the estimates (per 10 units higher score on the index, 
insulin resistance: β= -0.09 (-0.10, -0.08), prediabetes risk: HR=0.91 (0.82, 1.00), and T2D risk: 
HR=0.81 (0.71, 0.91)).  
Additional adjustment for hypertension and hypercholesterolemia did not change effect estimates (per 
10 units higher score on the index, insulin resistance: β= -0.08 (-0.10, -0.07), risk of prediabetes: 
HR=0.90 (0.82, 0.99), and risk of T2D: HR=0.84 (0.75, 0.94)), and estimates remained similar after 
excluding participants with chronic diseases at baseline (per 10 units higher score on the index, insulin 
resistance: β= -0.09 (-0.11, -0.07), prediabetes risk: HR=0.88 (0.79, 0.97), and T2D risk: HR=0.81 
(0.72, 0.92)). Finally, excluding participants who developed T2D or prediabetes in the first 2 years of 
follow-up modestly attenuated the associations for prediabetes (per 10 units higher score on the index, 
HR=0.91 (0.83, 1.01)), and T2D (HR=0.82 (0.73, 0.92)).  
 
DISCUSSION  
In this large population-based cohort, we observed that a diet higher in plant-based foods and lower 
in animal-based foods was associated with lower insulin resistance, and a lower risk of prediabetes and 
T2D, suggesting a protective role of a more plant-based opposed to a more animal-based diet in the 
development to T2D, beyond strict adherence to a vegetarian or vegan diet.  
The inverse association between plant-based diets and T2D risk is in agreement with previous research 
showing lower T2D risk for vegans or vegetarians, compared to non-vegetarians.10 Moreover, our 
observed associations confirmed the observations of Satija and colleagues in a US sample,11 the only 
other prospective study examining adherence to plant-based diets in a continuous graduation with risk 
of T2D. Compared to this previous study in the US population, we have extended this evidence by 
also showing associations between plant-based diets in a continuous graduation with earlier stages of 
the development of T2D: insulin resistance, and prediabetes in a European population. 
Our results imply a beneficial effect of adherence to a diet higher in plant-based foods and lower in 
animal-based foods on the development of T2D, irrespective of general healthfulness of the specific 
plant-based and animal-based foods. With these results, we provide a different view on what a healthy 
diet may entail. However, we acknowledge that our plant-based diet included positive scoring for some 
components that are not necessarily healthy choices for prevention of T2D, or a healthy diet in general. 
Sugary beverages, for example, have been associated with adverse effects for T2D in other studies.22, 
23 
 
 
 
To further clarify whether these less healthy plant foods contributed to the observed associations, we 
examined the associations between less healthy plant-based diet score with insulin resistance, and risk 
of prediabetes and T2D in our sensitivity analyses, and observed null associations; suggesting 
beneficial associations were mainly driven by higher intake of healthy plant-based food groups and 
lower intake of animal-based food groups. This emphasizes that it is important to also consider the 
quality of plant-based foods consumed, which has important public health implications. Furthermore, 
the estimates for the plant-based dietary index remained similar after excluding these plant-based 
beverages combined, or after excluding the less healthy plant-based foods combined, which indicated 
that our results were stable in diverse versions of plant-based diets, thus increased our confidence in 
the validity of the findings. We also observed that excluding each one of 23 components one by one 
at a time resulted in similar associations as observed for the total plant-based index, indicating that the 
associations were not mainly explained by any one specific food group, which supports the importance 
of recognizing overall plant-based diet. Finally, we extended our analyses to examine if adherence to 
a plant-based diet was independent of adherence to current Dutch dietary guidelines. In line with 
results from the large prospective cohort study in the US which examined if adherence to a plant-
based diet was independent of general healthy dietary patterns that have been linked to prevention of 
T2D, such as the Mediterranean diet, the alternative Healthy Eating Index (aHEI), and the Dietary 
approaches to stop hypertension (DASH) diet.24-26 We observed that associations of the plant-based 
dietary index with outcomes remained similar after additional adjustment for adherence to current 
Dutch dietary guidelines. This lends support to novelty of the plant-based dietary index. 
Taken together, a more plant-based, less animal-based diet may help prevent the development of T2D. 
Still more important, a more plant-based diet, does not require a radical change in diet or a total 
elimination of meat or animal products but instead can be achieved in various ways, increasing the 
potential for population-wide health recommendations. For example, if a participant in our cohort 
would increase fruits intake from 95 grams per day to 200 grams per day, increase vegetables intake 
from 100 grams to 260 grams, and at the same time decrease red meat intake from 129 grams per day 
to 55 grams per day, this would improve the plant-based dietary index by 10 units, which may decrease 
risk of T2D by 13%, assuming other covariates remain stable.  
Potential biological mechanisms  
Several mechanisms behind the inverse associations could involve the intermediate conditions of T2D, 
such as obesity and inflammation, can offer explanations for the observed protection and T2D. On 
the one hand, a plant-based diet usually has more fiber, chlorogenic acids, certain amino acids, 
unsaturated fatty acids, and antioxidants. For example, vegetables and fruits are the main sources of 
fiber, anti-oxidants, and chlorogenic acids; nuts are rich in poly-unsaturated fatty acids; soy and beans 
are main sources of plant protein; whole grains are rich in fiber and plant protein; and coffee and tea 
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also showing associations between plant-based diets in a continuous graduation with earlier stages of 
the development of T2D: insulin resistance, and prediabetes in a European population. 
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diet may entail. However, we acknowledge that our plant-based diet included positive scoring for some 
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beneficial associations were mainly driven by higher intake of healthy plant-based food groups and 
lower intake of animal-based food groups. This emphasizes that it is important to also consider the 
quality of plant-based foods consumed, which has important public health implications. Furthermore, 
the estimates for the plant-based dietary index remained similar after excluding these plant-based 
beverages combined, or after excluding the less healthy plant-based foods combined, which indicated 
that our results were stable in diverse versions of plant-based diets, thus increased our confidence in 
the validity of the findings. We also observed that excluding each one of 23 components one by one 
at a time resulted in similar associations as observed for the total plant-based index, indicating that the 
associations were not mainly explained by any one specific food group, which supports the importance 
of recognizing overall plant-based diet. Finally, we extended our analyses to examine if adherence to 
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dietary index with outcomes remained similar after additional adjustment for adherence to current 
Dutch dietary guidelines. This lends support to novelty of the plant-based dietary index. 
Taken together, a more plant-based, less animal-based diet may help prevent the development of T2D. 
Still more important, a more plant-based diet, does not require a radical change in diet or a total 
elimination of meat or animal products but instead can be achieved in various ways, increasing the 
potential for population-wide health recommendations. For example, if a participant in our cohort 
would increase fruits intake from 95 grams per day to 200 grams per day, increase vegetables intake 
from 100 grams to 260 grams, and at the same time decrease red meat intake from 129 grams per day 
to 55 grams per day, this would improve the plant-based dietary index by 10 units, which may decrease 
risk of T2D by 13%, assuming other covariates remain stable.  
Potential biological mechanisms  
Several mechanisms behind the inverse associations could involve the intermediate conditions of T2D, 
such as obesity and inflammation, can offer explanations for the observed protection and T2D. On 
the one hand, a plant-based diet usually has more fiber, chlorogenic acids, certain amino acids, 
unsaturated fatty acids, and antioxidants. For example, vegetables and fruits are the main sources of 
fiber, anti-oxidants, and chlorogenic acids; nuts are rich in poly-unsaturated fatty acids; soy and beans 
are main sources of plant protein; whole grains are rich in fiber and plant protein; and coffee and tea 
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are rich in anti-oxidants and phenol chlorogenic acid. These beneficial components may influence the 
development of T2D through impact on the potential intermediate conditions, such as obesity and 
inflammation. Fiber is known to lower gastric emptying and thereby glycemic responsiveness,27 and 
might improve inflammation,28, 29 and obesity.30 Chlorogenic acids can improve inflammation, glucose 
tolerance and glucose levels, and improve increasing insulin secretion.31 Soy protein contains high 
amounts of the amino acids arginine and glycine, which have been associated with a decrease in 
cholesterol levels.32 High intake of unsaturated fatty acids has also been associated to lower 
inflammation and less obesity.28, 33 Phenol chlorogenic acid was reported to reduce insulin resistance.34 
On the other hand, a plant-based diet, usually has less animal protein, saturated fatty acids, and heme 
iron. Animal protein is rich in branched-chain amino acids and aromatic amino acids and may impair 
glucose metabolisms and increase T2D risk;35-38 animal protein is also rich in heme iron, which has 
been suggested to increase risk of cardio-metabolic diseases.39-41 Higher saturated fatty acids have been 
suggested to be associated higher inflammation,33 higher risk of obesity33 and T2D.42, 43 Besides, other 
nutrients from processed red meat, such as sodium and nitrites, may increase risk of cardio-metabolic 
diseases.41 More research is needed to explore whether the mechanisms also involve an effect of plant 
foods on gut microbiome. Finally, these different mechanisms may influence each other because of 
inter-relations between different food components. This also highlights the relevance of examining 
overall diets in additional to isolated food items, as this enables capturing of the combined effects of 
the potential pathways.  
Strengths and limitations  
This study has several strengths. First, to our knowledge, we are the first to investigate the associations 
between plant-based diets with longitudinal insulin resistance and prediabetes, for which we had 
longitudinal data from long follow-up available. Studying these early risk stages help minimize reverse 
causation, understand how plant-based diet influences the development of T2D. Second, we observed 
that the potential beneficial effect of a more plant-based diet was independent of less healthy plant 
foods, such as sweets, sugary beverages and refined grains, emphasizing the importance of considering 
the quality of plant-based foods consumed. We also observed associations of the plant-based dietary 
score independent of overall adherence to dietary guidelines, indicating that the plant-based diet score 
may reflect more than only a healthful dietary pattern as reflected by current dietary guidelines. Other 
strengths also included the population-based nature of the study, the detailed and thorough data 
collected on the outcomes and the assessment of the extent to which diets were plant-based and animal 
based, based upon overall dietary intake patterns of the general population. 
Nevertheless, there are several limitations we should consider. First, the assessment of a plant-based 
diet with this index has its limitations as several sometimes-arbitrary decisions had to be made. A 
decision was, for example, to add up food items within categories based on the intake in grams per 
 
 
 
day. As a result, products that were high in water-content will have contributed less energy or nutrients 
compared to products containing less water in the same category. However, using grams per day 
reflects intake of foods as they are consumed and recommended.19 Also, decisions had to be made for 
the categorization of foods and the number of categories. We chose categories reflecting those used 
in the Dutch dietary guidelines, which are based on similarities of the food items in (botanical) origin, 
nutrient composition, and nutrient density;18 thereby reducing nutritional differences between food 
items within one category. Furthermore, in our main analyses, we treated all plant-based foods equally 
by giving all plant-based foods positive scores, and all animal-based foods equally by giving all animal-
based foods reverse scores, irrespective of their nutrient-density or previous evidence for a role in 
T2D prevention and general health. For example, less healthy plant-based foods, such as sugary 
beverages and refined grains, were included as positive scores, although sugary beverages,23 and refined 
grains44 have been linked to higher T2D risk; by contrast, healthy animal-based foods, such as dairy 
and fish, were included as reverse scores, although dairy45 and fish46 have been linked to lower T2D 
risk or mortality risk. That is because our study aimed to emphasize an overall plant-based diet 
including various increased plant-based foods consumption and decreased animal-based foods 
consumption, which would increase the potential for population-wide recommendation. However, in 
our sensitivity analyses, excluding any one of alcoholic beverages, sugary beverages, sweets, potatoes, 
refined grains, fish, and dairy did not substantially change our estimates. 
In addition to the choices we had to make in the construction of the index, this study has some other 
limitations. First, dietary data were derived from self-reported diet measured with FFQs, making 
measurement-errors likely. However, because we used relative scores (quintiles) of intake and the 
FFQs were shown in several validation studies to adequately rank subjects according to intake,13-16 we 
do not expect these measurement-errors to have largely affected our results. Second, we did not have 
dietary data for many of the participants of the original cohort, which might have resulted in selection 
bias if associations of plant-based diets with T2D risk differed in those included and those not included 
in our current analyses. Third, we assumed stable diets over time. However, the estimates were similar 
after excluding the participants who were likely to change their diet during follow-up, such as 
participants with CHD, stroke, and cancers at baseline. Last, our results may be generalizable only to 
people of similar age and race. 
Conclusions 
In this large population-based cohort, higher adherence to an overall plant-based diet is associated 
with lower longitudinal insulin resistance, and lower risk of prediabetes and T2D, indicating a 
protective role of diets high in plant-based foods and low in animal-based foods in the development 
to T2D beyond strict adherence to a vegetarian or vegan diet. These promising findings call for further 
exploration of overall plant-based dietary recommendations aimed at T2D prevention. 
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are rich in anti-oxidants and phenol chlorogenic acid. These beneficial components may influence the 
development of T2D through impact on the potential intermediate conditions, such as obesity and 
inflammation. Fiber is known to lower gastric emptying and thereby glycemic responsiveness,27 and 
might improve inflammation,28, 29 and obesity.30 Chlorogenic acids can improve inflammation, glucose 
tolerance and glucose levels, and improve increasing insulin secretion.31 Soy protein contains high 
amounts of the amino acids arginine and glycine, which have been associated with a decrease in 
cholesterol levels.32 High intake of unsaturated fatty acids has also been associated to lower 
inflammation and less obesity.28, 33 Phenol chlorogenic acid was reported to reduce insulin resistance.34 
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iron. Animal protein is rich in branched-chain amino acids and aromatic amino acids and may impair 
glucose metabolisms and increase T2D risk;35-38 animal protein is also rich in heme iron, which has 
been suggested to increase risk of cardio-metabolic diseases.39-41 Higher saturated fatty acids have been 
suggested to be associated higher inflammation,33 higher risk of obesity33 and T2D.42, 43 Besides, other 
nutrients from processed red meat, such as sodium and nitrites, may increase risk of cardio-metabolic 
diseases.41 More research is needed to explore whether the mechanisms also involve an effect of plant 
foods on gut microbiome. Finally, these different mechanisms may influence each other because of 
inter-relations between different food components. This also highlights the relevance of examining 
overall diets in additional to isolated food items, as this enables capturing of the combined effects of 
the potential pathways.  
Strengths and limitations  
This study has several strengths. First, to our knowledge, we are the first to investigate the associations 
between plant-based diets with longitudinal insulin resistance and prediabetes, for which we had 
longitudinal data from long follow-up available. Studying these early risk stages help minimize reverse 
causation, understand how plant-based diet influences the development of T2D. Second, we observed 
that the potential beneficial effect of a more plant-based diet was independent of less healthy plant 
foods, such as sweets, sugary beverages and refined grains, emphasizing the importance of considering 
the quality of plant-based foods consumed. We also observed associations of the plant-based dietary 
score independent of overall adherence to dietary guidelines, indicating that the plant-based diet score 
may reflect more than only a healthful dietary pattern as reflected by current dietary guidelines. Other 
strengths also included the population-based nature of the study, the detailed and thorough data 
collected on the outcomes and the assessment of the extent to which diets were plant-based and animal 
based, based upon overall dietary intake patterns of the general population. 
Nevertheless, there are several limitations we should consider. First, the assessment of a plant-based 
diet with this index has its limitations as several sometimes-arbitrary decisions had to be made. A 
decision was, for example, to add up food items within categories based on the intake in grams per 
 
 
 
day. As a result, products that were high in water-content will have contributed less energy or nutrients 
compared to products containing less water in the same category. However, using grams per day 
reflects intake of foods as they are consumed and recommended.19 Also, decisions had to be made for 
the categorization of foods and the number of categories. We chose categories reflecting those used 
in the Dutch dietary guidelines, which are based on similarities of the food items in (botanical) origin, 
nutrient composition, and nutrient density;18 thereby reducing nutritional differences between food 
items within one category. Furthermore, in our main analyses, we treated all plant-based foods equally 
by giving all plant-based foods positive scores, and all animal-based foods equally by giving all animal-
based foods reverse scores, irrespective of their nutrient-density or previous evidence for a role in 
T2D prevention and general health. For example, less healthy plant-based foods, such as sugary 
beverages and refined grains, were included as positive scores, although sugary beverages,23 and refined 
grains44 have been linked to higher T2D risk; by contrast, healthy animal-based foods, such as dairy 
and fish, were included as reverse scores, although dairy45 and fish46 have been linked to lower T2D 
risk or mortality risk. That is because our study aimed to emphasize an overall plant-based diet 
including various increased plant-based foods consumption and decreased animal-based foods 
consumption, which would increase the potential for population-wide recommendation. However, in 
our sensitivity analyses, excluding any one of alcoholic beverages, sugary beverages, sweets, potatoes, 
refined grains, fish, and dairy did not substantially change our estimates. 
In addition to the choices we had to make in the construction of the index, this study has some other 
limitations. First, dietary data were derived from self-reported diet measured with FFQs, making 
measurement-errors likely. However, because we used relative scores (quintiles) of intake and the 
FFQs were shown in several validation studies to adequately rank subjects according to intake,13-16 we 
do not expect these measurement-errors to have largely affected our results. Second, we did not have 
dietary data for many of the participants of the original cohort, which might have resulted in selection 
bias if associations of plant-based diets with T2D risk differed in those included and those not included 
in our current analyses. Third, we assumed stable diets over time. However, the estimates were similar 
after excluding the participants who were likely to change their diet during follow-up, such as 
participants with CHD, stroke, and cancers at baseline. Last, our results may be generalizable only to 
people of similar age and race. 
Conclusions 
In this large population-based cohort, higher adherence to an overall plant-based diet is associated 
with lower longitudinal insulin resistance, and lower risk of prediabetes and T2D, indicating a 
protective role of diets high in plant-based foods and low in animal-based foods in the development 
to T2D beyond strict adherence to a vegetarian or vegan diet. These promising findings call for further 
exploration of overall plant-based dietary recommendations aimed at T2D prevention. 
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SUPPLEMENTAL MATERIAL 
Supplemental Table 1. Food categories used for the plant-based diet index and examples of 
food items included in each of the food categories 
Plant-based food categories 
Fruits Apple, banana, pear, orange, strawberry, grapes, other fruits 
Vegetables Cauliflower, broccoli, spinach, carrots, onion, lettuce, tomato, cabbage, 
cooked vegetables 
Whole grains Whole grain bread, dark bread, rye bread, whole grain breakfast oats, 
whole grain pasta, brown rice  
Nuts Peanuts, walnuts, other nuts, peanut butter 
Legumes Legumes, tofu, soybeans, other soy products 
Potatoes Potatoes, fries 
Vegetable oils Olive oil, vegetable oils used for cooking, and all margarines 
Tea and coffee Black tea, green tea, herbal tea, coffee 
Sugary beverages Carbonated beverages with sugar, non-carbonated beverages with 
sugar, orange juice, fruit juice 
Refined grains Cornflakes, white bread, croissants, raisin bread, white pasta, white 
rice 
Sweets Sugar, cookies, cake, chocolate, candy-bars, honey, sweets, chocolate 
toppings, other sweet toppings 
Alcoholic beverages Red wine, white wine, beer, liquor, Dutch-eggnog 
Animal-based food categories 
Low-fat Yoghurt Skimmed yoghurt, semi-skimmed yoghurt, skimmed quark, buttermilk 
Full-fat Yoghurt Full-fat yoghurt, semi-skimmed quark, full quark 
Low-fat milk Skimmed milk, semi-skimmed milk, skimmed coffee creamer, semi-
skimmed coffee creamer 
Full-fat milk Full-fat milk, cream, coffee-cream 
Cheese Full fat cheese, low fat cheese, cheese fondue, other cheese 
Fish Salmon, tuna, trout, herring, mussels, other fish 
Eggs Boiled eggs, fried eggs 
Animal fat Butter on bread, butter used for cooking, lard 
Desserts and sugary 
dairy 
Custard, cream, ice cream, mousse, cream, chocolate milk, fruit 
yoghurt, yoghurt drinks 
Unprocessed lean meat Chicken 
Processed meat and 
red meat 
Beef, pork, meatballs, sate, bacon, liver, processed meats 
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SUPPLEMENTAL MATERIAL 
Supplemental Table 1. Food categories used for the plant-based diet index and examples of 
food items included in each of the food categories 
Plant-based food categories 
Fruits Apple, banana, pear, orange, strawberry, grapes, other fruits 
Vegetables Cauliflower, broccoli, spinach, carrots, onion, lettuce, tomato, cabbage, 
cooked vegetables 
Whole grains Whole grain bread, dark bread, rye bread, whole grain breakfast oats, 
whole grain pasta, brown rice  
Nuts Peanuts, walnuts, other nuts, peanut butter 
Legumes Legumes, tofu, soybeans, other soy products 
Potatoes Potatoes, fries 
Vegetable oils Olive oil, vegetable oils used for cooking, and all margarines 
Tea and coffee Black tea, green tea, herbal tea, coffee 
Sugary beverages Carbonated beverages with sugar, non-carbonated beverages with 
sugar, orange juice, fruit juice 
Refined grains Cornflakes, white bread, croissants, raisin bread, white pasta, white 
rice 
Sweets Sugar, cookies, cake, chocolate, candy-bars, honey, sweets, chocolate 
toppings, other sweet toppings 
Alcoholic beverages Red wine, white wine, beer, liquor, Dutch-eggnog 
Animal-based food categories 
Low-fat Yoghurt Skimmed yoghurt, semi-skimmed yoghurt, skimmed quark, buttermilk 
Full-fat Yoghurt Full-fat yoghurt, semi-skimmed quark, full quark 
Low-fat milk Skimmed milk, semi-skimmed milk, skimmed coffee creamer, semi-
skimmed coffee creamer 
Full-fat milk Full-fat milk, cream, coffee-cream 
Cheese Full fat cheese, low fat cheese, cheese fondue, other cheese 
Fish Salmon, tuna, trout, herring, mussels, other fish 
Eggs Boiled eggs, fried eggs 
Animal fat Butter on bread, butter used for cooking, lard 
Desserts and sugary 
dairy 
Custard, cream, ice cream, mousse, cream, chocolate milk, fruit 
yoghurt, yoghurt drinks 
Unprocessed lean meat Chicken 
Processed meat and 
red meat 
Beef, pork, meatballs, sate, bacon, liver, processed meats 
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Supplemental Table 3. Baseline characteristics of participants in original and multiple 
imputed dataset 
Characteristics Original data Mean (SD) or valid % 
After imputation 
Mean (SD) or % 
Age (years) 62.0 (7.8) NI 
missing (%) − − 
Gender (% male) 41.3 % NI 
missing (%) − − 
BMI (kg/m2) 26.6 (3.9) 26.6 (3.9) 
missing (%) 1.3 % − 
Smoking (%) 
  
- never 32.2 % 32.2 % 
- ever 45.1 % 45.1 % 
- current 22.7 % 22.7 % 
missing (%) 0.5 % − 
Physical activity1 (MET-hours/week) 
  
- RS-III (assessed with LASA 
Questionnaire, n=2194) 
58.4 (55.8) 58.4 (55.8) 
- RS-I and RS-II (assessed with Zutphen 
Questionnaire, n=4393) 
86.7 (44.7) 86.7 (44.7) 
missing (%) 3.9 % − 
Hypertension (%) 42.3 % 42.3 % 
missing (%) 0.9 % − 
Hypercholesterolemia (%) 45.6 % 45.4 % 
missing (%) 1.6 % − 
Family history of type 2 diabetes (%) 10.8 % NI 
missing (%) − − 
Education level (%) 
  
- primary  11.8 % 11.8 % 
- lower 40.9 % 40.9 % 
- intermediate  29.0 % 29.0 % 
- higher  18.3 % 18.3 % 
missing (%) 0.6 % − 
Current food supplement use (%) 16.5 % 16.5 % 
missing (%) 0.3 % − 
Total energy intake (kcal/day) 2134 (615) NI 
missing (%) − − 
Food category intake2 (grams/day) 
  
- Fruits 212.2 (115.5, 332.3) NI 
- Vegetables 209.1 (147.9, 286.87 NI 
- Whole grains 105.7 (61.3, 152.5) NI 
Plant-based diet and type 2 diabetes
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Supplemental Table 3. Baseline characteristics of participants in original and multiple 
imputed dataset 
Characteristics Original data Mean (SD) or valid % 
After imputation 
Mean (SD) or % 
Age (years) 62.0 (7.8) NI 
missing (%) − − 
Gender (% male) 41.3 % NI 
missing (%) − − 
BMI (kg/m2) 26.6 (3.9) 26.6 (3.9) 
missing (%) 1.3 % − 
Smoking (%) 
  
- never 32.2 % 32.2 % 
- ever 45.1 % 45.1 % 
- current 22.7 % 22.7 % 
missing (%) 0.5 % − 
Physical activity1 (MET-hours/week) 
  
- RS-III (assessed with LASA 
Questionnaire, n=2194) 
58.4 (55.8) 58.4 (55.8) 
- RS-I and RS-II (assessed with Zutphen 
Questionnaire, n=4393) 
86.7 (44.7) 86.7 (44.7) 
missing (%) 3.9 % − 
Hypertension (%) 42.3 % 42.3 % 
missing (%) 0.9 % − 
Hypercholesterolemia (%) 45.6 % 45.4 % 
missing (%) 1.6 % − 
Family history of type 2 diabetes (%) 10.8 % NI 
missing (%) − − 
Education level (%) 
  
- primary  11.8 % 11.8 % 
- lower 40.9 % 40.9 % 
- intermediate  29.0 % 29.0 % 
- higher  18.3 % 18.3 % 
missing (%) 0.6 % − 
Current food supplement use (%) 16.5 % 16.5 % 
missing (%) 0.3 % − 
Total energy intake (kcal/day) 2134 (615) NI 
missing (%) − − 
Food category intake2 (grams/day) 
  
- Fruits 212.2 (115.5, 332.3) NI 
- Vegetables 209.1 (147.9, 286.87 NI 
- Whole grains 105.7 (61.3, 152.5) NI 
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Supplemental Table 3. Baseline characteristics of participants in original and multiple 
imputed dataset (Continued) 
Characteristics Original data Mean (SD) or valid % 
After imputation 
Mean (SD) or % 
- Nuts 3.9 (0.0, 12.0) NI 
- Legumes 4.1 (0.0, 19.4) NI 
- Potatoes 99.7 (61.4, 148.2) NI 
- Vegetable oils 19.7 (9.2, 30.0) NI 
- Tea and coffee 758.9 (580.4, 1000) NI 
- Sugary beverages 46.3 (0.0, 139.6) NI 
- Refined grains 50.7 (23.9, 102.1) NI 
- Sweets 63.8 (37.1, 97.4) NI 
- Alcoholic beverages 56.4 (4.9, 159.8) NI 
- Low-fat milk 82.3 (0.0, 232.3) NI 
- Full-fat milk 0.0 (0.0, 0.0) NI 
- Low-fat yoghurt 56.1 (0.0, 164.6) NI 
- Full-fat yoghurt 0.0 (0.0, 4.9) NI 
- Cheese 30.8 (20, 47.1) NI 
- Unprocessed lean 10.7 (4.3, 18.1) NI 
- Fish 15.9 (3.9, 30.7) NI 
- Eggs 14.3 (7.1, 19.6) NI 
- Animal fat 0.0 (0.0, 0.9) NI 
- Desserts/dairy with sugars 14.1 (0.0, 54.6) NI 
- Processed meat/ red meat 86.8 (60.4, 118.9) NI 
Plant-based dietary index (score) 49.3 (7.1) NI 
Plant-based dietary index: a higher score indicates a higher adherence to a plant-based diet (theoretical 
range from 0 to 92). 
1Values shown are un-imputed; imputation was performed on z-scores of physical activity. 
2Variables expressed as median (IQR) because of their skewed distributions. 
Abbreviations: MET, metabolic equivalent of task; NI, not imputed; SD, standard deviation. 
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Supplemental Table 3. Baseline characteristics of participants in original and multiple 
imputed dataset (Continued) 
Characteristics Original data Mean (SD) or valid % 
After imputation 
Mean (SD) or % 
- Nuts 3.9 (0.0, 12.0) NI 
- Legumes 4.1 (0.0, 19.4) NI 
- Potatoes 99.7 (61.4, 148.2) NI 
- Vegetable oils 19.7 (9.2, 30.0) NI 
- Tea and coffee 758.9 (580.4, 1000) NI 
- Sugary beverages 46.3 (0.0, 139.6) NI 
- Refined grains 50.7 (23.9, 102.1) NI 
- Sweets 63.8 (37.1, 97.4) NI 
- Alcoholic beverages 56.4 (4.9, 159.8) NI 
- Low-fat milk 82.3 (0.0, 232.3) NI 
- Full-fat milk 0.0 (0.0, 0.0) NI 
- Low-fat yoghurt 56.1 (0.0, 164.6) NI 
- Full-fat yoghurt 0.0 (0.0, 4.9) NI 
- Cheese 30.8 (20, 47.1) NI 
- Unprocessed lean 10.7 (4.3, 18.1) NI 
- Fish 15.9 (3.9, 30.7) NI 
- Eggs 14.3 (7.1, 19.6) NI 
- Animal fat 0.0 (0.0, 0.9) NI 
- Desserts/dairy with sugars 14.1 (0.0, 54.6) NI 
- Processed meat/ red meat 86.8 (60.4, 118.9) NI 
Plant-based dietary index (score) 49.3 (7.1) NI 
Plant-based dietary index: a higher score indicates a higher adherence to a plant-based diet (theoretical 
range from 0 to 92). 
1Values shown are un-imputed; imputation was performed on z-scores of physical activity. 
2Variables expressed as median (IQR) because of their skewed distributions. 
Abbreviations: MET, metabolic equivalent of task; NI, not imputed; SD, standard deviation. 
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ABSTRACT  
Background/Aims: We explored whether the degree of adherence to a plant-based diet was 
associated with body mass index (BMI kg/m2), waist circumference (cm), fat mass index (kg/m2), and 
body fat percentage over time in a middle-aged and elderly population. 
Methods: We included 9633 participants from the Rotterdam Study, a prospective cohort in the 
Netherlands. Dietary data were collected using food-frequency questionnaires at baseline of three sub-
cohorts of the Rotterdam Study (1989-93, 2000-01, 2006-08). We created a plant-based diet index by 
giving plant-based foods positive scores and animal-based foods reverse scores. A higher score on the 
index reflected an overall more plant-based and less animal-based diet. Data on anthropometrics and 
body composition (using dual energy X-ray absorptiometry) were collected every 3-5 years from 1989-
2016. We used multivariable linear mixed models to analyze the associations. 
Results: In the 9633 participants, baseline plant-based diet score ranged from 21.0 to 73.0 with a 
mean ± SD of 49.0 ± 7.0. In multivariable-adjusted analyses, higher adherence to a plant-based diet 
was associated with lower BMI, waist circumference, fat mass index, and body fat percentage across 
a median follow-up period of 7.1 years (per 10 points higher score, BMI: β= -0.70 kg/m2, (95% CI -
0.81, -0.59); waist circumference: -2.0 cm (-2.3, -1.7); fat mass index: -0.66 kg/m2 (-0.80, -0.52); body 
fat percentage: -1.1 (-1.3, -0.84)).  
Conclusions: Higher adherence to plant-based diets beyond vegan or vegetarian diets may prevent 
obesity, irrespective of general healthfulness of the specific plant- and animal-based foods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Diet is an important modifiable lifestyle determinant of body adiposity. Several studies have indicated 
that plant-based diets may lower body mass index (BMI).1-5 Potential mechanisms behind the link 
between plant-based diets with BMI may involve numerous biological pathways, such as changes in 
satiety,6 inflammation,7-10 and gut microbiome composition.11 However, most of these studies 
classified participants dichotomously, and only defined plant-based diets as vegetarian or vegan versus 
non-vegetarian diets;4 and few studies roughly classified plant-based diets as semi-vegetarian, 
lactovegetarian, and vegan diets, but they still did not address the gradual variation of plant-based 
diets.1, 2, 5 Since the majority of the general populations do not follow strict vegan and vegetarian diets, 
and are more likely to adopt plant-based diets rich in plant-based foods and low in animal-based foods, 
from a clinical and public health point of view, it is interesting to question if and how the degree of 
adherence to an overall more plant-based and less animal-based diet influences body adiposity. 
Furthermore, the degree of adherence to an overall more plant-based and less animal-based diet can 
be assessed using a continuous plant-based diet score.12, 13 Recent evidence has indicated that a plant-
based diet score may represent a novel assessment of quality of dietary patterns, and reflect a 
complementary approach of what a healthful diet entails, different from the other diet quality scores, 
such as the Mediterranean Diet score, the Dietary Approaches to Stop Hypertension diet score, and 
diet quality scores on the basis of dietary guidelines.13, 14 For example, Satija et al observed low or 
moderate correlations between a plant-based diet score with the Mediterranean Diet score and the 
Dietary Approaches to Stop Hypertension diet score.13 We previously reported low correlation 
between a plant-based diet score with a diet quality score reflecting adherence to Dutch dietary 
guidelines.14 These low or moderate correlations may be explained by the fact that some, but not all 
components are between the different scores and different scoring criteria. For example, the 
Mediterranean Diet score usually includes positive scores not only for healthy plant-based foods that 
appear beneficial for general health, such as whole grains, fruits, vegetables, legumes, nuts, and olive 
oil, but also for healthy animal-based foods, such as fish. A plant-based diet score, however, is allowed 
to include positive scores for plant-based foods and negative scores for animal-based foods 
irrespective of their known healthfulness.  
Therefore, we aimed to examine the associations between the degree of adherence to plant-based diet 
assessed by a plant-based diet score with changes in measures of adiposity including BMI, waist 
circumference, fat mass index, and body fat percentage in a large Dutch middle-aged and elderly 
population with a median follow-up of 7.1 years (range 0-25 years). 
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ABSTRACT  
Background/Aims: We explored whether the degree of adherence to a plant-based diet was 
associated with body mass index (BMI kg/m2), waist circumference (cm), fat mass index (kg/m2), and 
body fat percentage over time in a middle-aged and elderly population. 
Methods: We included 9633 participants from the Rotterdam Study, a prospective cohort in the 
Netherlands. Dietary data were collected using food-frequency questionnaires at baseline of three sub-
cohorts of the Rotterdam Study (1989-93, 2000-01, 2006-08). We created a plant-based diet index by 
giving plant-based foods positive scores and animal-based foods reverse scores. A higher score on the 
index reflected an overall more plant-based and less animal-based diet. Data on anthropometrics and 
body composition (using dual energy X-ray absorptiometry) were collected every 3-5 years from 1989-
2016. We used multivariable linear mixed models to analyze the associations. 
Results: In the 9633 participants, baseline plant-based diet score ranged from 21.0 to 73.0 with a 
mean ± SD of 49.0 ± 7.0. In multivariable-adjusted analyses, higher adherence to a plant-based diet 
was associated with lower BMI, waist circumference, fat mass index, and body fat percentage across 
a median follow-up period of 7.1 years (per 10 points higher score, BMI: β= -0.70 kg/m2, (95% CI -
0.81, -0.59); waist circumference: -2.0 cm (-2.3, -1.7); fat mass index: -0.66 kg/m2 (-0.80, -0.52); body 
fat percentage: -1.1 (-1.3, -0.84)).  
Conclusions: Higher adherence to plant-based diets beyond vegan or vegetarian diets may prevent 
obesity, irrespective of general healthfulness of the specific plant- and animal-based foods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Diet is an important modifiable lifestyle determinant of body adiposity. Several studies have indicated 
that plant-based diets may lower body mass index (BMI).1-5 Potential mechanisms behind the link 
between plant-based diets with BMI may involve numerous biological pathways, such as changes in 
satiety,6 inflammation,7-10 and gut microbiome composition.11 However, most of these studies 
classified participants dichotomously, and only defined plant-based diets as vegetarian or vegan versus 
non-vegetarian diets;4 and few studies roughly classified plant-based diets as semi-vegetarian, 
lactovegetarian, and vegan diets, but they still did not address the gradual variation of plant-based 
diets.1, 2, 5 Since the majority of the general populations do not follow strict vegan and vegetarian diets, 
and are more likely to adopt plant-based diets rich in plant-based foods and low in animal-based foods, 
from a clinical and public health point of view, it is interesting to question if and how the degree of 
adherence to an overall more plant-based and less animal-based diet influences body adiposity. 
Furthermore, the degree of adherence to an overall more plant-based and less animal-based diet can 
be assessed using a continuous plant-based diet score.12, 13 Recent evidence has indicated that a plant-
based diet score may represent a novel assessment of quality of dietary patterns, and reflect a 
complementary approach of what a healthful diet entails, different from the other diet quality scores, 
such as the Mediterranean Diet score, the Dietary Approaches to Stop Hypertension diet score, and 
diet quality scores on the basis of dietary guidelines.13, 14 For example, Satija et al observed low or 
moderate correlations between a plant-based diet score with the Mediterranean Diet score and the 
Dietary Approaches to Stop Hypertension diet score.13 We previously reported low correlation 
between a plant-based diet score with a diet quality score reflecting adherence to Dutch dietary 
guidelines.14 These low or moderate correlations may be explained by the fact that some, but not all 
components are between the different scores and different scoring criteria. For example, the 
Mediterranean Diet score usually includes positive scores not only for healthy plant-based foods that 
appear beneficial for general health, such as whole grains, fruits, vegetables, legumes, nuts, and olive 
oil, but also for healthy animal-based foods, such as fish. A plant-based diet score, however, is allowed 
to include positive scores for plant-based foods and negative scores for animal-based foods 
irrespective of their known healthfulness.  
Therefore, we aimed to examine the associations between the degree of adherence to plant-based diet 
assessed by a plant-based diet score with changes in measures of adiposity including BMI, waist 
circumference, fat mass index, and body fat percentage in a large Dutch middle-aged and elderly 
population with a median follow-up of 7.1 years (range 0-25 years). 
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METHODS  
Study population  
This study was embedded in three sub-cohorts of the Rotterdam Study (RS), a prospective cohort of 
adults living in the district of Ommoord in Rotterdam, the Netherlands. A detailed description of the 
Rotterdam Study methodology is described elsewhere.15 Briefly, the first sub-cohort (RS-I) started in 
1990 with participants aged ≥55 years (n=7983). The study was extended with a second sub-cohort 
(RS-II) in 2000 with new participants aged ≥55 years (n=3011), and a third sub-cohort (RS-III) in 
2006 (n=3932), in which new participants aged ≥45 years were included. In each sub-cohort, follow-
up examinations were performed in a research center every 3-5 years. The Rotterdam Study has been 
approved by the Medical Ethics Committee of Erasmus Medical Center and by the review board of 
The Netherlands Ministry of Health, Welfare and Sports. Informed consent was obtained from all 
participants. 
 
14926 participants 
5225 without dietary data participants 
68 without any measures of body 
composition 
9701 participants with dietary data at baseline 
9633 underwent examinations of body composition 
before end of follow-up 
9620 with BMI 
9474 with waist circumference 
6153 with fat mass index and body fat percentage 
Figure 1. Participants selection 
 
 
 
Population for current analyses  
For our current analyses, of the 14926 participants from the three sub-cohorts combined, we excluded 
5225 participants without valid dietary data (5141 without dietary data or unreliable dietary intake 
according to a trained nutritionist and 84 with an estimated energy intake of 500 or >5000 kcal/day), 
leaving 9701 participants with valid dietary data at baseline.14 Of the 9701 participants, 9633 
participants had at least one time measurement of body composition: resulting in 9620 for longitudinal 
BMI analyses, 9474 for longitudinal waist circumference analyses, and 6153 for longitudinal fat mass 
index and body fat percentage analyses. Figure 1 shows details of the participant selection.  
Dietary assessment and plant-based diet index  
Dietary intake was assessed at baseline of all sub-cohorts using a semi-quantitative food-frequency 
questionnaires (FFQ), as described in detail elsewhere.16 Briefly, for RS-I (RS-I-1: 1989-93) and RS-II 
(RS-II-1: 2000-01) an FFQ with 170 food items was used;17 and for RS-III (RS-III-1: 2006-08) an FFQ 
with 389 food items was used.18 The validity of the questionnaires has been described previously.16-18 
Based on the dietary data, we constructed a plant-based diet index to assess variation in degree of 
adherence to a plant-based diet, which was a modified version of two previously created indices.12, 13 
First, the food items measured by FFQs were divided into 23 food groups (Supplemental Table 1) 
based on the Dutch food-based dietary guidelines, which were on the basis of similarities of the food 
items in (botanical) origin, nutrient composition. Of the 23 food groups, twelve food groups were 
plant-based (fruits, vegetables, whole grains, nuts, legumes, potatoes, vegetable oils, tea and coffee, 
sugary beverages, refined grains, sweets, alcoholic beverages), and eleven food groups were animal-
based (low-fat milk, low-fat yoghurt, full-fat milk, full-fat yoghurt, cheese, fish, eggs, animal fat, 
unprocessed lean meat, processed and red meat, dessert and sugary dairy). For each food group, we 
divided the intake (gram) into cohort-specific quintiles. Each quintile was scored between 0 to 4. We 
gave plant-based foods positive scores. Consumption of plant-based foods within the highest quintile 
was scored a 4, consumption of plant-based foods within the second highest quintile was scored a 3, 
ending with consumption of plant-based food within the lowest quintile was scored a 0. By contrast, 
we gave animal-based foods reverse scores. Consumption of animal-based foods within the highest 
quintile was scored a 0, consumption of animal-based food within the second highest quintile was 
scored a 1, ending with consumption within the lowest quintile was scored a 4. Additionally, all 
participants with null consumption were given the score belonging to the lowest quintile by re-scoring 
when necessary. Finally, these category quintile-scores were added up for each participant to create a 
plant-based diet index, which measured degree of adherence to a plant-based diet on a continuous 
scale, with a lowest possible score of 0 (low adherence to a diet high in plant-based foods and low in 
animal-based foods) and a highest possible score of 92 (high adherence: high plant-based and low 
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sugary beverages, refined grains, sweets, alcoholic beverages), and eleven food groups were animal-
based (low-fat milk, low-fat yoghurt, full-fat milk, full-fat yoghurt, cheese, fish, eggs, animal fat, 
unprocessed lean meat, processed and red meat, dessert and sugary dairy). For each food group, we 
divided the intake (gram) into cohort-specific quintiles. Each quintile was scored between 0 to 4. We 
gave plant-based foods positive scores. Consumption of plant-based foods within the highest quintile 
was scored a 4, consumption of plant-based foods within the second highest quintile was scored a 3, 
ending with consumption of plant-based food within the lowest quintile was scored a 0. By contrast, 
we gave animal-based foods reverse scores. Consumption of animal-based foods within the highest 
quintile was scored a 0, consumption of animal-based food within the second highest quintile was 
scored a 1, ending with consumption within the lowest quintile was scored a 4. Additionally, all 
participants with null consumption were given the score belonging to the lowest quintile by re-scoring 
when necessary. Finally, these category quintile-scores were added up for each participant to create a 
plant-based diet index, which measured degree of adherence to a plant-based diet on a continuous 
scale, with a lowest possible score of 0 (low adherence to a diet high in plant-based foods and low in 
animal-based foods) and a highest possible score of 92 (high adherence: high plant-based and low 
Chapter 2
144
 
 
 
animal-based). Further details of this index were described elsewhere.14 Information on intake of each 
food group across quintiles of this plant-based diet score is shown in Supplemental Table 2. 
Assessment of anthropometrics and body composition 
Anthropometrics and body composition were repeatedly measured in our research center 
(Supplemental Table 3). Body weight was measured using a digital scale and body height was measured 
using a stadiometer, while participants wore light clothing and no shoes. BMI (kg/m2) was calculated: 
Body weight (kg) / (Height (m) × Height (m)). We measured height and weight at six time points in 
RS-I (1989-2015); at four time points in RS-II (2000-16); and at two time points in RS-III (2006-14). 
Waist circumference (cm) was measured at the level midway between the lower rib margin and the 
iliac crest with the participants in a standing position. We measured waist circumference at five time 
points in RS-I (1989-2015), at four time points in RS-II (2000-16), and at two time points in RS-III 
(2006-14). Body fat and fat-free mass were measured with dual energy X-ray absorptiometry (DXA) 
Prodigy and iDXA devices (starting in 2002). Data for these outcomes were therefore available for 
the three time points in RS-I (2002-15) and RS-II (2004-16), respectively; and for two time points for 
RS-III (2006-14). From the DXA data we calculated adiposity outcomes: fat mass index (Fat mass (kg) 
/ (Height (m) × Height (m)), and body fat percentage (fat mass (kg) / weight (kg)*100)). We also 
calculated fat-free mass index (Fat-free mass (kg) / (Height (m) × Height (m)). 
Assessment of covariates 
Information on smoking status and educational level was obtained during home interviews at baseline. 
Physical activity was assessed with an adapted version of the Zutphen Physical Activity Questionnaire 
at RS-I-3 and RS-II-1, and with the LASA Physical Activity Questionnaire at RS-III-1.19 To account 
for differences between the two questionnaires, questionnaire-specific z-scores of metabolic 
equivalent of task-hours per week were calculated. Obesity was defined as BMI ≥ 30 kg/m2.20 
Information of diabetes, coronary heart disease, and cancers were obtained from general practitioners, 
pharmacies’ databases, Nationwide Medical Register, and follow-up examinations in our research 
center.21-23  
Data analyses 
We specified linear mixed models to analyze associations of the score on the plant-based diet index 
with adiposity outcomes over time. Likelihood ratio test, an objective model selection tool,24 was used 
to determine random-effect structure and fixed-effect structure. We constructed 2 models with a 
fixed-effect structure that included the plant-based diet score and possible confounders and a random-
effect structure including a random intercept and slope (for time of repeated measurements of 
adiposity outcomes). Non-linearity of associations of the score with outcomes using cubic splines 
 
 
 
(degree of freedom = 3) were explored, as no indications for non-linear associations for the main 
models were found, all primary analyses were performed using models assuming linearity. The plant-
based diet score was entered in models per 10 points higher score as 1 unit. Model 1 included plant-
based diet score, baseline age, sex, total energy intake (kcal/day), RS sub-cohort, time of repeated 
measurements of BMI, waist circumference, fat mass index, or body fat percentage. Model 2 
additionally included smoking status, education levels, physical activity, and food supplement use. The 
effect estimate for the plant-based diet score in the models indicates associations of the plant-based 
diet score with adiposity outcomes averaged across the median follow-up of 7.1 years. To explore 
whether an annual change in adiposity related to the plant-based diet score existed, i.e., whether the 
association between the plant-based diet score with adiposity differed across the follow-up time, a 
plant-based diet score × time interaction term was added to model 2 in a subsequent step.  
We also conducted several additional analyses. First, we examined whether the associations differed 
by baseline age or sex by including interaction with baseline age or sex in model 2. Second, we repeated 
our main analyses by examining the index categorized into quintiles with the lowest quartile as 
reference. Last, we analyzed the associations with fat-free mass index based on model 2.  
We performed sensitivity analyses based on model 2. First, we analyzed the associations with adiposity 
by excluding ‘alcoholic beverages’ from plant-based diet index. Second, to examine whether the 
associations of the plant-based diet with adiposity were independent of diet quality on the basis of 
dietary guidelines, we additionally adjusted for a diet quality score reflecting adherence to current 
Dutch dietary guidelines. Third, to examine whether our main results were robust after incorporating 
potential effect of dietary intake at follow-up, we further adjusted for plant-based diet score measured 
at RS-I-5 and RS-II-3 (20 years after RS-I baseline and 10 years after RS-II baseline) among 
participants with these data available. In this sensitivity analysis, we also adjusted for physical activity 
at RS-I-5 and RS-II-3. Fourth, to examine the individual contributions of healthy plant-based foods 
combined (fruits, vegetables, whole grains, legumes, nuts, vegetable oils, coffee and tea) and less 
healthy plant-based foods combined (sweets, sugary beverages, refined grains, potatoes) in the 
potential associations, we repeated our analyses by excluding these less healthy plant-based foods 
combined at a time, or these healthy plant-based foods combined at a time from the plant-based diet 
index and additionally adjusting for the excluded food groups. Fifth, we examined the association 
between a plant-based diet that is also high in healthy animal-based foods including fish, eggs, low-fat 
milk and low-fat yoghurt with adiposity. Sixth, we additionally adjusted for baseline health conditions 
including baseline diabetes, coronary heart disease, obesity, and cancers. Seventh, we excluded the 
participants with diabetes, coronary heart disease, obesity, or cancers at baseline, and further censored 
body composition data measured after onset of diabetes, coronary heart disease, and cancers during 
follow-up, and examined the associations. Last, we repeated our main analyses in three sub-cohorts, 
respectively. 
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We also conducted several additional analyses. First, we examined whether the associations differed 
by baseline age or sex by including interaction with baseline age or sex in model 2. Second, we repeated 
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reference. Last, we analyzed the associations with fat-free mass index based on model 2.  
We performed sensitivity analyses based on model 2. First, we analyzed the associations with adiposity 
by excluding ‘alcoholic beverages’ from plant-based diet index. Second, to examine whether the 
associations of the plant-based diet with adiposity were independent of diet quality on the basis of 
dietary guidelines, we additionally adjusted for a diet quality score reflecting adherence to current 
Dutch dietary guidelines. Third, to examine whether our main results were robust after incorporating 
potential effect of dietary intake at follow-up, we further adjusted for plant-based diet score measured 
at RS-I-5 and RS-II-3 (20 years after RS-I baseline and 10 years after RS-II baseline) among 
participants with these data available. In this sensitivity analysis, we also adjusted for physical activity 
at RS-I-5 and RS-II-3. Fourth, to examine the individual contributions of healthy plant-based foods 
combined (fruits, vegetables, whole grains, legumes, nuts, vegetable oils, coffee and tea) and less 
healthy plant-based foods combined (sweets, sugary beverages, refined grains, potatoes) in the 
potential associations, we repeated our analyses by excluding these less healthy plant-based foods 
combined at a time, or these healthy plant-based foods combined at a time from the plant-based diet 
index and additionally adjusting for the excluded food groups. Fifth, we examined the association 
between a plant-based diet that is also high in healthy animal-based foods including fish, eggs, low-fat 
milk and low-fat yoghurt with adiposity. Sixth, we additionally adjusted for baseline health conditions 
including baseline diabetes, coronary heart disease, obesity, and cancers. Seventh, we excluded the 
participants with diabetes, coronary heart disease, obesity, or cancers at baseline, and further censored 
body composition data measured after onset of diabetes, coronary heart disease, and cancers during 
follow-up, and examined the associations. Last, we repeated our main analyses in three sub-cohorts, 
respectively. 
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All results were examined based on the combined data from RS-I, RS-II, and RS-III. All variables 
included in analyses were used to predict missingness patterns. Missing values on covariates 
(Supplemental Table 4) were assumed to be missing at random and accounted for using multiple 
imputations (m=10 imputations). We used SPSS version 21 (IBM Corp., Armonk, NY, USA) and R 
version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) to perform these analyses. 
 
RESULTS  
Baseline characteristics  
Baseline characteristics of the study population are shown in Table 1. In 9633 participants, the baseline 
plant-based diet score (with a theoretical range from 0.0 to 92.0) ranged from 21.0 to 73.0, with a 
mean ± SD score of 49.0±7.0. Mean age of the study population at baseline was 64.2±8.7 years. Mean 
baseline BMI, waist circumference, fat mass index, and body fat percentage was 26.8±4.0 kg/m2, 
91.6±11.8 cm, 9.2±3.4 kg/m2, and 34.2±8.4, respectively. Compared with the participants in the 
lowest quintile of the score, the participants in the highest quintile were older, more active, more highly 
educated, and less likely to smoke.    
Repeated measurements of adiposity were performed during a median follow-up of 7.1 years (range 
0-25 years) (Supplemental Table 3). Of the 9620 participants with BMI measurements, 8215 
underwent at least two examinations of BMI; of the 9474 participants with waist circumference 
measurements, 6196 underwent at least two examinations of waist circumference; and of 6153 
participants with fat mass index and body fat percentage measurements, 3806 underwent at the least 
two examinations of fat mass index and body fat percentage. 
Degree of adherence to a plant-based diet and adiposity 
After multivariable adjustment, more adherence to a plant-based diet was associated with lower BMI, 
waist circumference, fat mass index, and body fat percentage averaged across the median follow-up 
of 7.1 years (per 10 points higher score, BMI: β= -0.70, 95% CI: -0.81, -0.59; waist circumference: β= 
-2.0, 95% CI: -2.3, -1.7; fat mass index: β= -0.66, 95% CI: -0.80, -0.52; body fat percentage: β= -1.1, 
95% CI: -1.3, -0.84) (Table 2). Interactions of the plant-based diet score with time were not statistically 
significant for any of the outcomes (Table 2), indicating that no change in the strength of associations 
with BMI, fat mass index, waist circumference, and body fat percentage across the follow-up period. 
Therefore, our models estimated that for participants having a 10 points higher score on the plant-
based diet index, their mean BMI, waist circumference, fat mass index, and body fat percentage were 
0.70 kg/m2 lower, 2.0 cm lower, 0.66 kg/m2 lower, and 1.1 lower across the median follow-up of 7.1 
years.   
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All results were examined based on the combined data from RS-I, RS-II, and RS-III. All variables 
included in analyses were used to predict missingness patterns. Missing values on covariates 
(Supplemental Table 4) were assumed to be missing at random and accounted for using multiple 
imputations (m=10 imputations). We used SPSS version 21 (IBM Corp., Armonk, NY, USA) and R 
version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) to perform these analyses. 
 
RESULTS  
Baseline characteristics  
Baseline characteristics of the study population are shown in Table 1. In 9633 participants, the baseline 
plant-based diet score (with a theoretical range from 0.0 to 92.0) ranged from 21.0 to 73.0, with a 
mean ± SD score of 49.0±7.0. Mean age of the study population at baseline was 64.2±8.7 years. Mean 
baseline BMI, waist circumference, fat mass index, and body fat percentage was 26.8±4.0 kg/m2, 
91.6±11.8 cm, 9.2±3.4 kg/m2, and 34.2±8.4, respectively. Compared with the participants in the 
lowest quintile of the score, the participants in the highest quintile were older, more active, more highly 
educated, and less likely to smoke.    
Repeated measurements of adiposity were performed during a median follow-up of 7.1 years (range 
0-25 years) (Supplemental Table 3). Of the 9620 participants with BMI measurements, 8215 
underwent at least two examinations of BMI; of the 9474 participants with waist circumference 
measurements, 6196 underwent at least two examinations of waist circumference; and of 6153 
participants with fat mass index and body fat percentage measurements, 3806 underwent at the least 
two examinations of fat mass index and body fat percentage. 
Degree of adherence to a plant-based diet and adiposity 
After multivariable adjustment, more adherence to a plant-based diet was associated with lower BMI, 
waist circumference, fat mass index, and body fat percentage averaged across the median follow-up 
of 7.1 years (per 10 points higher score, BMI: β= -0.70, 95% CI: -0.81, -0.59; waist circumference: β= 
-2.0, 95% CI: -2.3, -1.7; fat mass index: β= -0.66, 95% CI: -0.80, -0.52; body fat percentage: β= -1.1, 
95% CI: -1.3, -0.84) (Table 2). Interactions of the plant-based diet score with time were not statistically 
significant for any of the outcomes (Table 2), indicating that no change in the strength of associations 
with BMI, fat mass index, waist circumference, and body fat percentage across the follow-up period. 
Therefore, our models estimated that for participants having a 10 points higher score on the plant-
based diet index, their mean BMI, waist circumference, fat mass index, and body fat percentage were 
0.70 kg/m2 lower, 2.0 cm lower, 0.66 kg/m2 lower, and 1.1 lower across the median follow-up of 7.1 
years.   
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Additional results 
The interaction of the index with baseline age or sex was not statistically significant (Supplemental 
Table 5). However, we observed that compared to the participants in the lowest quintile, those in the 
highest quintile had a lower BMI, waist circumference, fat mass index, and body fat percentage (Table 
3). Furthermore, we observed that more adherence to a plant-based diet was associated with slightly 
lower fat-free mass index based on model 2 (per 10 points higher score, fat-free mass index: -0.16 (-
0.21, -0.11) averaged across the median follow-up of 7.1 years). 
Sensitivity analyses results 
Exclusion of alcoholic beverages from plant-based diet index did not substantially change our 
estimates (Supplemental Table 6). The estimates were similar after additional adjustment for dietary 
intake and physical activity at RS-I-5 and RS-II-3 or for baseline diet quality reflecting adherence to 
dietary guidelines (Supplemental Table 7). Exclusion of the less healthy plant-based foods combined 
from the plant-based diet index did not substantially change the estimates; while exclusion of the 
healthy plant-based foods combined from the plant-based diet index moderately attenuated the inverse 
associations (Supplemental Table 8). The associations were also moderately attenuated by giving fish, 
eggs, low-fat milk, and low-yoghurt positive scores (Supplemental Table 9). Adjustment for baseline 
health conditions or exclusion of participants with obesity, diabetes, coronary heart disease, or cancers 
at baseline and censoring body composition data collected after onset of these diseases did not 
substantially affect our findings (Supplemental Table 10). The estimates were similar in the three sub-
cohorts (Supplemental Table 11). 
 
DISCUSSION  
In the present study, we observed that higher adherence to a plant-based diet was associated with 
lower adiposity status averaged across the median follow-up of 7.1 years, and the inverse associations 
with adiposity remained stable over time. Our results were in line with the results from previous studies 
reporting reverse associations of vegetarian or vegan diets with BMI.1-5 More importantly, we extended 
this evidence by showing associations of adherence to a plant-based diet beyond vegetarian or vegan 
diets irrespective of general healthfulness of the specific plant- and animal-based foods, and by 
presenting that this is not only associated with BMI, but with detailed measures of adiposity over time.  
However, we acknowledge that our plant-based diet included less healthy plant-based foods (sweets, 
potatoes, refined grains, sugary beverages). That is because we took into account the fact that most of 
populations are not likely to completely avoid less healthy plant-based foods intake in real life. To 
further clarify the individual contributions of these healthy plant-based foods combined and less 
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Additional results 
The interaction of the index with baseline age or sex was not statistically significant (Supplemental 
Table 5). However, we observed that compared to the participants in the lowest quintile, those in the 
highest quintile had a lower BMI, waist circumference, fat mass index, and body fat percentage (Table 
3). Furthermore, we observed that more adherence to a plant-based diet was associated with slightly 
lower fat-free mass index based on model 2 (per 10 points higher score, fat-free mass index: -0.16 (-
0.21, -0.11) averaged across the median follow-up of 7.1 years). 
Sensitivity analyses results 
Exclusion of alcoholic beverages from plant-based diet index did not substantially change our 
estimates (Supplemental Table 6). The estimates were similar after additional adjustment for dietary 
intake and physical activity at RS-I-5 and RS-II-3 or for baseline diet quality reflecting adherence to 
dietary guidelines (Supplemental Table 7). Exclusion of the less healthy plant-based foods combined 
from the plant-based diet index did not substantially change the estimates; while exclusion of the 
healthy plant-based foods combined from the plant-based diet index moderately attenuated the inverse 
associations (Supplemental Table 8). The associations were also moderately attenuated by giving fish, 
eggs, low-fat milk, and low-yoghurt positive scores (Supplemental Table 9). Adjustment for baseline 
health conditions or exclusion of participants with obesity, diabetes, coronary heart disease, or cancers 
at baseline and censoring body composition data collected after onset of these diseases did not 
substantially affect our findings (Supplemental Table 10). The estimates were similar in the three sub-
cohorts (Supplemental Table 11). 
 
DISCUSSION  
In the present study, we observed that higher adherence to a plant-based diet was associated with 
lower adiposity status averaged across the median follow-up of 7.1 years, and the inverse associations 
with adiposity remained stable over time. Our results were in line with the results from previous studies 
reporting reverse associations of vegetarian or vegan diets with BMI.1-5 More importantly, we extended 
this evidence by showing associations of adherence to a plant-based diet beyond vegetarian or vegan 
diets irrespective of general healthfulness of the specific plant- and animal-based foods, and by 
presenting that this is not only associated with BMI, but with detailed measures of adiposity over time.  
However, we acknowledge that our plant-based diet included less healthy plant-based foods (sweets, 
potatoes, refined grains, sugary beverages). That is because we took into account the fact that most of 
populations are not likely to completely avoid less healthy plant-based foods intake in real life. To 
further clarify the individual contributions of these healthy plant-based foods combined and less 
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healthy plants-based foods combined to the inverse associations with adiposity, we examined the 
associations of the plant-based diet score by excluding less healthy plant-based foods combined or 
healthy plant-based foods combined from the index in sensitivity analyses. We observed that a higher 
plant-based diet score remained strongly associated with less adiposity irrespective of exclusion of 
healthy plant-based foods or less healthy plant-based foods, although exclusion of the healthy plant-
based foods moderately attenuated the associations. This indicates that the beneficial associations of 
the plant-based diet score were contributed to by both of substitution of the healthy plant-based foods 
and the less plant-based foods for animal-based foods, although substitution of the healthy plant-
based foods for animal-based foods appeared to contribute more. Our findings suggest a beneficial 
effect of an overall plant-based diet on adiposity, irrespective of general healthfulness of the specific 
plant- and animal-based foods, which increase potentials of recommendation for population. Our 
findings also suggest that healthy plant-based foods may contribute more to the beneficial effect, 
which emphasizes that it is important to also consider the quality of plant-based foods consumed.  
Potential mechanisms underlying the inverse association with adiposity 
The inverse associations of a plant-based diet with adiposity could be partly explained by more intake 
of certain components of plant-based foods.25 A diet high in plant-based foods usually contains more 
fiber, chlorogenic acids, antioxidants, plant protein and plant unsaturated fatty acids. For example, 
vegetables and fruits are the main sources of fiber, antioxidants, and chlorogenic acids; nuts are rich 
in poly-unsaturated fatty acids; soy and pulses are main sources of plant protein; and coffee and tea 
are rich in antioxidants and phenol chlorogenic acid. These components have been suggested to 
reduce adiposity through different pathways and intermediate conditions, such as satiety,6 
inflammation,7-10 oxidative stress,10 and gut microbiome composition.11 Lower intake of certain 
components of animal-based foods also may explain our findings. A diet low in animal-based foods 
contains less animal protein and saturated fatty acids. Lower intake of these components has been 
suggested to be beneficial for prevention of obesity.9, 26  
Important implication 
Our findings have important public health implications. In our study, based on the comparison of 
food components in lowest quintile of the score as reference and highest quintile of the score that was 
associated with lower adiposity status, we observed that a beneficial plant-based diet for improvement 
of adiposity does not require a total elimination of meat or animal products, but instead can be 
achieved by a moderate decrease in animal-based foods intake, and a moderate increase in plant-based 
foods intake, increasing the potential for population-wide health recommendations. For example, we 
observed that the participants in the highest quintile of the score might have an averagely 4.1 cm lower 
waist circumference and 1.3 kg/m2 lower BMI across the median follow-up of 7.1 years, compared 
 
 
 
with those in the lowest quintile of the score, yet the participants in the highest quintile had a median 
red meat consumption of 81.6 g per day and a median vegetables consumption of 234.4 g per day, 
relative to a median red meat consumption of 92.5 g per day and a median vegetable consumption of 
178.7 g per day of the participants in the lowest quintile .  
Study strengths and limitations 
Our study has several strengths. First, to our knowledge, this is the first study to examine associations 
of degree of adherence to a plant-based diet with adiposity over time, for which we had longitudinal 
detailed data on adiposity including BMI, waist circumference, fat mass index, and body fat percentage. 
Second, to assess the gradations of adherence to a plant-based diet, we used a novel plant-based diet 
score. Previous studies have indicated low and moderate correlations between the novel plant-based 
diet score with other known diet scores, such as the Mediterranean Diet score. Furthermore, our 
results showed beneficial associations of an overall plant-based diet score with adiposity, independent 
of adherence to current dietary guidelines, which indicated that our plant-based diet score might reflect 
another distinguishing aspect of a healthful diet more than solely assessment of diet quality according 
to current guidelines. Last, our study highlights that higher adherence to plant-based diets beyond 
vegan or vegetarian diets may help prevent obesity, irrespective of general healthfulness of the specific 
plant- and animal-based foods, which increase the potential for population-wide health 
recommendations.  
However, we also acknowledge some limitations. First, dietary information was derived from self-
report, measurement-errors was possible. However, because the FFQs used in our cohort were shown 
in several validation studies to adequately rank subjects according to food and nutrient intake,17, 18 and 
because we used relative quintiles of foods intake (gram) to create the score, we do not expect these 
measurement-errors to have largely affected the index. Second, we only used baseline measurement 
of dietary intake in main analyses, whereas diet could change over time, and repeated measurements 
of diet over time would be preferable. We also only adjusted for baseline covariates, instead of time-
varying covariates in main analyses, whereas, these covariates were not necessarily constant through 
the follow-up. However, we explored the potential effect of dietary intake and physical activity at 
follow-up on the associations in a subgroup of participants with these data available and observed 
similar results. Furthermore, after excluding the participants who were likely to change their diet and 
lifestyle at follow-up, such as participants with diabetes and cancers at baseline, the estimates were still 
similar. Combined, these results indicate that our findings were robust. Third, many of the participants 
of the original cohort were excluded due to report of invalid dietary information, which might have 
led to selection bias if associations of plant-based diet with adiposity differed in those included and 
those not included in our current analyses. Fourth, we used two different FFQs to measure dietary 
intake and two different physical activity questionnaires to measure physical activity level at different 
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healthy plants-based foods combined to the inverse associations with adiposity, we examined the 
associations of the plant-based diet score by excluding less healthy plant-based foods combined or 
healthy plant-based foods combined from the index in sensitivity analyses. We observed that a higher 
plant-based diet score remained strongly associated with less adiposity irrespective of exclusion of 
healthy plant-based foods or less healthy plant-based foods, although exclusion of the healthy plant-
based foods moderately attenuated the associations. This indicates that the beneficial associations of 
the plant-based diet score were contributed to by both of substitution of the healthy plant-based foods 
and the less plant-based foods for animal-based foods, although substitution of the healthy plant-
based foods for animal-based foods appeared to contribute more. Our findings suggest a beneficial 
effect of an overall plant-based diet on adiposity, irrespective of general healthfulness of the specific 
plant- and animal-based foods, which increase potentials of recommendation for population. Our 
findings also suggest that healthy plant-based foods may contribute more to the beneficial effect, 
which emphasizes that it is important to also consider the quality of plant-based foods consumed.  
Potential mechanisms underlying the inverse association with adiposity 
The inverse associations of a plant-based diet with adiposity could be partly explained by more intake 
of certain components of plant-based foods.25 A diet high in plant-based foods usually contains more 
fiber, chlorogenic acids, antioxidants, plant protein and plant unsaturated fatty acids. For example, 
vegetables and fruits are the main sources of fiber, antioxidants, and chlorogenic acids; nuts are rich 
in poly-unsaturated fatty acids; soy and pulses are main sources of plant protein; and coffee and tea 
are rich in antioxidants and phenol chlorogenic acid. These components have been suggested to 
reduce adiposity through different pathways and intermediate conditions, such as satiety,6 
inflammation,7-10 oxidative stress,10 and gut microbiome composition.11 Lower intake of certain 
components of animal-based foods also may explain our findings. A diet low in animal-based foods 
contains less animal protein and saturated fatty acids. Lower intake of these components has been 
suggested to be beneficial for prevention of obesity.9, 26  
Important implication 
Our findings have important public health implications. In our study, based on the comparison of 
food components in lowest quintile of the score as reference and highest quintile of the score that was 
associated with lower adiposity status, we observed that a beneficial plant-based diet for improvement 
of adiposity does not require a total elimination of meat or animal products, but instead can be 
achieved by a moderate decrease in animal-based foods intake, and a moderate increase in plant-based 
foods intake, increasing the potential for population-wide health recommendations. For example, we 
observed that the participants in the highest quintile of the score might have an averagely 4.1 cm lower 
waist circumference and 1.3 kg/m2 lower BMI across the median follow-up of 7.1 years, compared 
 
 
 
with those in the lowest quintile of the score, yet the participants in the highest quintile had a median 
red meat consumption of 81.6 g per day and a median vegetables consumption of 234.4 g per day, 
relative to a median red meat consumption of 92.5 g per day and a median vegetable consumption of 
178.7 g per day of the participants in the lowest quintile .  
Study strengths and limitations 
Our study has several strengths. First, to our knowledge, this is the first study to examine associations 
of degree of adherence to a plant-based diet with adiposity over time, for which we had longitudinal 
detailed data on adiposity including BMI, waist circumference, fat mass index, and body fat percentage. 
Second, to assess the gradations of adherence to a plant-based diet, we used a novel plant-based diet 
score. Previous studies have indicated low and moderate correlations between the novel plant-based 
diet score with other known diet scores, such as the Mediterranean Diet score. Furthermore, our 
results showed beneficial associations of an overall plant-based diet score with adiposity, independent 
of adherence to current dietary guidelines, which indicated that our plant-based diet score might reflect 
another distinguishing aspect of a healthful diet more than solely assessment of diet quality according 
to current guidelines. Last, our study highlights that higher adherence to plant-based diets beyond 
vegan or vegetarian diets may help prevent obesity, irrespective of general healthfulness of the specific 
plant- and animal-based foods, which increase the potential for population-wide health 
recommendations.  
However, we also acknowledge some limitations. First, dietary information was derived from self-
report, measurement-errors was possible. However, because the FFQs used in our cohort were shown 
in several validation studies to adequately rank subjects according to food and nutrient intake,17, 18 and 
because we used relative quintiles of foods intake (gram) to create the score, we do not expect these 
measurement-errors to have largely affected the index. Second, we only used baseline measurement 
of dietary intake in main analyses, whereas diet could change over time, and repeated measurements 
of diet over time would be preferable. We also only adjusted for baseline covariates, instead of time-
varying covariates in main analyses, whereas, these covariates were not necessarily constant through 
the follow-up. However, we explored the potential effect of dietary intake and physical activity at 
follow-up on the associations in a subgroup of participants with these data available and observed 
similar results. Furthermore, after excluding the participants who were likely to change their diet and 
lifestyle at follow-up, such as participants with diabetes and cancers at baseline, the estimates were still 
similar. Combined, these results indicate that our findings were robust. Third, many of the participants 
of the original cohort were excluded due to report of invalid dietary information, which might have 
led to selection bias if associations of plant-based diet with adiposity differed in those included and 
those not included in our current analyses. Fourth, we used two different FFQs to measure dietary 
intake and two different physical activity questionnaires to measure physical activity level at different 
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sub-cohorts. However, we do not expect the use of different questionnaires to considerably influence 
our findings, since the associations were similar in the three RS sub-cohorts. Fifth, we noticed that 
more adherence to a plant-based diet was associated with slightly lower fat-free mass index in 
additional analyses, which indicated that more adherence to a plant-based diet might not be beneficial 
for prevention of fat-free mass loss. However, the inverse association of a plant-based diet was much 
stronger for fat mass than for fat-free mass, suggesting overall beneficial effect on adiposity, which 
was also reflected by the lower body fat percentage. Finally, our results may not be generalizable to 
people of other race and age, therefore replication in other populations is warranted. 
Conclusions  
A diet higher in plant-based foods and lower in animal-based foods beyond strict vegan or vegetarian 
diet, was associated with lower adiposity status over time, irrespective of healthfulness of specific 
plant- and animal- based foods. 
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GENERAL DISCUSSION 
AIMS 
The main aim of this thesis was to investigate the role of nutrition and gut microbiome in type 2 
diabetes (T2D) risk. Regarding nutrition, I was interested in dietary protein intake and plant-based diet, 
because evidence for dietary protein intake was inconsistent, and because evidence for plant-based 
diets, defined as a low frequency of animal-based foods, and T2D risk was very limited. To better 
understand the role of nutrition in T2D, including its early stages and its consequences, we also 
investigated associations with obesity, insulin resistance, prediabetes, and mortality. Another interest 
in my research was gut microbiome composition as an important potential determinant of T2D risk, 
which in turn may be modified by diet. In this part, I was interested in not only microbial alpha and 
beta diversities, but also gut microbial taxa at phylum, order, class, family, and genus levels. We studied 
associations between this detailed composition of the microbiome and T2D risk, and we also 
investigated associations of overall diet quality and food groups intake with gut microbiome 
composition.  
 
MAIN FINDINGS 
Chapter 2: The role of nutrition in T2D risk 
In Chapter 2, we studied associations of dietary protein intake and plant-based diet with T2D risk, and 
additionally with obesity, insulin resistance, prediabetes risk, and risk of all-cause and cause-specific 
mortality. We observed that in middle-aged and elderly Dutch participants, higher intake of animal 
protein was associated with higher insulin resistance, and risk of prediabetes and T2D, which did not 
differ by protein from meat, fish or dairy. In contrast, plant protein intake was not associated with 
insulin resistance, and risk of prediabetes and T2D, which also did not differ by more specific protein 
sources, including protein from legumes and nuts, from potatoes, from grains, or from vegetables and 
fruits. We also observed that higher total or animal protein intake was associated with higher all-cause 
mortality and cardiovascular diseases (CVD) mortality, although not with cancer mortality and other 
mortality. And plant protein intake was not associated with all-cause and cause-specific mortality in 
middle-aged and elderly Dutch participants. These findings for animal protein intake and mortality 
were supported in a meta-analysis pooling results from the Rotterdam Study and other cohorts. 
However, this meta-analysis indicated that higher plant protein intake was associated with lower all-
cause and CVD mortality. In line with our findings on animal and plant protein, in another separate 
analysis, we observed a beneficial association between an overall more plant-based and less animal-
based diet with adiposity, insulin resistance, and risk of prediabetes and T2D.  
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Chapter 3: The role of gut microbiome in T2D risk 
In chapter 3, we investigated associations between gut microbiome with insulin resistance and T2D 
risk. In the Rotterdam Study we observed that higher alpha diversity (higher Shannon index, richness, 
or Inverse Simpson index) was associated with lower insulin resistance or T2D risk. Insulin resistance 
and T2D also may explain beta diversity (Bray-Curtis distance). Furthermore, we also observed that 
more abundance of family Christensenellaceae, genus Marvinbryantia, genus RuminococcaceaeUCG005, 
genus RuminococcaceaeUCG008, genus RuminococcaceaeUCG010, and genus RuminococcaceaeNK4A214group 
was associated with lower insulin resistance; and that more abundance of family Clostridiaceae, family 
Peptostreptococcaceae, genus Clostridiumsensustricto, genus Intestinibacter, or genus Romboutsia was 
associated with lower prevalence of T2D. Moreover, we also observed similar results for alpha 
diversity, beta diversity, and gut microbial taxa in the Lifelines-Deep Study. Furthermore, a meta-
analysis of results from the two cohort studies corroborated the results of the Rotterdam Study.   
Chapter 4: The link between nutrition and gut microbiome 
In chapter 4, we studied the associations between overall diet quality as adherence to Dutch dietary 
guidelines and the 14 food groups included in the diet quality score with gut microbiome composition. 
In the Rotterdam Study, we observed that higher overall diet quality was suggestively associated with 
higher alpha diversity (higher Shannon index, and richness); that diet quality explained the variation 
of the beta diversity (Bray-Curtis distance); and that overall diet quality was associated with relative 
abundance of 29 gut microbial taxa. Some of the taxa, such as the family Erysipelotrichia, and 
Ruminococcaceae, have previously suggested to be related to inflammatory and metabolic diseases. 
Furthermore, we also observed that most of the individual food groups included in the diet quality 
were associated with gut microbiome composition. For example, higher intake of fruit and vegetable 
was associated with higher alpha diversity. Fruits, vegetables, legumes, whole grains, fish, and meat 
explained beta diversity. Fruits, vegetables, legumes, nuts, tea, whole grains, and meat were all 
associated with relative abundance of certain gut microbial taxa. 
Taken together, our studies have indicated that nutrition and gut microbiome composition may 
influence the development of T2D, and that gut microbiome composition may be modified by 
nutrition. On basis of these results, I think that gut microbiome might be a mechanism or mediator 
for the associations between nutrition and the development of T2D.  
 
METHODOLOGICAL CONSIDERATIONS 
In this section, I present and discuss some of the methodological issues that I faced in identifying the 
associations of nutrition and gut microbiome with T2D. In particularly, I focus on methodological 
 
 
 
issues of the overall study design, and the measurement of nutrition and gut microbiome composition. 
Furthermore, I also highlight emerging methodological trends in the assessment of nutrition and gut 
microbiome, in the context of the aims of my research. 
Study design and study population     
For the studies in this thesis, most data were from the Rotterdam Study, and replication analyses were 
performed in the Lifelines-Deep Study, which are both population-based prospective cohorts. The 
Rotterdam Study consists of middle-aged and elderly participants in Ommoord district of the 
Rotterdam city.1 The Linelines-Deep Study contains participants aged 18 years or older from the 
northern regions of the Netherlands.2  
Therefore, all the data were of observational nature. When interpreting results of our studies, both 
internal validity and external validity should be considered. Regarding internal validity, three different 
types of bias should be taken into account, i.e. selection bias, information bias, and confounding. Here 
I first discuss selection bias and confounding; information bias is discussed in the next paragraph on 
dietary assessment.  
In this thesis, the analyses population from the Rotterdam Study tended toward a selection of a 
healthier population with a higher social-economic status, compared to the populations from the 
Rotterdam Study that could not be included into our analyses due to various reasons, such as lack of 
measures of dietary intake data at baseline. However, previous studies have indicated that selective 
non-participation at baseline is not likely to be related to future risk of diseases and therefore do not 
strongly influence associations, making bias due to selection less likely.3 However, the selection of 
participants still may affect the external validity of our findings, which should be considered when 
extending the application of our findings into other populations. For example, the Rotterdam Study 
and the Lifelines-Deep Study included general populations living in a Rotterdam suburb and the 
northern parts of the Netherlands, respectively. Therefore, our findings from these studies may not 
be completely generalizable to populations in other regions or countries where populations for 
example may have different dietary patterns and social economic status, such as Asian and African 
populations. A second type of bias that can threaten the internal validity in our observational studies, 
is confounding. Although the rich data in the Rotterdam Study and the Lifelines-Deep Study allowed 
us to adjust for various possible confounders in different associations studied in this thesis, the 
possibility of residual confounding cannot be completely ruled out. For example, in chapter 2.2 level 
of physical activity was measured at the third visit of the Rotterdam Study, while dietary intake 
questionnaires were completed in the first visit of the first sub-cohort of the Rotterdam Study. In 
chapters 3 and 4, I could not adjust for the status of the stool samples. Therefore, we cannot fully 
exclude residual confounding by the levels of physical activity, and the status of stools. The residual 
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confounding can lead to either overestimation or underestimation of the observed effect estimate. 
Given this, a simplistic and favorite response to concern about residual confounding and causality is 
to conduct a randomized controlled trial. Conducting a randomized controlled trial for research on 
nutrition and gut microbiome, or for gut microbiome and glucose metabolism could be possible, 
because evidence has shown that gut microbiome composition could be changed in 24 hours by diet,4 
and that insulin resistance of individuals with metabolic syndrome could be improved by fecal 
microbiota transplantation in a six-weeks trial.5 However, doing randomized trails is often infeasible 
in research on nutrition and chronic diseases, because decades of follow-up are needed for clinically 
relevant outcomes, such as T2D and CVD, to develop. When the potential for interventional research 
is limited, several other approaches such as Mendelian randomization analysis6 and Directed Acyclic 
Graphs,7 are considered to help to infer causality. However, these approaches face other challenges. 
A main challenge is that these approaches are based on a few underlying assumptions that are hard to 
verify in practice. For Mendelian randomization for example, strong claims of causality cannot be 
justified when the assumptions required for the instrumental variable analysis such as reproducible in 
multiple independent samples, and functionally related to the exposures, would be violated.8 Another 
helpful way of inferring causality could be to consider different types of exposure (i.e., dietary patterns, 
foods, nutrients, and biomarkers) and different types of data, such as longitudinal data9 within 
frameworks of well-conducted prospective cohort studies. We would consider whether findings from 
well-conducted prospective cohort studies keep in line with findings from other types of studies, such 
as animal studies, mechanic studies in human, randomized trials of intermediate trials of intermediate 
outcomes, and the Mendelian randomization analysis, if possible. If these findings are taken together 
to arrive a consensus, which can strengthen the inference of causality. For example, adherence to a 
plant-based diet has been suggested to have a beneficial effect on cardiometabolic intermediate risk 
factors in observational studies10 and RCTs.11 Staples of a plant-based diet such as fruits, vegetables, 
and whole grains, have been individually linked to lower risk of cardiometabolic risk factors.12, 13 
Reviews of major nutrients abundant in these foods, such as fibers, unsaturated fats and polyphenols, 
have confirmed this finding as well.10 Furthermore, adherence to a plant-based diet has also been 
associated with lower risk of cardiovascular hard endpoints, such as adiposity,14 T2D,15 and 
cardiovascular mortality.16-18 Besides, these findings are supported by some biological mechanisms and 
pathways.10 Such a convergence among these studies provides convincing support for adoption of a 
plant-based diet in prevention of CVD. Overall, corroborating data from multiple study types and 
populations can enhance the weight of evidence and help to infer causality. Furthermore, valid 
conclusions and policy decisions for dietary recommendation also need to evaluate and quantify 
sources of biases and to use the totality of the best available evidence, which is an iterative process.19  
  
 
 
 
Nutrition assessments  
For our studies involving dietary protein intake and plant-based diet, we used semi-food 
questionnaires (FFQs) to collect dietary intake data. The FFQ method is most widely used for dietary 
assessment in epidemiological studies for two reasons.19, 20 One reason is that researchers are generally 
interested in average relative long-term dietary intake, rather than on one or several specific days, and 
an FFQ measures this habitual dietary intake. The other reason is that FFQs are relatively easy to 
complete for study participants and relatively easy to process in large quantities without high cost 
compared to measurements of dietary biomarkers; these practical aspects make an FFQ as the method 
of choice for large studies. The main limitation of an FFQ is that a self-reported retrospective dietary 
assessment method, making measurement-errors likely. This measurement error is an important 
source of information bias in studies on dietary intake in relation to health or disease. This 
measurement error, or misclassification of exposure, is assumed to be mainly non-differential, 
indicating that it is random and not related to the outcomes under study. Non-differential 
measurement error of the exposure may result in attenuation of the observed associations and in wider 
confidence intervals. Hence, it leads to underestimation of associations and reduces statistical power 
to detect associations. However, errors in dietary intake assessment may also be differential, i.e., related 
to outcome. For example, evidence has indicated that obese people are more likely to underreport 
their habitual food intake than people with a normal weight.21 When one examines the association of 
diet with obesity or outcomes closely related to obesity, this underreporting could therefore lead to 
differential misclassification of exposure, which could be associated an overestimation or 
underestimation of the associations. We expect that the dietary measurement errors in our studies are 
unlikely to be strongly related to outcomes. However, differential measurement error cannot be ruled 
out.  
In our studies, we took some statistical-related methods to attempt to account for these potential 
measurement errors of dietary intake. For example, in analyses for dietary protein intake or a plant-
based diet score and outcomes, we adjusted for total energy intake. Energy adjustment addresses not 
only confounding by energy, but also the measurement error that is related to energy intake.22 
Furthermore, in analyses for dietary protein intake, we also used nutrients-density models.23 
Additionally, in analyses for a plant-based diet score, we created this plant-based diet score by using 
relative scores (quintiles) of intake of individual food items rather than absolute intakes, and the FFQs 
were shown in several validation studies to adequately rank subjects according to intake.24-27  
Another aspect of dietary assessment is repeated measurements of diet using FFQs. I acknowledge 
that repeated measurements of diet are also particularly useful in representing long-term dietary habits. 
Unfortunately, we did not measure dietary intake repeatedly among all participants of the Rotterdam 
Study, only in a subgroup of participants, with many years apart and using a different updated FFQ. 
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Nutrition assessments  
For our studies involving dietary protein intake and plant-based diet, we used semi-food 
questionnaires (FFQs) to collect dietary intake data. The FFQ method is most widely used for dietary 
assessment in epidemiological studies for two reasons.19, 20 One reason is that researchers are generally 
interested in average relative long-term dietary intake, rather than on one or several specific days, and 
an FFQ measures this habitual dietary intake. The other reason is that FFQs are relatively easy to 
complete for study participants and relatively easy to process in large quantities without high cost 
compared to measurements of dietary biomarkers; these practical aspects make an FFQ as the method 
of choice for large studies. The main limitation of an FFQ is that a self-reported retrospective dietary 
assessment method, making measurement-errors likely. This measurement error is an important 
source of information bias in studies on dietary intake in relation to health or disease. This 
measurement error, or misclassification of exposure, is assumed to be mainly non-differential, 
indicating that it is random and not related to the outcomes under study. Non-differential 
measurement error of the exposure may result in attenuation of the observed associations and in wider 
confidence intervals. Hence, it leads to underestimation of associations and reduces statistical power 
to detect associations. However, errors in dietary intake assessment may also be differential, i.e., related 
to outcome. For example, evidence has indicated that obese people are more likely to underreport 
their habitual food intake than people with a normal weight.21 When one examines the association of 
diet with obesity or outcomes closely related to obesity, this underreporting could therefore lead to 
differential misclassification of exposure, which could be associated an overestimation or 
underestimation of the associations. We expect that the dietary measurement errors in our studies are 
unlikely to be strongly related to outcomes. However, differential measurement error cannot be ruled 
out.  
In our studies, we took some statistical-related methods to attempt to account for these potential 
measurement errors of dietary intake. For example, in analyses for dietary protein intake or a plant-
based diet score and outcomes, we adjusted for total energy intake. Energy adjustment addresses not 
only confounding by energy, but also the measurement error that is related to energy intake.22 
Furthermore, in analyses for dietary protein intake, we also used nutrients-density models.23 
Additionally, in analyses for a plant-based diet score, we created this plant-based diet score by using 
relative scores (quintiles) of intake of individual food items rather than absolute intakes, and the FFQs 
were shown in several validation studies to adequately rank subjects according to intake.24-27  
Another aspect of dietary assessment is repeated measurements of diet using FFQs. I acknowledge 
that repeated measurements of diet are also particularly useful in representing long-term dietary habits. 
Unfortunately, we did not measure dietary intake repeatedly among all participants of the Rotterdam 
Study, only in a subgroup of participants, with many years apart and using a different updated FFQ. 
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Given this, we only conducted sensitivity analyses using these repeated dietary intake data available, 
and similar results were observed after adjustment for dietary intake at six to eight years of follow-up. 
Moreover, we also conducted several sets of sensitivity analyses by excluding participants who were 
expected to have changed their dietary intake over time and observed similar results. Additionally, our 
findings for dietary protein intake, plant-based diets and T2D risk were also similar with those 
observed in Nurse Health Study, Nurse Health Study II, and Health Professionals Follow-Up Study 
that had repeated measurements of dietary intake over time among a large US population during a 
long-time follow-up.  
Although FFQs have been widely used to measure dietary data in nutritional epidemiology research, 
and well-designed FFQs have been shown to adequately rank participant according to their usual diet, 
novel methods may improve the accuracy of dietary assessment, thereby benefit research of nutritional 
epidemiology. To date, objective biomarkers of nutrient intake or nutrient status (such as urine 
nitrogen levels for protein intake, blood levels of fat acids for certain fat intake, and carotenoids for 
certain plant-based foods) have been considered as powerful complementary tools to further improve 
the accuracy of dietary assessment.19 Especially, new omics technologies such as metabolomics might 
hold potentials as biomarkers of dietary intake or overall diet patterns, because metabolomics can 
measure the full profile of small-molecule metabolites in biofluids, thereby probably providing a 
comprehensive picture of an individual’s overall dietary intake.28 Overall, much effort is being paid to 
improve assessment of biomarkers for individual nutrients or foods and overall dietary patterns. 
However, improvement of dietary assessment is challenging, for example, some dietary biomarkers, 
such as fat biomarkers, appear not to accurately reflect specific dietary fat intake, which may be caused 
by some factors, such as genetic variability, lifestyle, and physiological factors.29 Furthermore, while 
many studies have indicated the association between dietary patterns and metabolomics profiles, only 
limited studies have shown the ability to classify or assign people into certain dietary patterns based 
on the metabolomics profiles as biomarkers.28 And these concentration biomarkers will not reflect 
only intake but also metabolism of the individual.19 Besides, these dietary biomarkers measures are 
generally more expensive and invasive, such as need of blood samples, which limits the wide use in 
large-scale epidemiological studies.  
Given this, I would consider that these objective measures, as complementary tools, rather than a 
replacement of self-reported FFQ to further improve assessment of dietary intake in nutritional 
epidemiologic studies.11 Further research on dietary biomarkers should be directed at: 1) refining 
existing dietary biomarkers by accounting for confounders, such as genetic variability, and lifestyles; 
2) discovering new valid biomarkers of individual nutrients, foods, and overall dietary patterns; and 3) 
developing new measure technologies that would be cost-effective, non-invasive, and rapid for use 
among large populations. 
 
 
 
Gut microbiome composition  
For our studies involving gut microbiome, we measured gut microbiome composition using 16S 
rRNA method in the Rotterdam Study and in the Lifelines-Deep Cohort Study.  
Briefly, we collected the stool samples from the participants. Once all samples were collected, we used 
the 16S rRNA method to detect gut microbiome composition. So far, 16S rRNA profiling is the most 
direct and cost-effective approach to obtain phylogenetic profiles. Nevertheless, 16S rRNA profiling 
has several typical limitations, including bias introduced by hyper-variable region selection and the 
profiling pipeline, the inability to detect novel, unknown operational taxonomic units (OTUs), 
overestimation of alpha diversity, and difficulty to compare samples with varying numbers of reads.30 
The effect of some of these limitations can be covered in the bioinformatic pipeline as well as by large 
integrated studies.30 Therefore, to minimize these limitations, in the process of bioinformatics pipeline 
of our Rotterdam Study, we only included OTUs clustering on basis of homology of the reads, and 
OTUs with <0.005% of total sequence reads were filtered out to account for sequencing errors. We 
also excluded OTUs presented in less than 10% of samples. Furthermore, when we analyzed the role 
of gut microbiome in the development of T2D risk by analyzing data from the Rotterdam Study and 
the Lifelines-Deep Study, to provide a platform for robust and reliable results, we further standardized 
all the procedures and protocols for the Rotterdam Study and the Lifelines-Deep Study, for which we 
implemented the 16S data processing pipeline, which comprised a naive Bayesian classifier from the 
Ribosomal Database Project, and the recent, SILVA database release 128: we only analyzed 
taxonomical results using genus and higher taxonomic levels.31 This OTU-independent approach was 
utilized to decrease domain-dependent bias. However, there are also some main limitations of the 16S 
rRNA method that could not be covered in the bioinformatics pipeline and using larger integrated 
studies. For example, in this method specific genes are not directly sequenced, but rather predicted 
based on the OUT, therefore, the 16S rRNA method often reports less precise gut microbiome data 
at the species level. An alternative approach to the 16S rRNA method is whole metagenome shotgun 
sequencing in which random fragments of genome are sequenced.32, 33 Compared with 16S rRNA 
method, whole metagenome shotgun sequencing can capture sequences from all the organisms, 
including accurate taxa at the species and lower levels, viruses and fungi. Furthermore, whole 
metagenome shotgun sequencing can be used to identify rare or novel organisms in the community, 
which 16S rRNA method cannot do. Additionally, it is less susceptible to the biases that are inherent 
in targeted gene amplification.33 Perhaps most interestingly, whole metagenome shotgun sequencing 
method can also provide direct information about the presence or absence of specific functional 
pathways in samples, also known as the ‘hologenome’. This can provide potentially important 
information about the capabilities and functions of the organisms in the community.33 However, 
whole metagenome shotgun method is more expensive and requires more extensive data analysis. 
Recently, another new approach to measure gut microbiome composition, the metatranscriptome, has 
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been developed.34 Compared with the 16S rRNA and the whole metagenome shotgun methods, the 
metatranscriptome method estimates which microorganisms in a community are actively transcribing, 
and inherently discriminates between active live organisms versus dormant or dead microorganisms 
and extracelluar DNA. Therefore, it can capture dynamic intra-individual variation, and directly 
evaluates microbial activity, including responses to intervention and event exposure. However, this 
latter method is more expensive. To summarize, 16S rRNA method highlights high-level community 
profiling, whole metagenome shotgun sequencing highlights functional profiling, and 
metatranscriptome sequencing highlights real-time functional profiling. Therefore, after conducting 
16S rRNA method to gain a low-resolution understanding of the gut microbiome composition, 
researchers could move on to metsgenome sequencing and metatranscriptome sequencing to further 
capture function profile of gut microbiome composition.34 
Additionally, like data on dietary intake in our main analysis, gut microbiome data were also measured 
once. However, gut microbiome is a complex, and dynamic ecosystem, which can easily change over 
time,34 thereby, repeated measurements of gut microbiome over time in longitudinal cohort study are 
particularly useful to further understand gut microbiome. 
 
PUBLIC HEALTH AND CLINICAL IMPLICATIONS & DIRECTIONS FOR FUTURE 
RESEARCH  
In the studies presented in this thesis, I have sought to respond to a series of research questions related 
to the role of nutrition and gut microbiome in T2D risk. Additionally, I also investigated the 
associations of nutritional factors with obesity, insulin resistance, prediabetes and mortality. In this 
section, I conclude by briefly foregrounding some of the studies’ implication for public health and 
clinical practice, and some of the directions for future research that stem from these studies and 
expand to this whole field.  
Public health and clinical implications 
I conducted the studies, with special attention to the public health and clinical practice whereby my 
studies made the results knowledgeable for researchers, medical professionals, policy makers, and even 
public readers. Accordingly, the first major public health and the clinical practical contribution derives 
from our findings on dietary protein intake, and a plant-based diet and T2D risk. Our findings point 
out that high total protein intake, especially high animal protein intake may increase T2D risk; instead, 
adherence a plant-based diet may reduce T2D risk. Overall, these studies have indicated the 
importance of foods sources, supporting more plant-based foods intake and less animal-based foods 
intake. However, I have also felt that more effective strategies and actions are needed to effectively 
 
 
 
translate these existing nutritional knowledges or dietary guidelines into public health practice, because 
in our research I saw that diets of individuals in the Rotterdam Study and several other studies 
remained far from optimal. In these populations, the total amount of protein intake was usually higher 
than the amount recommended by WHO, and animal-based foods were usually the main source.35 
Furthermore, in our Rotterdam Study population, the individuals had only 7 or less points out of 14 
on a scale of adherence to the most recent Dutch dietary guidelines.24 In this sense, I believe that our 
research is especially timely, which calls for the communities to further improve nutrition practice, 
such as lower intake of animal-based foods, and also call for more effective strategies by the scientists, 
physicians, policy-makers, nutritionists, medias, and the communities to better transfer these existing 
nutritional knowledges into public health practice. For example, nutritional education in schools and 
communities should be greatly encouraged.  
A second important implication of our research derives from our findings on associations between 
gut microbiome with insulin resistance and T2D. These findings may provide insights into the etiology 
of T2D, potential targets for the therapies, and safety and effectiveness of the treatment. For example, 
it is possible, that increasing gut microbial diversity and abundance of certain bacteria, such as 
butyrate-producing bacteria, (e.g. family Clostridum) might be a promising approach to prevent and 
treat T2D. Furthermore, as some drugs, (e.g. antibiotics) could have adverse effect on the gut 
microbiome composition, which might further fuel unbalanced gut microbiome composition of T2D 
patients, I would advise caution in use of these drugs among T2D patients. Additionally, previous 
evidence has indicated that gut microbiome composition is related to response to chemotherapy and 
immunotherapy, thereby, the response to chemotherapy and immunotherapy might differ among for 
example cancers patients with and without T2D.36  
Finally, our findings suggest that high overall diet quality may improve gut microbial diversity, along 
with a beneficial change of abundance of certain bacteria, which seems to be explained by various 
food items, not by any single foods item. These findings have indicated the importance of nutritional 
factors, especially overall diet quality for gut microbiome composition. Therefore, it is very likely that 
in a next future, a targeted modulation of the gut microbiome through ad hoc dietary interventions, 
used along or combined with the administration of mixtures of gut microbial species, may improve 
gut microbiome composition, which would benefit prevention and treatment of T2D and other 
diseases. Gut microbiome composition, in turn, might also be used to personalize diet, which together 
may thereby hold potential for enhancing public health.36  
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Directions for future research  
Our studies have answered some research questions about nutrition, gut microbiome, and T2D; but 
also raised a number of additional questions for future research. More research will in fact be needed 
to refine, elaborate and extend most of our novel findings. 
First, in line with previous studies, our studies in this thesis have indicated that lower intake of animal 
protein intake, and a more plant-based diet are associated with lower insulin resistance, and lower risk 
of prediabetes and T2D and other health events. However, our studies and most previous studies were 
embedded in European or North American populations. In these populations, a western dietary 
pattern is more likely and nutrition excess is of concern. For example, the total amount of protein 
intake is usually higher than the amount recommended by WHO, and animal products are usually the 
main source. Therefore, further studies in other populations who are more likely to have different 
dietary patterns, such as Asian and African populations, are needed. Additionally, further research is 
needed not only in general populations but also in more specific populations with health conditions, 
where nutrition requirements may differ. These efforts will help make targeted dietary 
recommendations and define optimal nutrients ranges and overall dietary patterns for different 
populations in different geographic locations and health stages.19 Moreover, further research on 
mechanisms through which nutritional factors influence health is needed. New molecular fields of 
nutritional epidemiological research have developed by remarkable advances in omics technologies, 
including genomics, metabolomics, and proteomics, and by the study of the human gut microbiome. 
Research on these new fields will provide molecular insights on mechanisms pathways, which will help 
to discover novel biomarkers of nutritional factors, understand individual variability in dietary 
responses, and identify high-risk T2D populations to target for intervention. Additional aspects of 
nutrition for T2D risk deserve to be investigated further, such as effects of contaminants, food 
processing, and cooking methods. Our food supply and personal choices are constantly changing over 
time, so that new issues are continuously emerging, such as effects of highly manufactured meat 
alternatives and gluten-free diets.37 Last, as I have addressed above, further research regarding how to 
effectively translate existing nutritional knowledge or dietary guidelines into public health practice is 
also needed. 
Second, we have observed the associations of gut microbiome composition with insulin resistance and 
T2D. However, our study was based on a cross-sectional study, which failed to distinguish whether 
alterations of the gut microbiome were a cause or consequence of changes in difference of insulin 
resistance and T2D risk. Therefore, future research should further attempt to explore the temporal 
direction and causality in the framework of longitudinal repeated measures of gut microbiome and 
clinical interventional studies. In this process, we could also in turn explore how T2D influences gut 
microbiome composition. Furthermore, future research could further explore the mechanisms behind 
 
 
 
the role of gut microbiome composition in T2D risk. For this aim, much work is needed. For example, 
we could extend our research from investigation of effect of gut composition profile into that of gut 
microbiome function using metagenome sequencing and metatranscriptome sequencing data. We also 
could explore the effect of metabolomics of gut microbiome on T2D risk. Besides, more replication 
analyses for gut microbiome and T2D risk among various populations are needed, as gut microbiome 
composition varied to some extent by different populations. Finally, based on the existing knowledge, 
we should further develop more effective strategies to apply these existing knowledges to early prevent 
progression or even the overt manifestation of T2D in public health and clinical practice settings (e.g. 
dietary interventions including prebiotics, probiotics, and FMT).  
Third, we have explored the associations between nutrition and gut microbiome in Chapter 4. Similar 
to our study on gut microbiome and T2D risk, the study on overall diet quality and gut microbiome 
could also be extended: 1) to replicate the findings in various populations; 2) to infer causality of the 
findings; and 3) to further explore mechanisms behind the associations of diet and gut microbiome. 
Furthermore, given that diet habit could change over time, we could further elaborate if and how 
change of nutrition including overall diet quality and specific foods items over time influences gut 
microbiome composition over time. Moreover, it would be necessary to extend the existing evidence 
by exploring the associations between prebiotic foods and organic foods and gut microbiome 
composition. For example, we could explore if and how prebiotic foods, such as garlic and onions, 
influence gut microbiome composition; how effects of natural prebiotic foods compare to probiotic 
supplements; and if and how organic foods influence gut microbiome composition. Besides, further 
research could take a perspective of clinical practice and ask how to improve gut microbiome through 
dietary intervention in various specific patients, such as cancer patients. Additionally, we could also 
investigate whether gut microbiome can influence food choices and appetite, which could lead to 
positive feedback loops when these dietary changes in turn alter the gut microbiome. Overall, to date, 
insufficient public health and clinical evidence exists to draw clear conclusions or firm 
recommendations based on gut microbiome composition. Further research is needed to infer the 
causality for the known associations, and to further explore the potential effect for probiotic foods, 
organic foods, and food additives. The potential research will help to update dietary guidelines and 
develop precision nutrition approach to benefit public health and clinical practice. 
Finally, on basis of all the studies presented in the thesis, I think that gut microbiome could be a 
mechanism and mediator behind the associations of nutrition and T2D. However, the current work 
in the thesis has not shown more specific evidence of how the gut microbiome mediates the 
associations between nutrition and T2D, therefore, more work is needed to examine how gut 
microbiome mediates the associations in detail, which will help to develop precision nutrition 
strategies for preventing and treating T2D in clinical and public health settings.  
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time, so that new issues are continuously emerging, such as effects of highly manufactured meat 
alternatives and gluten-free diets.37 Last, as I have addressed above, further research regarding how to 
effectively translate existing nutritional knowledge or dietary guidelines into public health practice is 
also needed. 
Second, we have observed the associations of gut microbiome composition with insulin resistance and 
T2D. However, our study was based on a cross-sectional study, which failed to distinguish whether 
alterations of the gut microbiome were a cause or consequence of changes in difference of insulin 
resistance and T2D risk. Therefore, future research should further attempt to explore the temporal 
direction and causality in the framework of longitudinal repeated measures of gut microbiome and 
clinical interventional studies. In this process, we could also in turn explore how T2D influences gut 
microbiome composition. Furthermore, future research could further explore the mechanisms behind 
 
 
 
the role of gut microbiome composition in T2D risk. For this aim, much work is needed. For example, 
we could extend our research from investigation of effect of gut composition profile into that of gut 
microbiome function using metagenome sequencing and metatranscriptome sequencing data. We also 
could explore the effect of metabolomics of gut microbiome on T2D risk. Besides, more replication 
analyses for gut microbiome and T2D risk among various populations are needed, as gut microbiome 
composition varied to some extent by different populations. Finally, based on the existing knowledge, 
we should further develop more effective strategies to apply these existing knowledges to early prevent 
progression or even the overt manifestation of T2D in public health and clinical practice settings (e.g. 
dietary interventions including prebiotics, probiotics, and FMT).  
Third, we have explored the associations between nutrition and gut microbiome in Chapter 4. Similar 
to our study on gut microbiome and T2D risk, the study on overall diet quality and gut microbiome 
could also be extended: 1) to replicate the findings in various populations; 2) to infer causality of the 
findings; and 3) to further explore mechanisms behind the associations of diet and gut microbiome. 
Furthermore, given that diet habit could change over time, we could further elaborate if and how 
change of nutrition including overall diet quality and specific foods items over time influences gut 
microbiome composition over time. Moreover, it would be necessary to extend the existing evidence 
by exploring the associations between prebiotic foods and organic foods and gut microbiome 
composition. For example, we could explore if and how prebiotic foods, such as garlic and onions, 
influence gut microbiome composition; how effects of natural prebiotic foods compare to probiotic 
supplements; and if and how organic foods influence gut microbiome composition. Besides, further 
research could take a perspective of clinical practice and ask how to improve gut microbiome through 
dietary intervention in various specific patients, such as cancer patients. Additionally, we could also 
investigate whether gut microbiome can influence food choices and appetite, which could lead to 
positive feedback loops when these dietary changes in turn alter the gut microbiome. Overall, to date, 
insufficient public health and clinical evidence exists to draw clear conclusions or firm 
recommendations based on gut microbiome composition. Further research is needed to infer the 
causality for the known associations, and to further explore the potential effect for probiotic foods, 
organic foods, and food additives. The potential research will help to update dietary guidelines and 
develop precision nutrition approach to benefit public health and clinical practice. 
Finally, on basis of all the studies presented in the thesis, I think that gut microbiome could be a 
mechanism and mediator behind the associations of nutrition and T2D. However, the current work 
in the thesis has not shown more specific evidence of how the gut microbiome mediates the 
associations between nutrition and T2D, therefore, more work is needed to examine how gut 
microbiome mediates the associations in detail, which will help to develop precision nutrition 
strategies for preventing and treating T2D in clinical and public health settings.  
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Precision nutrition for preventing and treating T2D is an emerging new research direction. It aims to 
tailor personalized dietary interventions or recommendations by integrating traditional nutritional 
factors research and new molecular mechanisms research (e.g. gut microbiome research, genetics 
research, and metabolomics research).38 Currently, precision nutrition for T2D and other diseases is 
still in its infancy and much research is needed before it can be widely used in clinical and public health 
settings. There are many challenges to be faced in the field of precision nutrition, such as a lack of 
robust and reproducible results, the high cost of omics technologies, and methodological issues in 
study design as well as high-dimensional data analyses and interpretation.38 Further research is needed 
to address these issues. Furthermore, as precision nutrition research is moving towards prevention 
and treatment of T2D, parallel efforts, such as precision medicine, are also needed to make the 
precision approaches more completed. Overall, personalized precision nutrition approach by 
integrating findings from traditional nutritional factors research and new molecular mechanisms 
research, such as gut microbiome research, together with other parallel efforts, might have the 
potential to reduce the burden of illness and disability due to T2D and its related disorders, which 
thereby points to a new direction for research of prevention and treatment of T2D and its related 
diseases. 
 
CONCLUSIONS 
The findings of the studies in this thesis provide new recommendations and implications for 
prevention of the development of T2D. Specifically, lower animal protein intake, and higher degree 
of adherence to plant-based diet may reduce T2D risk. More gut microbial diversity and beneficial 
change of certain gut microbial communities (e.g. butyrate-producing bacteria) may benefit T2D risk, 
which might be achieved by improving overall diet quality and higher intake of  specific plant-based 
foods, such as vegetables, fruits, nuts, whole grains, and lower intake of certain animal-based foods, 
such as red and processed meat. Overall, our findings give novel insights regarding pathophysiology 
of T2D and indicates potential mechanisms related to gut microbiome underlying associations 
between nutrition and T2D. Awaiting further research, these findings carry potential to contribute to 
improvement of T2D and its related cardio-metabolic events, treatment, and prognosis.   
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